BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Richon VM, Sandhoff TW, Rifkind RA, Marks PA. Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc Natl Acad Sci USA. 2000;97:10014-10019. [PMID: 10954755 DOI: 10.1073/pnas.180316197] [Cited by in Crossref: 817] [Cited by in F6Publishing: 754] [Article Influence: 37.1] [Reference Citation Analysis]
Number Citing Articles
1 Sasakawa Y, Naoe Y, Inoue T, Sasakawa T, Matsuo M, Manda T, Mutoh S. Effects of FK228, a novel histone deacetylase inhibitor, on human lymphoma U-937 cells in vitro and in vivo. Biochemical Pharmacology 2002;64:1079-90. [DOI: 10.1016/s0006-2952(02)01261-3] [Cited by in Crossref: 71] [Cited by in F6Publishing: 26] [Article Influence: 3.6] [Reference Citation Analysis]
2 Sonnemann J, Dreyer L, Hartwig M, Palani CD, Hong LTT, Klier U, Bröker B, Völker U, Beck JF. Histone deacetylase inhibitors induce cell death and enhance the apoptosis-inducing activity of TRAIL in Ewing’s sarcoma cells. J Cancer Res Clin Oncol 2007;133:847-58. [DOI: 10.1007/s00432-007-0227-8] [Cited by in Crossref: 53] [Cited by in F6Publishing: 54] [Article Influence: 3.5] [Reference Citation Analysis]
3 Altmann A, Eisenhut M, Bauder-wüst U, Markert A, Askoxylakis V, Hess-stumpp H, Haberkorn U. Therapy of thyroid carcinoma with the histone deacetylase inhibitor MS-275. Eur J Nucl Med Mol Imaging 2010;37:2286-97. [DOI: 10.1007/s00259-010-1573-3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
4 Newbold A, Salmon JM, Martin BP, Stanley K, Johnstone RW. The role of p21(waf1/cip1) and p27(Kip1) in HDACi-mediated tumor cell death and cell cycle arrest in the Eμ-myc model of B-cell lymphoma. Oncogene 2014;33:5415-23. [PMID: 24292681 DOI: 10.1038/onc.2013.482] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 3.8] [Reference Citation Analysis]
5 Xu WS, Parmigiani RB, Marks PA. Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene. 2007;26:5541-5552. [PMID: 17694093 DOI: 10.1038/sj.onc.1210620] [Cited by in Crossref: 1010] [Cited by in F6Publishing: 949] [Article Influence: 67.3] [Reference Citation Analysis]
6 Cooper AL, Greenberg VL, Lancaster PS, van Nagell JR, Zimmer SG, Modesitt SC. In vitro and in vivo histone deacetylase inhibitor therapy with suberoylanilide hydroxamic acid (SAHA) and paclitaxel in ovarian cancer. Gynecologic Oncology 2007;104:596-601. [DOI: 10.1016/j.ygyno.2006.09.011] [Cited by in Crossref: 42] [Cited by in F6Publishing: 38] [Article Influence: 2.8] [Reference Citation Analysis]
7 Haery L, Thompson RC, Gilmore TD. Histone acetyltransferases and histone deacetylases in B- and T-cell development, physiology and malignancy. Genes Cancer 2015;6:184-213. [PMID: 26124919 DOI: 10.18632/genesandcancer.65] [Cited by in Crossref: 60] [Cited by in F6Publishing: 59] [Article Influence: 8.6] [Reference Citation Analysis]
8 Mrakovcic M, Fröhlich LF. Molecular Determinants of Cancer Therapy Resistance to HDAC Inhibitor-Induced Autophagy. Cancers (Basel) 2019;12:E109. [PMID: 31906235 DOI: 10.3390/cancers12010109] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
9 Papeleu P, Vanhaecke T, Elaut G, Vinken M, Henkens T, Snykers S, Rogiers V. Differential effects of histone deacetylase inhibitors in tumor and normal cells-what is the toxicological relevance? Crit Rev Toxicol. 2005;35:363-378. [PMID: 15989141 DOI: 10.1080/10408440590935639] [Cited by in Crossref: 47] [Cited by in F6Publishing: 43] [Article Influence: 2.8] [Reference Citation Analysis]
10 Pratap J, Akech J, Wixted JJ, Szabo G, Hussain S, McGee-Lawrence ME, Li X, Bedard K, Dhillon RJ, van Wijnen AJ, Stein JL, Stein GS, Westendorf JJ, Lian JB. The histone deacetylase inhibitor, vorinostat, reduces tumor growth at the metastatic bone site and associated osteolysis, but promotes normal bone loss. Mol Cancer Ther 2010;9:3210-20. [PMID: 21159607 DOI: 10.1158/1535-7163.MCT-10-0572] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 2.9] [Reference Citation Analysis]
11 Duvic M, Vu J. Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma. Expert Opin Investig Drugs 2007;16:1111-20. [PMID: 17594194 DOI: 10.1517/13543784.16.7.1111] [Cited by in Crossref: 225] [Cited by in F6Publishing: 215] [Article Influence: 15.0] [Reference Citation Analysis]
12 Su Y, Hopfinger NR, Nguyen TD, Pogash TJ, Santucci-Pereira J, Russo J. Epigenetic reprogramming of epithelial mesenchymal transition in triple negative breast cancer cells with DNA methyltransferase and histone deacetylase inhibitors. J Exp Clin Cancer Res 2018;37:314. [PMID: 30547810 DOI: 10.1186/s13046-018-0988-8] [Cited by in Crossref: 37] [Cited by in F6Publishing: 35] [Article Influence: 9.3] [Reference Citation Analysis]
13 Furuya F, Shimura H, Suzuki H, Taki K, Ohta K, Haraguchi K, Onaya T, Endo T, Kobayashi T. Histone Deacetylase Inhibitors Restore Radioiodide Uptake and Retention in Poorly Differentiated and Anaplastic Thyroid Cancer Cells by Expression of the Sodium/Iodide Symporter Thyroperoxidase and Thyroglobulin. Endocrinology 2004;145:2865-75. [DOI: 10.1210/en.2003-1258] [Cited by in Crossref: 107] [Cited by in F6Publishing: 94] [Article Influence: 5.9] [Reference Citation Analysis]
14 Zhang B, Wang Y, Pang X. Enhanced radiosensitivity of EC109 cells by inhibition of HDAC1 expression. Med Oncol 2012;29:340-8. [PMID: 20464640 DOI: 10.1007/s12032-010-9559-3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
15 Xu Q, Lu R, Zhu ZF, Lv JQ, Wang LJ, Zhang W, Hu JW, Meng J, Lin G, Yao Z. Effects of tyroservatide on histone acetylation in lung carcinoma cells. Int J Cancer. 2011;128:460-472. [PMID: 20309941 DOI: 10.1002/ijc.25346] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
16 Palmieri C, Coombes RC, Vigushin DM. Targeted histone deacetylase inhibition for cancer prevention and therapy. Prog Drug Res 2005;63:147-81. [PMID: 16265880 DOI: 10.1007/3-7643-7414-4_7] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
17 Hölsken A, Eyüpoglu IY, Lueders M, Tränkle C, Dieckmann D, Buslei R, Hahnen E, Blümcke I, Siebzehnrübl FA. Ex vivo therapy of malignant melanomas transplanted into organotypic brain slice cultures using inhibitors of histone deacetylases. Acta Neuropathol 2006;112:205-15. [DOI: 10.1007/s00401-006-0082-8] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 0.8] [Reference Citation Analysis]
18 Laws MT, Bonomi RE, Kamal S, Gelovani DJ, Llaniguez J, Potukutchi S, Lu X, Mangner T, Gelovani JG. Molecular imaging HDACs class IIa expression-activity and pharmacologic inhibition in intracerebral glioma models in rats using PET/CT/(MRI) with [18F]TFAHA. Sci Rep 2019;9:3595. [PMID: 30837601 DOI: 10.1038/s41598-019-40054-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
19 Hellebrekers DM, Griffioen AW, van Engeland M. Dual targeting of epigenetic therapy in cancer. Biochim Biophys Acta. 2007;1775:76-91. [PMID: 16930846 DOI: 10.1016/j.bbcan.2006.07.003] [Cited by in Crossref: 20] [Cited by in F6Publishing: 54] [Article Influence: 1.3] [Reference Citation Analysis]
20 Umesawa M, Iso H, Mikami K, Kubo T, Suzuki K, Watanabe Y, Mori M, Miki T, Tamakoshi A; JACC Study Group. Relationship between vegetable and carotene intake and risk of prostate cancer: the JACC study. Br J Cancer 2014;110:792-6. [PMID: 24169341 DOI: 10.1038/bjc.2013.685] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
21 Gui CY, Ngo L, Xu WS, Richon VM, Marks PA. Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1. Proc Natl Acad Sci USA. 2004;101:1241-1246. [PMID: 14734806 DOI: 10.1073/pnas.0307708100] [Cited by in Crossref: 417] [Cited by in F6Publishing: 386] [Article Influence: 23.2] [Reference Citation Analysis]
22 Parbin S, Kar S, Shilpi A, Sengupta D, Deb M, Rath SK, Patra SK. Histone deacetylases: a saga of perturbed acetylation homeostasis in cancer. J Histochem Cytochem 2014;62:11-33. [PMID: 24051359 DOI: 10.1369/0022155413506582] [Cited by in Crossref: 69] [Cited by in F6Publishing: 61] [Article Influence: 7.7] [Reference Citation Analysis]
23 Jadhav V, Ray P, Sachdeva G, Bhatt P. Biocompatible arsenic trioxide nanoparticles induce cell cycle arrest by p21WAF1/CIP1 expression via epigenetic remodeling in LNCaP and PC3 cell lines. Life Sciences 2016;148:41-52. [DOI: 10.1016/j.lfs.2016.02.042] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
24 Varshochi R, Halim F, Sunters A, Alao JP, Madureira PA, Hart SM, Ali S, Vigushin DM, Coombes RC, Lam EW. ICI182,780 induces p21Waf1 gene transcription through releasing histone deacetylase 1 and estrogen receptor alpha from Sp1 sites to induce cell cycle arrest in MCF-7 breast cancer cell line. J Biol Chem 2005;280:3185-96. [PMID: 15557281 DOI: 10.1074/jbc.M408063200] [Cited by in Crossref: 48] [Cited by in F6Publishing: 23] [Article Influence: 2.7] [Reference Citation Analysis]
25 de Ruijter AJ, van Gennip AH, Caron HN, Kemp S, van Kuilenburg AB. Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem J. 2003;370:737-749. [PMID: 12429021 DOI: 10.1042/bj20021321] [Cited by in Crossref: 1978] [Cited by in F6Publishing: 1780] [Article Influence: 104.1] [Reference Citation Analysis]
26 Wagner JM, Hackanson B, Lübbert M, Jung M. Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy. Clin Epigenetics 2010;1:117-36. [PMID: 21258646 DOI: 10.1007/s13148-010-0012-4] [Cited by in Crossref: 289] [Cited by in F6Publishing: 265] [Article Influence: 24.1] [Reference Citation Analysis]
27 Wang TY, Jia YL, Zhang X, Sun QL, Li YC, Zhang JH, Zhao CP, Wang XY, Wang L. Treating Colon Cancer Cells with FK228 Reveals a Link between Histone Lysine Acetylation and Extensive Changes in the Cellular Proteome. Sci Rep 2015;5:18443. [PMID: 26675280 DOI: 10.1038/srep18443] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
28 Witt O, Deubzer HE, Milde T, Oehme I. HDAC family: What are the cancer relevant targets? Cancer Lett. 2009;277:8-21. [PMID: 18824292 DOI: 10.1016/j.canlet.2008.08.016] [Cited by in Crossref: 679] [Cited by in F6Publishing: 630] [Article Influence: 48.5] [Reference Citation Analysis]
29 Tang J, Yan H, Zhuang S. Histone deacetylases as targets for treatment of multiple diseases. Clin Sci (Lond). 2013;124:651-662. [PMID: 23414309 DOI: 10.1042/cs20120504] [Cited by in Crossref: 113] [Cited by in F6Publishing: 61] [Article Influence: 12.6] [Reference Citation Analysis]
30 Eot-Houllier G, Fulcrand G, Magnaghi-Jaulin L, Jaulin C. Histone deacetylase inhibitors and genomic instability. Cancer Lett 2009;274:169-76. [PMID: 18635312 DOI: 10.1016/j.canlet.2008.06.005] [Cited by in Crossref: 95] [Cited by in F6Publishing: 87] [Article Influence: 6.8] [Reference Citation Analysis]
31 Catley L, Weisberg E, Kiziltepe T, Tai YT, Hideshima T, Neri P, Tassone P, Atadja P, Chauhan D, Munshi NC. Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells. Blood. 2006;108:3441-3449. [PMID: 16728695 DOI: 10.1182/blood-2006-04-016055] [Cited by in Crossref: 266] [Cited by in F6Publishing: 236] [Article Influence: 16.6] [Reference Citation Analysis]
32 Ungerstedt JS, Sowa Y, Xu WS, Shao Y, Dokmanovic M, Perez G, Ngo L, Holmgren A, Jiang X, Marks PA. Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors. Proc Natl Acad Sci USA. 2005;102:673-678. [PMID: 15637150 DOI: 10.1073/pnas.0408732102] [Cited by in Crossref: 365] [Cited by in F6Publishing: 330] [Article Influence: 21.5] [Reference Citation Analysis]
33 Takai N, Ueda T, Nishida M, Nasu K, Matsuda K, Kusumoto M, Narahara H. CBHA Is a Family of Hybrid Polar Compounds That Inhibit Histone Deacetylase, and Induces Growth Inhibition, Cell Cycle Arrest and Apoptosis in Human Endometrial and Ovarian Cancer Cells. Oncology 2006;70:97-105. [DOI: 10.1159/000092585] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
34 Zhao L, Wang P, Yan S, Gao F, Li H, Hou H, Zhang Q, Tan J, Li L. Promoter-associated histone acetylation is involved in the osmotic stress-induced transcriptional regulation of the maize ZmDREB2A gene. Physiol Plant 2014;151:459-67. [PMID: 24299295 DOI: 10.1111/ppl.12136] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 2.7] [Reference Citation Analysis]
35 Jones A, Lechner M, Fourkala EO, Kristeleit R, Widschwendter M. Emerging promise of epigenetics and DNA methylation for the diagnosis and management of women's cancers. Epigenomics 2010;2:9-38. [PMID: 22122746 DOI: 10.2217/epi.09.47] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
36 Pinz S, Unser S, Buob D, Fischer P, Jobst B, Rascle A. Deacetylase inhibitors repress STAT5-mediated transcription by interfering with bromodomain and extra-terminal (BET) protein function. Nucleic Acids Res 2015;43:3524-45. [PMID: 25769527 DOI: 10.1093/nar/gkv188] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 3.7] [Reference Citation Analysis]
37 Tambo Y, Hosomi Y, Sakai H, Nogami N, Atagi S, Sasaki Y, Kato T, Takahashi T, Seto T, Maemondo M, Nokihara H, Koyama R, Nakagawa K, Kawaguchi T, Okamura Y, Nakamura O, Nishio M, Tamura T. Phase I/II study of docetaxel combined with resminostat, an oral hydroxamic acid HDAC inhibitor, for advanced non-small cell lung cancer in patients previously treated with platinum-based chemotherapy. Invest New Drugs 2017;35:217-26. [PMID: 28138828 DOI: 10.1007/s10637-017-0435-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
38 Beekman KW, Bradley D, Hussain M. New molecular targets and novel agents in the treatment of advanced urothelial cancer. Semin Oncol 2007;34:154-64. [PMID: 17382799 DOI: 10.1053/j.seminoncol.2006.12.007] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 1.4] [Reference Citation Analysis]
39 Nidhyanandan S, Thippeswamy BS, Chandrasekhar KB, Reddy ND, Kulkarni NM, Karthikeyan K, Khan FR, Raghul J, Vijaykanth G, Narayanan S. Enhanced anticancer efficacy of histone deacetyl inhibitor, suberoylanilide hydroxamic acid, in combination with a phosphodiesterase inhibitor, pentoxifylline, in human cancer cell lines and in-vivo tumor xenografts. Anti-Cancer Drugs 2017;28:1002-17. [DOI: 10.1097/cad.0000000000000544] [Cited by in Crossref: 3] [Article Influence: 0.6] [Reference Citation Analysis]
40 Chopin V, Toillon RA, Jouy N, Le Bourhis X. P21(WAF1/CIP1) is dispensable for G1 arrest, but indispensable for apoptosis induced by sodium butyrate in MCF-7 breast cancer cells. Oncogene. 2004;23:21-29. [PMID: 14712207 DOI: 10.1038/sj.onc.1207020] [Cited by in Crossref: 72] [Cited by in F6Publishing: 66] [Article Influence: 4.0] [Reference Citation Analysis]
41 Balch C, Fang F, Matei DE, Huang TH, Nephew KP. Minireview: epigenetic changes in ovarian cancer. Endocrinology 2009;150:4003-11. [PMID: 19574400 DOI: 10.1210/en.2009-0404] [Cited by in Crossref: 105] [Cited by in F6Publishing: 96] [Article Influence: 8.1] [Reference Citation Analysis]
42 Pulukuri SM, Gorantla B, Knost JA, Rao JS. Frequent loss of cystatin E/M expression implicated in the progression of prostate cancer. Oncogene 2009;28:2829-38. [PMID: 19503093 DOI: 10.1038/onc.2009.134] [Cited by in Crossref: 28] [Cited by in F6Publishing: 30] [Article Influence: 2.2] [Reference Citation Analysis]
43 Savickiene J, Treigyte G, Magnusson K, Navakauskiene R. Response of Retinoic Acid-Resistant KG1 Cells to Combination of Retinoic Acid with Diverse Histone Deacetylase Inhibitors. Annals of the New York Academy of Sciences 2009;1171:321-33. [DOI: 10.1111/j.1749-6632.2009.04718.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
44 Saito T, Nishida K, Furumatsu T, Yoshida A, Ozawa M, Ozaki T. Histone deacetylase inhibitors suppress mechanical stress-induced expression of RUNX-2 and ADAMTS-5 through the inhibition of the MAPK signaling pathway in cultured human chondrocytes. Osteoarthritis Cartilage 2013;21:165-74. [PMID: 23017871 DOI: 10.1016/j.joca.2012.09.003] [Cited by in Crossref: 43] [Cited by in F6Publishing: 40] [Article Influence: 4.3] [Reference Citation Analysis]
45 Mohammadi K, Safaralizadeh R, Hosseinpour-Feizi M, Dastmalchi N, Moaddab Y. Investigation of the changes in the expression levels of MOZ gene in colorectal cancer tissues. J Gastrointest Oncol 2019;10:68-73. [PMID: 30788161 DOI: 10.21037/jgo.2018.09.12] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
46 Li X, Chen BD. Histone Deacetylase Inhibitor M344 Inhibits Cell Proliferation and Induces Apoptosis in Human THP-1 Leukemia Cells. Am J Biomed Sci 2009;1:352-63. [PMID: 20526416 DOI: 10.5099/aj090400352] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
47 Zhang H, Yue M, Zheng X, Gautam M, He S, Li L. The Role of Promoter-Associated Histone Acetylation of Haem Oxygenase-1 (HO-1) and Giberellic Acid-Stimulated Like-1 (GSL-1) Genes in Heat-Induced Lateral Root Primordium Inhibition in Maize. Front Plant Sci 2018;9:1520. [PMID: 30459784 DOI: 10.3389/fpls.2018.01520] [Cited by in Crossref: 21] [Cited by in F6Publishing: 9] [Article Influence: 5.3] [Reference Citation Analysis]
48 Ibragimova I, Maradeo ME, Dulaimi E, Cairns P. Aberrant promoter hypermethylation of PBRM1, BAP1, SETD2, KDM6A and other chromatin-modifying genes is absent or rare in clear cell RCC. Epigenetics 2013;8:486-93. [PMID: 23644518 DOI: 10.4161/epi.24552] [Cited by in Crossref: 38] [Cited by in F6Publishing: 36] [Article Influence: 4.2] [Reference Citation Analysis]
49 Duncan H, Smith A, Fleming G, Cooper P. HDACi: Cellular Effects, Opportunities for Restorative Dentistry. J Dent Res 2011;90:1377-88. [DOI: 10.1177/0022034511406919] [Cited by in Crossref: 32] [Cited by in F6Publishing: 25] [Article Influence: 2.9] [Reference Citation Analysis]
50 Findeisen HM, Gizard F, Zhao Y, Qing H, Heywood EB, Jones KL, Cohn D, Bruemmer D. Epigenetic regulation of vascular smooth muscle cell proliferation and neointima formation by histone deacetylase inhibition. Arterioscler Thromb Vasc Biol. 2011;31:851-860. [PMID: 21233448 DOI: 10.1161/atvbaha.110.221952] [Cited by in Crossref: 86] [Cited by in F6Publishing: 45] [Article Influence: 7.8] [Reference Citation Analysis]
51 Hesson LB, Krex D, Latif F. Epigenetic markers in human gliomas: prospects for therapeutic intervention. Expert Rev Neurother 2008;8:1475-96. [PMID: 18928342 DOI: 10.1586/14737175.8.10.1475] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
52 Li H, Wu X. Histone deacetylase inhibitor, Trichostatin A, activates p21WAF1/CIP1 expression through downregulation of c-myc and release of the repression of c-myc from the promoter in human cervical cancer cells. Biochem Biophys Res Commun 2004;324:860-7. [PMID: 15474507 DOI: 10.1016/j.bbrc.2004.09.130] [Cited by in Crossref: 67] [Cited by in F6Publishing: 55] [Article Influence: 3.7] [Reference Citation Analysis]
53 Royston KJ, Paul B, Nozell S, Rajbhandari R, Tollefsbol TO. Withaferin A and sulforaphane regulate breast cancer cell cycle progression through epigenetic mechanisms. Exp Cell Res. 2018;368:67-74. [PMID: 29689276 DOI: 10.1016/j.yexcr.2018.04.015] [Cited by in Crossref: 33] [Cited by in F6Publishing: 36] [Article Influence: 8.3] [Reference Citation Analysis]
54 Kim TY, Jong HS, Song SH, Dimtchev A, Jeong SJ, Lee JW, Kim TY, Kim NK, Jung M, Bang YJ. Transcriptional silencing of the DLC-1 tumor suppressor gene by epigenetic mechanism in gastric cancer cells. Oncogene 2003;22:3943-51. [PMID: 12813468 DOI: 10.1038/sj.onc.1206573] [Cited by in Crossref: 78] [Cited by in F6Publishing: 72] [Article Influence: 4.1] [Reference Citation Analysis]
55 Phiel CJ, Zhang F, Huang EY, Guenther MG, Lazar MA, Klein PS. Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J Biol Chem 2001;276:36734-41. [PMID: 11473107 DOI: 10.1074/jbc.M101287200] [Cited by in Crossref: 1161] [Cited by in F6Publishing: 493] [Article Influence: 55.3] [Reference Citation Analysis]
56 Sun JY, Tseng H, Xu L, Hunter Z, Ciccarelli B, Fulciniti M, Zhu B, Maghsoudi K, Yang G, Gong P, Zhou Y, Liu X, Munshi NC, Patterson CJ, Treon SP. Vorinostat induced cellular stress disrupts the p38 mitogen activated protein kinase and extracellular signal regulated kinase pathways leading to apoptosis in Waldenström macroglobulinemia cells. Leukemia & Lymphoma 2011;52:1777-86. [DOI: 10.3109/10428194.2011.577850] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
57 Wu CH, Tsai YC, Tsai TH, Kuo KL, Su YF, Chang CH, Lin CL. Valproic Acid Reduces Vasospasm through Modulation of Akt Phosphorylation and Attenuates Neuronal Apoptosis in Subarachnoid Hemorrhage Rats. Int J Mol Sci 2021;22:5975. [PMID: 34205883 DOI: 10.3390/ijms22115975] [Reference Citation Analysis]
58 Kalebic T. Epigenetic transitions: towards therapeutic targets. Expert Opinion on Therapeutic Targets 2005;7:693-9. [DOI: 10.1517/14728222.7.6.693] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
59 Sangwan R, Rajan R, Mandal PK. HDAC as onco target: Reviewing the synthetic approaches with SAR study of their inhibitors. European Journal of Medicinal Chemistry 2018;158:620-706. [DOI: 10.1016/j.ejmech.2018.08.073] [Cited by in Crossref: 45] [Cited by in F6Publishing: 39] [Article Influence: 11.3] [Reference Citation Analysis]
60 Hristov AC, Tejasvi T, Wilcox RA. Mycosis fungoides and Sézary syndrome: 2019 update on diagnosis, risk-stratification, and management. Am J Hematol 2019;94:1027-41. [PMID: 31313347 DOI: 10.1002/ajh.25577] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 8.7] [Reference Citation Analysis]
61 Zhang Y, Fatima N, Dufau ML. Coordinated changes in DNA methylation and histone modifications regulate silencing/derepression of luteinizing hormone receptor gene transcription. Mol Cell Biol 2005;25:7929-39. [PMID: 16135786 DOI: 10.1128/MCB.25.18.7929-7939.2005] [Cited by in Crossref: 75] [Cited by in F6Publishing: 37] [Article Influence: 4.4] [Reference Citation Analysis]
62 Zhang X, Zhou D, Strakovsky R, Zhang Y, Pan YX. Hepatic cellular senescence pathway genes are induced through histone modifications in a diet-induced obese rat model. Am J Physiol Gastrointest Liver Physiol 2012;302:G558-64. [PMID: 22194422 DOI: 10.1152/ajpgi.00032.2011] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 2.8] [Reference Citation Analysis]
63 Federico M, Bagella L. Histone deacetylase inhibitors in the treatment of hematological malignancies and solid tumors. J Biomed Biotechnol. 2011;2011:475641. [PMID: 21188171 DOI: 10.1155/2011/475641] [Cited by in Crossref: 57] [Cited by in F6Publishing: 60] [Article Influence: 4.8] [Reference Citation Analysis]
64 Mims A, Walker AR, Huang X, Sun J, Wang H, Santhanam R, Dorrance AM, Walker C, Hoellerbauer P, Tarighat SS, Chan KK, Klisovic RB, Perrotti D, Caligiuri MA, Byrd JC, Chen CS, James Lee L, Jacob S, Mrózek K, Bloomfield CD, Blum W, Garzon R, Schwind S, Marcucci G. Increased anti-leukemic activity of decitabine via AR-42-induced upregulation of miR-29b: a novel epigenetic-targeting approach in acute myeloid leukemia. Leukemia 2013;27:871-8. [PMID: 23178755 DOI: 10.1038/leu.2012.342] [Cited by in Crossref: 46] [Cited by in F6Publishing: 42] [Article Influence: 4.6] [Reference Citation Analysis]
65 Zhang T, Li J, Ma X, Yang Y, Sun W, Jin W, Wang L, He Y, Yang F, Yi Z, Hua Y, Liu M, Chen Y, Cai Z. Inhibition of HDACs-EphA2 Signaling Axis with WW437 Demonstrates Promising Preclinical Antitumor Activity in Breast Cancer. EBioMedicine 2018;31:276-86. [PMID: 29759486 DOI: 10.1016/j.ebiom.2018.05.003] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
66 Kai L, Samuel SK, Levenson AS. Resveratrol enhances p53 acetylation and apoptosis in prostate cancer by inhibiting MTA1/NuRD complex. Int J Cancer 2010;126:1538-48. [PMID: 19810103 DOI: 10.1002/ijc.24928] [Cited by in Crossref: 33] [Cited by in F6Publishing: 62] [Article Influence: 2.8] [Reference Citation Analysis]
67 Maldonado L, Hoque MO. Epigenomics and ovarian carcinoma. Biomark Med 2010;4:543-70. [PMID: 20701443 DOI: 10.2217/bmm.10.72] [Cited by in Crossref: 24] [Cited by in F6Publishing: 27] [Article Influence: 2.0] [Reference Citation Analysis]
68 Steffan JS, Thompson LM. Targeting aggregation in the development of therapeutics for the treatment of Huntington's disease and other polyglutamine repeat diseases. Expert Opin Ther Targets 2003;7:201-13. [PMID: 12667098 DOI: 10.1517/14728222.7.2.201] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
69 Johnson AA, Sarthi J, Pirooznia SK, Reube W, Elefant F. Increasing Tip60 HAT levels rescues axonal transport defects and associated behavioral phenotypes in a Drosophila Alzheimer's disease model. J Neurosci 2013;33:7535-47. [PMID: 23616558 DOI: 10.1523/JNEUROSCI.3739-12.2013] [Cited by in Crossref: 44] [Cited by in F6Publishing: 25] [Article Influence: 4.9] [Reference Citation Analysis]
70 Holkova B, Supko JG, Ames MM, Reid JM, Shapiro GI, Perkins EB, Ramakrishnan V, Tombes MB, Honeycutt C, McGovern RM. A phase I trial of vorinostat and alvocidib in patients with relapsed, refractory, or poor prognosis acute leukemia, or refractory anemia with excess blasts-2. Clin Cancer Res. 2013;19:1873-1883. [PMID: 23515411 DOI: 10.1158/1078-0432.ccr-12-2926] [Cited by in Crossref: 22] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
71 Chen H, Hardy TM, Tollefsbol TO. Epigenomics of ovarian cancer and its chemoprevention. Front Genet 2011;2:67. [PMID: 22303362 DOI: 10.3389/fgene.2011.00067] [Cited by in Crossref: 25] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
72 Maehara K, Uekawa N, Isobe K. Effects of histone acetylation on transcriptional regulation of manganese superoxide dismutase gene. Biochemical and Biophysical Research Communications 2002;295:187-92. [DOI: 10.1016/s0006-291x(02)00646-0] [Cited by in Crossref: 35] [Cited by in F6Publishing: 19] [Article Influence: 1.8] [Reference Citation Analysis]
73 Li Q, Liu F, Dang R, Feng C, Xiao R, Hua Y, Wang W, Jia Z, Liu D. Epigenetic modifier trichostatin A enhanced osteogenic differentiation of mesenchymal stem cells by inhibiting NF-κB (p65) DNA binding and promoted periodontal repair in rats. J Cell Physiol 2020;235:9691-701. [PMID: 32399963 DOI: 10.1002/jcp.29780] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
74 Wilson PM, Labonte MJ, Martin SC, Kuwahara ST, El-Khoueiry A, Lenz HJ, Ladner RD. Sustained inhibition of deacetylases is required for the antitumor activity of the histone deactylase inhibitors panobinostat and vorinostat in models of colorectal cancer. Invest New Drugs 2013;31:845-57. [PMID: 23299388 DOI: 10.1007/s10637-012-9914-7] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
75 Matei DE, Nephew KP. Epigenetic therapies for chemoresensitization of epithelial ovarian cancer. Gynecol Oncol. 2010;116:195-201. [PMID: 19854495 DOI: 10.1016/j.ygyno.2009.09.043] [Cited by in Crossref: 71] [Cited by in F6Publishing: 63] [Article Influence: 5.5] [Reference Citation Analysis]
76 Balliu M, Guandalini L, Romanelli MN, D'Amico M, Paoletti F. HDAC-inhibitor (S)-8 disrupts HDAC6-PP1 complex prompting A375 melanoma cell growth arrest and apoptosis. J Cell Mol Med 2015;19:143-54. [PMID: 25376115 DOI: 10.1111/jcmm.12345] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
77 Apuri S, Sokol L. An overview of investigational Histone deacetylase inhibitors (HDACis) for the treatment of non-Hodgkin’s lymphoma. Expert Opinion on Investigational Drugs 2016;25:687-96. [DOI: 10.1517/13543784.2016.1164140] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
78 Wu TY, Hassig C, Wu Y, Ding S, Schultz PG. Design, synthesis, and activity of HDAC inhibitors with a N-formyl hydroxylamine head group. Bioorg Med Chem Lett 2004;14:449-53. [PMID: 14698179 DOI: 10.1016/j.bmcl.2003.10.055] [Cited by in Crossref: 41] [Cited by in F6Publishing: 35] [Article Influence: 2.3] [Reference Citation Analysis]
79 Gao S, Wang Z, Di K, Chang G, Tao L, An L, Wu F, Xu J, Liu Y, Wu Z, Li X, Gao S, Tian J. Melatonin improves the reprogramming efficiency of murine-induced pluripotent stem cells using a secondary inducible system. J Pineal Res 2013;55:31-9. [DOI: 10.1111/jpi.12047] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.2] [Reference Citation Analysis]
80 Archer SY, Meng S, Shei A, Hodin RA. p21(WAF1) is required for butyrate-mediated growth inhibition of human colon cancer cells. Proc Natl Acad Sci U S A. 1998;95:6791-6796. [PMID: 17720775 DOI: 10.1073/pnas.95.12.6791] [Cited by in Crossref: 393] [Cited by in F6Publishing: 372] [Article Influence: 26.2] [Reference Citation Analysis]
81 Duncan HF, Smith AJ, Fleming GJ, Cooper PR. Histone deacetylase inhibitors epigenetically promote reparative events in primary dental pulp cells. Experimental Cell Research 2013;319:1534-43. [DOI: 10.1016/j.yexcr.2013.02.022] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 3.6] [Reference Citation Analysis]
82 Hughes RE. Polyglutamine disease: acetyltransferases awry. Curr Biol 2002;12:R141-3. [PMID: 11864588 DOI: 10.1016/s0960-9822(02)00709-1] [Cited by in Crossref: 23] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
83 Shanmugam G, Rakshit S, Sarkar K. HDAC inhibitors: Targets for tumor therapy, immune modulation and lung diseases. Transl Oncol 2021;16:101312. [PMID: 34922087 DOI: 10.1016/j.tranon.2021.101312] [Reference Citation Analysis]
84 Bommi PV, Dimri M, Sahasrabuddhe AA, Khandekar J, Dimri GP. The polycomb group protein BMI1 is a transcriptional target of HDAC inhibitors. Cell Cycle 2010;9:2663-73. [PMID: 20543557 DOI: 10.4161/cc.9.13.12147] [Cited by in Crossref: 60] [Cited by in F6Publishing: 54] [Article Influence: 5.5] [Reference Citation Analysis]
85 Butt NA, Kumar A, Dhar S, Rimando AM, Akhtar I, Hancock JC, Lage JM, Pound CR, Lewin JR, Gomez CR, Levenson AS. Targeting MTA1/HIF-1α signaling by pterostilbene in combination with histone deacetylase inhibitor attenuates prostate cancer progression. Cancer Med 2017;6:2673-85. [PMID: 29024573 DOI: 10.1002/cam4.1209] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 6.0] [Reference Citation Analysis]
86 Singh AK, Bishayee A, Pandey AK. Targeting Histone Deacetylases with Natural and Synthetic Agents: An Emerging Anticancer Strategy. Nutrients. 2018;10:731. [PMID: 29882797 DOI: 10.3390/nu10060731] [Cited by in Crossref: 79] [Cited by in F6Publishing: 77] [Article Influence: 19.8] [Reference Citation Analysis]
87 Yan B, Claxton D, Huang S, Qiu Y. AML chemoresistance: The role of mutant TP53 subclonal expansion and therapy strategy. Exp Hematol 2020;87:13-9. [PMID: 32569759 DOI: 10.1016/j.exphem.2020.06.003] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
88 Lundh M, Christensen DP, Rasmussen DN, Mascagni P, Dinarello CA, Billestrup N, Grunnet LG, Mandrup-Poulsen T. Lysine deacetylases are produced in pancreatic beta cells and are differentially regulated by proinflammatory cytokines. Diabetologia 2010;53:2569-78. [PMID: 20878317 DOI: 10.1007/s00125-010-1892-8] [Cited by in Crossref: 54] [Cited by in F6Publishing: 46] [Article Influence: 4.5] [Reference Citation Analysis]
89 Zhang J, Zhong Q. Histone deacetylase inhibitors and cell death. Cell Mol Life Sci 2014;71:3885-901. [PMID: 24898083 DOI: 10.1007/s00018-014-1656-6] [Cited by in Crossref: 112] [Cited by in F6Publishing: 106] [Article Influence: 14.0] [Reference Citation Analysis]
90 Di Bernardo G, Squillaro T, Dell’aversana C, Miceli M, Cipollaro M, Cascino A, Altucci L, Galderisi U. Histone Deacetylase Inhibitors Promote Apoptosis and Senescence in Human Mesenchymal Stem Cells. Stem Cells and Development 2009;18:573-82. [DOI: 10.1089/scd.2008.0172] [Cited by in Crossref: 48] [Cited by in F6Publishing: 45] [Article Influence: 3.7] [Reference Citation Analysis]
91 Tabe Y, Konopleva M, Contractor R, Munsell M, Schober WD, Jin L, Tsutsumi-Ishii Y, Nagaoka I, Igari J, Andreeff M. Up-regulation of MDR1 and induction of doxorubicin resistance by histone deacetylase inhibitor depsipeptide (FK228) and ATRA in acute promyelocytic leukemia cells. Blood 2006;107:1546-54. [PMID: 16223781 DOI: 10.1182/blood-2004-10-4126] [Cited by in Crossref: 65] [Cited by in F6Publishing: 66] [Article Influence: 3.8] [Reference Citation Analysis]
92 Kurdistani SK. Histone modifications as markers of cancer prognosis: a cellular view. Br J Cancer 2007;97:1-5. [PMID: 17592497 DOI: 10.1038/sj.bjc.6603844] [Cited by in Crossref: 85] [Cited by in F6Publishing: 77] [Article Influence: 5.7] [Reference Citation Analysis]
93 Wilcox RA. Cutaneous T-cell lymphoma: 2014 Update on diagnosis, risk-stratification, and management: Cutaneous T-Cell Lymphoma. Am J Hematol 2014;89:837-51. [DOI: 10.1002/ajh.23756] [Cited by in Crossref: 41] [Cited by in F6Publishing: 41] [Article Influence: 5.1] [Reference Citation Analysis]
94 Mishra N, Reilly CM, Brown DR, Ruiz P, Gilkeson GS. Histone deacetylase inhibitors modulate renal disease in the MRL-lpr/lpr mouse. J Clin Invest. 2003;111:539-552. [PMID: 12588892 DOI: 10.1172/jci200316153] [Cited by in Crossref: 28] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
95 Kuljaca S, Liu T, Tee AE, Haber M, Norris MD, Dwarte T, Marshall GM. Enhancing the anti-angiogenic action of histone deacetylase inhibitors. Mol Cancer 2007;6:68. [PMID: 17958916 DOI: 10.1186/1476-4598-6-68] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 1.4] [Reference Citation Analysis]
96 Watanabe T. Investigational histone deacetylase inhibitors for non-Hodgkin lymphomas. Expert Opin Investig Drugs 2010;19:1113-27. [PMID: 20649502 DOI: 10.1517/13543784.2010.504710] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
97 Kawai H, Li H, Avraham S, Jiang S, Avraham HK. Overexpression of histone deacetylase HDAC1 modulates breast cancer progression by negative regulation of estrogen receptor ? Int J Cancer 2003;107:353-8. [DOI: 10.1002/ijc.11403] [Cited by in Crossref: 147] [Cited by in F6Publishing: 134] [Article Influence: 7.7] [Reference Citation Analysis]
98 Sadikovic B, Rodenhiser DI. Epigenetic Mediation of Environmental Exposures to Polycyclic Aromatic Hydrocarbons. In: Sahu SC, editor. Toxicology and Epigenetics. Chichester: John Wiley & Sons, Ltd; 2012. pp. 111-27. [DOI: 10.1002/9781118349045.ch6] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
99 Trus MR, Yang L, Suarez Saiz F, Bordeleau L, Jurisica I, Minden MD. The histone deacetylase inhibitor valproic acid alters sensitivity towards all trans retinoic acid in acute myeloblastic leukemia cells. Leukemia 2005;19:1161-8. [DOI: 10.1038/sj.leu.2403773] [Cited by in Crossref: 44] [Cited by in F6Publishing: 41] [Article Influence: 2.6] [Reference Citation Analysis]
100 Arif M, Senapati P, Shandilya J, Kundu TK. Protein lysine acetylation in cellular function and its role in cancer manifestation. Biochim Biophys Acta 2010;1799:702-16. [PMID: 20965294 DOI: 10.1016/j.bbagrm.2010.10.002] [Cited by in Crossref: 34] [Cited by in F6Publishing: 26] [Article Influence: 2.8] [Reference Citation Analysis]
101 McClure JJ, Zhang C, Inks ES, Peterson YK, Li J, Chou CJ. Development of Allosteric Hydrazide-Containing Class I Histone Deacetylase Inhibitors for Use in Acute Myeloid Leukemia. J Med Chem 2016;59:9942-59. [PMID: 27754681 DOI: 10.1021/acs.jmedchem.6b01385] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 5.3] [Reference Citation Analysis]
102 Miles Prince H, Bishton M, Harrison S. The potential of histone deacetylase inhibitors for the treatment of multiple myeloma. Leukemia & Lymphoma 2009;49:385-7. [DOI: 10.1080/10428190801950058] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
103 Moore PS, Barbi S, Donadelli M, Costanzo C, Bassi C, Palmieri M, Scarpa A. Gene expression profiling after treatment with the histone deacetylase inhibitor trichostatin A reveals altered expression of both pro- and anti-apoptotic genes in pancreatic adenocarcinoma cells. Biochim Biophys Acta. 2004;1693:167-176. [PMID: 15363630 DOI: 10.1016/j.bbamcr.2004.07.001] [Cited by in Crossref: 54] [Cited by in F6Publishing: 55] [Article Influence: 3.0] [Reference Citation Analysis]
104 Park S, Park JA, Kim YE, Song S, Kwon HJ, Lee Y. Suberoylanilide hydroxamic acid induces ROS-mediated cleavage of HSP90 in leukemia cells. Cell Stress Chaperones 2015;20:149-57. [PMID: 25119188 DOI: 10.1007/s12192-014-0533-4] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
105 Perona M, Rodríguez C, Carpano M, Thomasz L, Nievas S, Olivera M, Thorp S, Curotto P, Pozzi E, Kahl S, Pisarev M, Juvenal G, Dagrosa A. Improvement of the boron neutron capture therapy (BNCT) by the previous administration of the histone deacetylase inhibitor sodium butyrate for the treatment of thyroid carcinoma. Radiat Environ Biophys 2013;52:363-73. [PMID: 23636505 DOI: 10.1007/s00411-013-0470-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
106 Bolden JE, Shi W, Jankowski K, Kan CY, Cluse L, Martin BP, MacKenzie KL, Smyth GK, Johnstone RW. HDAC inhibitors induce tumor-cell-selective pro-apoptotic transcriptional responses. Cell Death Dis. 2013;4:e519. [PMID: 23449455 DOI: 10.1038/cddis.2013.9] [Cited by in Crossref: 121] [Cited by in F6Publishing: 110] [Article Influence: 13.4] [Reference Citation Analysis]
107 Chen JS, Faller DV. Histone deacetylase inhibition-mediated post-translational elevation of p27KIP1 protein levels is required for G1 arrest in fibroblasts. J Cell Physiol 2005;202:87-99. [DOI: 10.1002/jcp.20094] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 1.4] [Reference Citation Analysis]
108 Minucci S, Pelicci PG. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer. 2006;6:38-51. [PMID: 16397526 DOI: 10.1038/nrc1779] [Cited by in Crossref: 1600] [Cited by in F6Publishing: 1500] [Article Influence: 100.0] [Reference Citation Analysis]
109 Wilson-Edell KA, Yevtushenko MA, Rothschild DE, Rogers AN, Benz CC. mTORC1/C2 and pan-HDAC inhibitors synergistically impair breast cancer growth by convergent AKT and polysome inhibiting mechanisms. Breast Cancer Res Treat. 2014;144:287-298. [PMID: 24562770 DOI: 10.1007/s10549-014-2877-y] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 4.3] [Reference Citation Analysis]
110 Sasakawa Y, Naoe Y, Sogo N, Inoue T, Sasakawa T, Matsuo M, Manda T, Mutoh S. Marker genes to predict sensitivity to FK228, a histone deacetylase inhibitor. Biochem Pharmacol 2005;69:603-16. [PMID: 15670579 DOI: 10.1016/j.bcp.2004.11.008] [Cited by in Crossref: 39] [Cited by in F6Publishing: 39] [Article Influence: 2.2] [Reference Citation Analysis]
111 Magner WJ, Tomasi TB. Apoptotic and necrotic cells induced by different agents vary in their expression of MHC and costimulatory genes. Mol Immunol 2005;42:1033-42. [PMID: 15829293 DOI: 10.1016/j.molimm.2004.09.030] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 0.8] [Reference Citation Analysis]
112 Melnick A, Licht JD. Histone deacetylases as therapeutic targets in hematologic malignancies: . Current Opinion in Hematology 2002;9:322-32. [DOI: 10.1097/00062752-200207000-00010] [Cited by in Crossref: 87] [Cited by in F6Publishing: 82] [Article Influence: 4.4] [Reference Citation Analysis]
113 Lewis CS, Voelkel-Johnson C, Smith CD. Suppression of c-Myc and RRM2 expression in pancreatic cancer cells by the sphingosine kinase-2 inhibitor ABC294640. Oncotarget 2016;7:60181-92. [PMID: 27517489 DOI: 10.18632/oncotarget.11112] [Cited by in Crossref: 23] [Cited by in F6Publishing: 26] [Article Influence: 5.8] [Reference Citation Analysis]
114 Chen Z, Lopez-Ramos DA, Yoshihara E, Maeda Y, Masutani H, Sugie K, Maeda M, Yodoi J. Thioredoxin-binding protein-2 (TBP-2/VDUP1/TXNIP) regulates T-cell sensitivity to glucocorticoid during HTLV-I-induced transformation. Leukemia 2011;25:440-8. [PMID: 21151022 DOI: 10.1038/leu.2010.286] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.4] [Reference Citation Analysis]
115 Kirschbaum M, Frankel P, Popplewell L, Zain J, Delioukina M, Pullarkat V, Matsuoka D, Pulone B, Rotter AJ, Espinoza-Delgado I. Phase II study of vorinostat for treatment of relapsed or refractory indolent non-Hodgkin’s lymphoma and mantle cell lymphoma. J Clin Oncol. 2011;29:1198-1203. [PMID: 21300924 DOI: 10.1200/jco.2010.32.1398] [Cited by in Crossref: 151] [Cited by in F6Publishing: 59] [Article Influence: 13.7] [Reference Citation Analysis]
116 Jia Y, Guo M. Epigenetic changes in colorectal cancer. Chin J Cancer. 2013;32:21-30. [PMID: 22059907 DOI: 10.5732/cjc.011.10245] [Cited by in Crossref: 38] [Cited by in F6Publishing: 37] [Article Influence: 3.5] [Reference Citation Analysis]
117 Tang YA, Wen WL, Chang JW, Wei TT, Tan YH, Salunke S, Chen CT, Chen CS, Wang YC. A novel histone deacetylase inhibitor exhibits antitumor activity via apoptosis induction, F-actin disruption and gene acetylation in lung cancer. PLoS One 2010;5:e12417. [PMID: 20856855 DOI: 10.1371/journal.pone.0012417] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 2.8] [Reference Citation Analysis]
118 Jung JH, Park JH, Lee S, To TK, Kim JM, Seki M, Park CM. The cold signaling attenuator HIGH EXPRESSION OF OSMOTICALLY RESPONSIVE GENE1 activates FLOWERING LOCUS C transcription via chromatin remodeling under short-term cold stress in Arabidopsis. Plant Cell 2013;25:4378-90. [PMID: 24220632 DOI: 10.1105/tpc.113.118364] [Cited by in Crossref: 62] [Cited by in F6Publishing: 57] [Article Influence: 6.9] [Reference Citation Analysis]
119 Kuo WY, Wu CY, Hwu L, Lee JS, Tsai CH, Lin KP, Wang HE, Chou TY, Tsai CM, Gelovani J, Liu RS. Enhancement of tumor initiation and expression of KCNMA1, MORF4L2 and ASPM genes in the adenocarcinoma of lung xenograft after vorinostat treatment. Oncotarget 2015;6:8663-75. [PMID: 25796627 DOI: 10.18632/oncotarget.3536] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
120 Sur I, Taipale J. The role of enhancers in cancer. Nat Rev Cancer 2016;16:483-93. [PMID: 27364481 DOI: 10.1038/nrc.2016.62] [Cited by in Crossref: 187] [Cited by in F6Publishing: 153] [Article Influence: 31.2] [Reference Citation Analysis]
121 Prashad N. miR-665 targets c-MYC and HDAC8 to inhibit murine neuroblastoma cell growth. Oncotarget 2018;9:33186-201. [PMID: 30237861 DOI: 10.18632/oncotarget.26046] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
122 Kolesar JM, Traynor AM, Holen KD, Hoang T, Seo S, Kim K, Alberti D, Espinoza-Delgado I, Wright JJ, Wilding G, Bailey HH, Schelman WR. Vorinostat in combination with bortezomib in patients with advanced malignancies directly alters transcription of target genes. Cancer Chemother Pharmacol 2013;72:661-7. [PMID: 23903894 DOI: 10.1007/s00280-013-2242-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
123 Tong A, Zhang H, Li Z, Gou L, Wang Z, Wei H, Tang M, Liang S, Chen L, Huang C, Wei Y. Proteomic analysis of liver cancer cells treated with suberonylanilide hydroxamic acid. Cancer Chemother Pharmacol 2008;61:791-802. [DOI: 10.1007/s00280-007-0536-2] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 2.1] [Reference Citation Analysis]
124 Zagni C, Pistarà V, Oliveira LA, Castilho RM, Romeo G, Chiacchio U, Rescifina A. Serendipitous discovery of potent human head and neck squamous cell carcinoma anti-cancer molecules: A fortunate failure of a rational molecular design. Eur J Med Chem 2017;141:188-96. [PMID: 29031066 DOI: 10.1016/j.ejmech.2017.09.075] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
125 Domingo-domènech J, Pippa R, Tápia M, Gascón P, Bachs O, Bosch M. Inactivation of NF-κB by proteasome inhibition contributes to increased apoptosis induced by histone deacetylase inhibitors in human breast cancer cells. Breast Cancer Res Treat 2008;112:53-62. [DOI: 10.1007/s10549-007-9837-8] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 2.1] [Reference Citation Analysis]
126 Bergougnoux A, Petit A, Knabe L, Bribes E, Chiron R, De Sario A, Claustres M, Molinari N, Vachier I, Taulan-Cadars M, Bourdin A. The HDAC inhibitor SAHA does not rescue CFTR membrane expression in Cystic Fibrosis. Int J Biochem Cell Biol 2017;88:124-32. [PMID: 28478266 DOI: 10.1016/j.biocel.2017.05.002] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
127 Sato A, Asano T, Horiguchi A, Ito K, Sumitomo M, Asano T. Combination of suberoylanilide hydroxamic acid and ritonavir is effective against renal cancer cells. Urology 2010;76:764.e7-13. [PMID: 20630573 DOI: 10.1016/j.urology.2010.04.042] [Cited by in Crossref: 7] [Cited by in F6Publishing: 12] [Article Influence: 0.6] [Reference Citation Analysis]
128 Johnstone RW, Licht JD. Histone deacetylase inhibitors in cancer therapy: is transcription the primary target? Cancer Cell. 2003;4:13-18. [PMID: 12892709 DOI: 10.1016/s1535-6108(03)00165-x] [Cited by in Crossref: 340] [Cited by in F6Publishing: 134] [Article Influence: 18.9] [Reference Citation Analysis]
129 Fang JY, Lu YY. Effects of histone acetylation and DNA methylation on p21WAF1 regulation. World J Gastroenterol 2002; 8(3): 400-405 [PMID: 12046058 DOI: 10.3748/wjg.v8.i3.400] [Cited by in CrossRef: 64] [Cited by in F6Publishing: 67] [Article Influence: 3.2] [Reference Citation Analysis]
130 Tabeshmehr P, Husnain HK, Salmannejad M, Sani M, Hosseini SM, Khorraminejad Shirazi MH. Nicorandil potentiates sodium butyrate induced preconditioning of neurons and enhances their survival upon subsequent treatment with H2O2. Transl Neurodegener 2017;6:29. [PMID: 29093814 DOI: 10.1186/s40035-017-0097-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
131 Qian DZ, Wei Y, Wang X, Kato Y, Cheng L, Pili R. Antitumor activity of the histone deacetylase inhibitor MS-275 in prostate cancer models. Prostate 2007;67:1182-93. [DOI: 10.1002/pros.20611] [Cited by in Crossref: 47] [Cited by in F6Publishing: 39] [Article Influence: 3.1] [Reference Citation Analysis]
132 Khandelwal A, Gediya L, Njar V. MS-275 synergistically enhances the growth inhibitory effects of RAMBA VN/66-1 in hormone-insensitive PC-3 prostate cancer cells and tumours. Br J Cancer 2008;98:1234-43. [PMID: 18349838 DOI: 10.1038/sj.bjc.6604295] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 0.9] [Reference Citation Analysis]
133 Espinosa JM, Verdun RE, Emerson BM. p53 functions through stress- and promoter-specific recruitment of transcription initiation components before and after DNA damage. Mol Cell 2003;12:1015-27. [PMID: 14580351 DOI: 10.1016/s1097-2765(03)00359-9] [Cited by in Crossref: 186] [Cited by in F6Publishing: 129] [Article Influence: 9.8] [Reference Citation Analysis]
134 Hu Y, Zhang L, He S, Huang M, Tan J, Zhao L, Yan S, Li H, Zhou K, Liang Y, Li L. Cold stress selectively unsilences tandem repeats in heterochromatin associated with accumulation of H3K9ac. Plant Cell Environ 2012;35:2130-42. [PMID: 22616903 DOI: 10.1111/j.1365-3040.2012.02541.x] [Cited by in Crossref: 47] [Cited by in F6Publishing: 37] [Article Influence: 4.7] [Reference Citation Analysis]
135 Kadia TM, Yang H, Ferrajoli A, Maddipotti S, Schroeder C, Madden TL, Holleran JL, Egorin MJ, Ravandi F, Thomas DA, Newsome W, Sanchez-Gonzalez B, Zwiebel JA, Espinoza-Delgado I, Kantarjian HM, Garcia-Manero G. A phase I study of vorinostat in combination with idarubicin in relapsed or refractory leukaemia. Br J Haematol 2010;150:72-82. [PMID: 20456355 DOI: 10.1111/j.1365-2141.2010.08211.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 17] [Article Influence: 0.3] [Reference Citation Analysis]
136 Myzak MC, Hardin K, Wang R, Dashwood RH, Ho E. Sulforaphane inhibits histone deacetylase activity in BPH-1, LnCaP and PC-3 prostate epithelial cells. Carcinogenesis. 2006;27:811-819. [PMID: 16280330 DOI: 10.1093/carcin/bgi265] [Cited by in Crossref: 210] [Cited by in F6Publishing: 187] [Article Influence: 12.4] [Reference Citation Analysis]
137 Dickinson M, Johnstone RW, Prince HM. Histone deacetylase inhibitors: potential targets responsible for their anti-cancer effect. Invest New Drugs 2010;28 Suppl 1:S3-20. [PMID: 21161327 DOI: 10.1007/s10637-010-9596-y] [Cited by in Crossref: 99] [Cited by in F6Publishing: 93] [Article Influence: 8.3] [Reference Citation Analysis]
138 Sarfstein R, Bruchim I, Fishman A, Werner H. The mechanism of action of the histone deacetylase inhibitor vorinostat involves interaction with the insulin-like growth factor signaling pathway. PLoS One. 2011;6:e24468. [PMID: 21931726 DOI: 10.1371/journal.pone.0024468] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 2.5] [Reference Citation Analysis]
139 Wilcox RA. Cutaneous T-cell lymphoma: 2016 update on diagnosis, risk-stratification, and management. Am J Hematol 2016;91:151-65. [PMID: 26607183 DOI: 10.1002/ajh.24233] [Cited by in Crossref: 72] [Cited by in F6Publishing: 60] [Article Influence: 10.3] [Reference Citation Analysis]
140 Glozak MA, Seto E. Histone deacetylases and cancer. Oncogene. 2007;26:5420-5432. [PMID: 17694083 DOI: 10.1038/sj.onc.1210610] [Cited by in Crossref: 648] [Cited by in F6Publishing: 618] [Article Influence: 43.2] [Reference Citation Analysis]
141 Ruefli AA, Ausserlechner MJ, Bernhard D, Sutton VR, Tainton KM, Kofler R, Smyth MJ, Johnstone RW. The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species. Proc Natl Acad Sci U S A 2001;98:10833-8. [PMID: 11535817 DOI: 10.1073/pnas.191208598] [Cited by in Crossref: 362] [Cited by in F6Publishing: 314] [Article Influence: 17.2] [Reference Citation Analysis]
142 Canes D, Chiang GJ, Billmeyer BR, Austin CA, Kosakowski M, Rieger-Christ KM, Libertino JA, Summerhayes IC. Histone deacetylase inhibitors upregulate plakoglobin expression in bladder carcinoma cells and display antineoplastic activity in vitro and in vivo. Int J Cancer 2005;113:841-8. [PMID: 15499627 DOI: 10.1002/ijc.20634] [Cited by in Crossref: 36] [Cited by in F6Publishing: 30] [Article Influence: 2.1] [Reference Citation Analysis]
143 Denlinger CE, Keller MD, Mayo MW, Broad RM, Jones DR. Combined proteasome and histone deacetylase inhibition in non-small cell lung cancer. J Thorac Cardiovasc Surg. 2004;127:1078-1086. [PMID: 15052205 DOI: 10.1016/s0022-5223(03)01321-7] [Cited by in Crossref: 58] [Cited by in F6Publishing: 17] [Article Influence: 3.2] [Reference Citation Analysis]
144 Sanda T, Okamoto T, Uchida Y, Nakagawa H, Iida S, Kayukawa S, Suzuki T, Oshizawa T, Suzuki T, Miyata N, Ueda R. Proteome analyses of the growth inhibitory effects of NCH-51, a novel histone deacetylase inhibitor, on lymphoid malignant cells. Leukemia 2007;21:2344-53. [PMID: 17690692 DOI: 10.1038/sj.leu.2404902] [Cited by in Crossref: 36] [Cited by in F6Publishing: 30] [Article Influence: 2.4] [Reference Citation Analysis]
145 Urbinati G, Marsaud V, Nicolas V, Vergnaud-Gauduchon J, Renoir JM. Liposomal trichostatin A: therapeutic potential in hormone-dependent and -independent breast cancer xenograft models. Horm Mol Biol Clin Investig 2011;6:215-25. [PMID: 25961258 DOI: 10.1515/HMBCI.2011.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
146 Patnaik S, Anupriya. Drugs Targeting Epigenetic Modifications and Plausible Therapeutic Strategies Against Colorectal Cancer. Front Pharmacol. 2019;10:588. [PMID: 31244652 DOI: 10.3389/fphar.2019.00588] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 11.3] [Reference Citation Analysis]
147 Rodrigues DA, Ferreira-Silva GÀ, Ferreira AC, Fernandes RA, Kwee JK, Sant'Anna CM, Ionta M, Fraga CA. Design, Synthesis, and Pharmacological Evaluation of Novel N-Acylhydrazone Derivatives as Potent Histone Deacetylase 6/8 Dual Inhibitors. J Med Chem 2016;59:655-70. [PMID: 26705137 DOI: 10.1021/acs.jmedchem.5b01525] [Cited by in Crossref: 54] [Cited by in F6Publishing: 48] [Article Influence: 9.0] [Reference Citation Analysis]
148 Kirschbaum MH, Goldman BH, Zain JM, Cook JR, Rimsza LM, Forman SJ, Fisher RI. A phase 2 study of vorinostat for treatment of relapsed or refractory Hodgkin lymphoma: Southwest Oncology Group Study S0517. Leuk Lymphoma 2012;53:259-62. [PMID: 21823829 DOI: 10.3109/10428194.2011.608448] [Cited by in Crossref: 52] [Cited by in F6Publishing: 47] [Article Influence: 4.7] [Reference Citation Analysis]
149 Hamblett CL, Methot JL, Mampreian DM, Sloman DL, Stanton MG, Kral AM, Fleming JC, Cruz JC, Chenard M, Ozerova N, Hitz AM, Wang H, Deshmukh SV, Nazef N, Harsch A, Hughes B, Dahlberg WK, Szewczak AA, Middleton RE, Mosley RT, Secrist JP, Miller TA. The discovery of 6-amino nicotinamides as potent and selective histone deacetylase inhibitors. Bioorganic & Medicinal Chemistry Letters 2007;17:5300-9. [DOI: 10.1016/j.bmcl.2007.08.023] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 2.1] [Reference Citation Analysis]
150 Adhikari N, Jha T, Ghosh B. Dissecting Histone Deacetylase 3 in Multiple Disease Conditions: Selective Inhibition as a Promising Therapeutic Strategy. J Med Chem 2021;64:8827-69. [PMID: 34161101 DOI: 10.1021/acs.jmedchem.0c01676] [Reference Citation Analysis]
151 Shapiro GI. Cyclin-dependent kinase pathways as targets for cancer treatment. J Clin Oncol. 2006;24:1770-1783. [PMID: 16603719 DOI: 10.1200/jco.2005.03.7689] [Cited by in Crossref: 690] [Cited by in F6Publishing: 292] [Article Influence: 43.1] [Reference Citation Analysis]
152 Mai A, Massa S, Rotili D, Cerbara I, Valente S, Pezzi R, Simeoni S, Ragno R. Histone deacetylation in epigenetics: an attractive target for anticancer therapy. Med Res Rev. 2005;25:261-309. [PMID: 15717297 DOI: 10.1002/med.20024] [Cited by in Crossref: 226] [Cited by in F6Publishing: 213] [Article Influence: 13.3] [Reference Citation Analysis]
153 Narita T, Ito S, Higashijima Y, Chu WK, Neumann K, Walter J, Satpathy S, Liebner T, Hamilton WB, Maskey E, Prus G, Shibata M, Iesmantavicius V, Brickman JM, Anastassiadis K, Koseki H, Choudhary C. Enhancers are activated by p300/CBP activity-dependent PIC assembly, RNAPII recruitment, and pause release. Mol Cell 2021;81:2166-2182.e6. [PMID: 33765415 DOI: 10.1016/j.molcel.2021.03.008] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
154 Sausville EA. Complexities in the development of cyclin-dependent kinase inhibitor drugs. Trends in Molecular Medicine 2002;8:S32-7. [DOI: 10.1016/s1471-4914(02)02308-0] [Cited by in Crossref: 107] [Cited by in F6Publishing: 21] [Article Influence: 5.4] [Reference Citation Analysis]
155 Tran TH, Ramasamy T, Truong DH, Shin BS, Choi HG, Yong CS, Kim JO. Development of vorinostat-loaded solid lipid nanoparticles to enhance pharmacokinetics and efficacy against multidrug-resistant cancer cells. Pharm Res 2014;31:1978-88. [PMID: 24562809 DOI: 10.1007/s11095-014-1300-z] [Cited by in Crossref: 50] [Cited by in F6Publishing: 48] [Article Influence: 6.3] [Reference Citation Analysis]
156 Kim IS, Kim H, Kim M, Kwon J, Kim E, Hwang H, Oh P, Lim ST, Sohn M, Kim DH, Jeong H. Synthesis and Evaluation of 2-[ 18 F]Fluoroethyltriazolesuberohydroxamine Acid for Histone Deacetylase in a Tumor Model as a Positron Emission Tomography Radiotracer. Cancer Biotherapy and Radiopharmaceuticals 2018;33:52-9. [DOI: 10.1089/cbr.2017.2320] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
157 Duncan HF, Smith AJ, Fleming GJ, Cooper PR. Histone Deacetylase Inhibitors Induced Differentiation and Accelerated Mineralization of Pulp-derived Cells. Journal of Endodontics 2012;38:339-45. [DOI: 10.1016/j.joen.2011.12.014] [Cited by in Crossref: 38] [Cited by in F6Publishing: 32] [Article Influence: 3.8] [Reference Citation Analysis]
158 Nimmanapalli R, Fuino L, Stobaugh C, Richon V, Bhalla K. Cotreatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances imatinib-induced apoptosis of Bcr-Abl–positive human acute leukemia cells. Blood 2003;101:3236-9. [DOI: 10.1182/blood-2002-08-2675] [Cited by in Crossref: 174] [Cited by in F6Publishing: 148] [Article Influence: 9.2] [Reference Citation Analysis]
159 Rossi M, Demidov ON, Anderson CW, Appella E, Mazur SJ. Induction of PPM1D following DNA-damaging treatments through a conserved p53 response element coincides with a shift in the use of transcription initiation sites. Nucleic Acids Res 2008;36:7168-80. [PMID: 19015127 DOI: 10.1093/nar/gkn888] [Cited by in Crossref: 42] [Cited by in F6Publishing: 40] [Article Influence: 3.0] [Reference Citation Analysis]
160 Gomes NP, Espinosa JM. Disparate chromatin landscapes and kinetics of inactivation impact differential regulation of p53 target genes. Cell Cycle 2010;9:3428-37. [PMID: 20818159 DOI: 10.4161/cc.9.17.12998] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
161 Fakhry H, Miyamoto T, Kashima H, Suzuki A, Ke H, Konishi I, Shiozawa T. Immunohistochemical detection of histone deacetylases in endometrial carcinoma: involvement of histone deacetylase 2 in the proliferation of endometrial carcinoma cells. Hum Pathol 2010;41:848-58. [PMID: 20178884 DOI: 10.1016/j.humpath.2009.11.012] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 1.7] [Reference Citation Analysis]
162 Vávrová J, Řezáčová M, Osterreicher J. Inhibitors of histone-deacetylase. J Appl Biomed 2005;3:115-21. [DOI: 10.32725/jab.2005.014] [Reference Citation Analysis]
163 Piekarz RL, Bates SE. Epigenetic modifiers: basic understanding and clinical development. Clin Cancer Res. 2009;15:3918-3926. [PMID: 19509169 DOI: 10.1158/1078-0432.ccr-08-2788] [Cited by in Crossref: 105] [Cited by in F6Publishing: 53] [Article Influence: 8.1] [Reference Citation Analysis]
164 He Y, Cai C, Tang D, Sun S, Li H. Effect of histone deacetylase inhibitors trichostatin A and valproic acid on hair cell regeneration in zebrafish lateral line neuromasts. Front Cell Neurosci 2014;8:382. [PMID: 25431550 DOI: 10.3389/fncel.2014.00382] [Cited by in Crossref: 20] [Cited by in F6Publishing: 25] [Article Influence: 2.5] [Reference Citation Analysis]
165 Nishida K, Komiyama T, Miyazawa S, Shen ZN, Furumatsu T, Doi H, Yoshida A, Yamana J, Yamamura M, Ninomiya Y. Histone deacetylase inhibitor suppression of autoantibody-mediated arthritis in mice via regulation of p16INK4a and p21(WAF1/Cip1) expression. Arthritis Rheum. 2004;50:3365-3376. [PMID: 15476220 DOI: 10.1002/art.20709] [Cited by in Crossref: 151] [Cited by in F6Publishing: 143] [Article Influence: 8.4] [Reference Citation Analysis]
166 Ammanamanchi S, Brattain MG. Sp3 is a transcriptional repressor of transforming growth factor-beta receptors. J Biol Chem. 2001;276:3348-3352. [PMID: 11027677 DOI: 10.1074/jbc.m305961200] [Cited by in Crossref: 96] [Cited by in F6Publishing: 43] [Article Influence: 4.4] [Reference Citation Analysis]
167 Sinn DI, Kim SJ, Chu K, Jung KH, Lee ST, Song EC, Kim JM, Park DK, Kun Lee S, Kim M, Roh JK. Valproic acid-mediated neuroprotection in intracerebral hemorrhage via histone deacetylase inhibition and transcriptional activation. Neurobiol Dis 2007;26:464-72. [PMID: 17398106 DOI: 10.1016/j.nbd.2007.02.006] [Cited by in Crossref: 126] [Cited by in F6Publishing: 128] [Article Influence: 8.4] [Reference Citation Analysis]
168 Ciaffaglione V, Modica MN, Pittalà V, Romeo G, Salerno L, Intagliata S. Mutual Prodrugs of 5-Fluorouracil: From a Classic Chemotherapeutic Agent to Novel Potential Anticancer Drugs. ChemMedChem 2021. [PMID: 34415107 DOI: 10.1002/cmdc.202100473] [Reference Citation Analysis]
169 Patella F, Lucotti S, Rizzo M, Evangelista M, Rainaldi G. The RNA Activator ds-p21 Potentiates the Cytotoxicity Induced by Fludarabine in Dohh2 Cells. Oligonucleotides 2011;21:39-45. [DOI: 10.1089/oli.2010.0249] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
170 Zhang Z, Qin X, Tong N, Zhao X, Gong Y, Shi Y, Wu X. Valproic acid-mediated neuroprotection in retinal ischemia injury via histone deacetylase inhibition and transcriptional activation. Experimental Eye Research 2012;94:98-108. [DOI: 10.1016/j.exer.2011.11.013] [Cited by in Crossref: 38] [Cited by in F6Publishing: 35] [Article Influence: 3.8] [Reference Citation Analysis]
171 Li Y, Kao GD, Garcia BA, Shabanowitz J, Hunt DF, Qin J, Phelan C, Lazar MA. A novel histone deacetylase pathway regulates mitosis by modulating Aurora B kinase activity. Genes Dev. 2006;20:2566-2579. [PMID: 16980585 DOI: 10.1101/gad.1455006] [Cited by in Crossref: 123] [Cited by in F6Publishing: 119] [Article Influence: 7.7] [Reference Citation Analysis]
172 Martin P, Leonard JP. Novel therapeutic targets in mantle cell lymphoma. Expert Opin Ther Targets 2007;11:929-40. [PMID: 17614761 DOI: 10.1517/14728222.11.7.929] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
173 Sultana F, Manasa KL, Shaik SP, Bonam SR, Kamal A. Zinc Dependent Histone Deacetylase Inhibitors in Cancer Therapeutics: Recent Update. Curr Med Chem 2019;26:7212-80. [PMID: 29852860 DOI: 10.2174/0929867325666180530094120] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
174 Lee S, Park JR, Seo MS, Roh KH, Park SB, Hwang JW, Sun B, Seo K, Lee YS, Kang SK, Jung JW, Kang KS. Histone deacetylase inhibitors decrease proliferation potential and multilineage differentiation capability of human mesenchymal stem cells. Cell Prolif 2009;42:711-20. [PMID: 19689470 DOI: 10.1111/j.1365-2184.2009.00633.x] [Cited by in Crossref: 107] [Cited by in F6Publishing: 102] [Article Influence: 8.2] [Reference Citation Analysis]
175 O'connor OA. Clinical experience with the novel histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid) in patients with relapsed lymphoma. Br J Cancer 2006;95:S7-S12. [DOI: 10.1038/sj.bjc.6603464] [Cited by in Crossref: 23] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
176 Singh A, Gupta S, Sachan M. Epigenetic Biomarkers in the Management of Ovarian Cancer: Current Prospectives. Front Cell Dev Biol 2019;7:182. [PMID: 31608277 DOI: 10.3389/fcell.2019.00182] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 6.0] [Reference Citation Analysis]
177 Protzel C, Hakenberg OW. Emerging apoptosis agonists for bladder cancer. Expert Opin Emerg Drugs 2009;14:607-18. [PMID: 19772372 DOI: 10.1517/14728210903251708] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
178 Yamashita Y, Shimada M, Harimoto N, Rikimaru T, Shirabe K, Tanaka S, Sugimachi K. Histone deacetylase inhibitor trichostatin A induces cell-cycle arrest/apoptosis and hepatocyte differentiation in human hepatoma cells. Int J Cancer. 2003;103:572-576. [PMID: 12494463 DOI: 10.1002/ijc.10699] [Cited by in Crossref: 109] [Cited by in F6Publishing: 104] [Article Influence: 5.7] [Reference Citation Analysis]
179 Kolli RT, Glenn TC, Brown BT, Kaur SP, Barnett LM, Lash LH, Cummings BS. Bromate-induced Changes in p21 DNA Methylation and Histone Acetylation in Renal Cells. Toxicol Sci 2019;168:460-73. [PMID: 30649504 DOI: 10.1093/toxsci/kfz016] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
180 Westendorf JJ, Zaidi SK, Cascino JE, Kahler R, van Wijnen AJ, Lian JB, Yoshida M, Stein GS, Li X. Runx2 (Cbfa1, AML-3) interacts with histone deacetylase 6 and represses the p21(CIP1/WAF1) promoter. Mol Cell Biol 2002;22:7982-92. [PMID: 12391164 DOI: 10.1128/MCB.22.22.7982-7992.2002] [Cited by in Crossref: 246] [Cited by in F6Publishing: 122] [Article Influence: 12.3] [Reference Citation Analysis]
181 Kristeleit R, Stimson L, Workman P, Aherne W. Histone modification enzymes: novel targets for cancer drugs. Expert Opinion on Emerging Drugs 2005;9:135-54. [DOI: 10.1517/14728214.9.1.135] [Cited by in Crossref: 61] [Cited by in F6Publishing: 31] [Article Influence: 3.6] [Reference Citation Analysis]
182 Makki MS, Heinzel T, Englert C. TSA downregulates Wilms tumor gene 1 (Wt1) expression at multiple levels. Nucleic Acids Res 2008;36:4067-78. [PMID: 18535006 DOI: 10.1093/nar/gkn356] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 1.9] [Reference Citation Analysis]
183 Zhao J, Huang WG, He J, Tan H, Liao QJ, Su Q. Diallyl disulfide suppresses growth of HL-60 cell through increasing histone acetylation and p21WAF1 expression in vivo and in vitro. Acta Pharmacol Sin 2006;27:1459-66. [PMID: 17049122 DOI: 10.1111/j.1745-7254.2006.00433.x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 1.6] [Reference Citation Analysis]
184 Shoshan MC, Linder S. Target specificity and off-target effects as determinants of cancer drug efficacy. Expert Opin Drug Metab Toxicol 2008;4:273-80. [PMID: 18363542 DOI: 10.1517/17425255.4.3.273] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 1.4] [Reference Citation Analysis]
185 Barua S, Rege K. The influence of mediators of intracellular trafficking on transgene expression efficacy of polymer–plasmid DNA complexes. Biomaterials 2010;31:5894-902. [DOI: 10.1016/j.biomaterials.2010.04.007] [Cited by in Crossref: 47] [Cited by in F6Publishing: 41] [Article Influence: 3.9] [Reference Citation Analysis]
186 Huang HL, Peng CY, Lai MJ, Chen CH, Lee HY, Wang JC, Liou JP, Pan SL, Teng CM. Novel oral histone deacetylase inhibitor, MPT0E028, displays potent growth-inhibitory activity against human B-cell lymphoma in vitro and in vivo. Oncotarget 2015;6:4976-91. [PMID: 25669976 DOI: 10.18632/oncotarget.3213] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
187 Gao P, Zhai F, Guan L, Zheng J. Nordihydroguaiaretic acid inhibits growth of cervical cancer SiHa cells by up-regulating p21. Oncol Lett 2011;2:123-8. [PMID: 22870140 DOI: 10.3892/ol.2010.205] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
188 Ellis D, Lawman Z, Bonham K. Histone acetylation is not an accurate predictor of gene expression following treatment with histone deacetylase inhibitors. Biochemical and Biophysical Research Communications 2008;367:656-62. [DOI: 10.1016/j.bbrc.2007.12.157] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.1] [Reference Citation Analysis]
189 Morgan SS, Cranmer LD. Vorinostat synergizes with ridaforolimus and abrogates the ridaforolimus-induced activation of AKT in synovial sarcoma cells. BMC Res Notes 2014;7:812. [PMID: 25406429 DOI: 10.1186/1756-0500-7-812] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
190 Marsboom G, Archer SL. Pathways of proliferation: new targets to inhibit the growth of vascular smooth muscle cells. Circ Res 2008;103:1047-9. [PMID: 18988899 DOI: 10.1161/CIRCRESAHA.108.188003] [Cited by in Crossref: 14] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
191 Harrison SJ, Bishton M, Bates SE, Grant S, Piekarz RL, Johnstone RW, Dai Y, Lee B, Araujo ME, Prince HM. A focus on the preclinical development and clinical status of the histone deacetylase inhibitor, romidepsin (depsipeptide, Istodax(®)). Epigenomics 2012;4:571-89. [PMID: 23130838 DOI: 10.2217/epi.12.52] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 3.3] [Reference Citation Analysis]
192 Chikamatsu K, Ishii H, Murata T, Sakakura K, Shino M, Toyoda M, Takahashi K, Masuyama K. Alteration of cancer stem cell-like phenotype by histone deacetylase inhibitors in squamous cell carcinoma of the head and neck. Cancer Sci. 2013;104:1468-1475. [PMID: 23992541 DOI: 10.1111/cas.12271] [Cited by in Crossref: 36] [Cited by in F6Publishing: 42] [Article Influence: 4.0] [Reference Citation Analysis]
193 Savickiene J, Borutinskaite VV, Treigyte G, Magnusson KE, Navakauskiene R. The novel histone deacetylase inhibitor BML-210 exerts growth inhibitory, proapoptotic and differentiation stimulating effects on the human leukemia cell lines. Eur J Pharmacol 2006;549:9-18. [PMID: 16978604 DOI: 10.1016/j.ejphar.2006.08.010] [Cited by in Crossref: 36] [Cited by in F6Publishing: 28] [Article Influence: 2.3] [Reference Citation Analysis]
194 Ha MW, Ma R, Shun LP, Gong YH, Yuan Y. Effects of allitridi on cell cycle arrest of human gastric cancer cells. World J Gastroenterol 2005; 11(35): 5433-5437 [PMID: 16222732 DOI: 10.3748/wjg.v11.i35.5433] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
195 Razidlo DF, Whitney TJ, Casper ME, McGee-Lawrence ME, Stensgard BA, Li X, Secreto FJ, Knutson SK, Hiebert SW, Westendorf JJ. Histone deacetylase 3 depletion in osteo/chondroprogenitor cells decreases bone density and increases marrow fat. PLoS One 2010;5:e11492. [PMID: 20628553 DOI: 10.1371/journal.pone.0011492] [Cited by in Crossref: 82] [Cited by in F6Publishing: 82] [Article Influence: 6.8] [Reference Citation Analysis]
196 Kim JW, Park K, Kang RJ, Gonzales EL, Oh HA, Seung H, Ko MJ, Cheong JH, Chung C, Shin CY. Gene-environment interaction counterbalances social impairment in mouse models of autism. Sci Rep 2019;9:11490. [PMID: 31391512 DOI: 10.1038/s41598-019-47680-w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
197 Garcia-Manero G, Kantarjian HM, Sanchez-Gonzalez B, Yang H, Rosner G, Verstovsek S, Rytting M, Wierda WG, Ravandi F, Koller C. Phase 1/2 study of the combination of 5-aza-2’-deoxycytidine with valproic acid in patients with leukemia. Blood. 2006;108:3271-3279. [PMID: 16882711 DOI: 10.1182/blood-2006-03-009142] [Cited by in Crossref: 372] [Cited by in F6Publishing: 332] [Article Influence: 23.3] [Reference Citation Analysis]
198 Bennett RL, Licht JD. Targeting Epigenetics in Cancer. Annu Rev Pharmacol Toxicol 2018;58:187-207. [PMID: 28992434 DOI: 10.1146/annurev-pharmtox-010716-105106] [Cited by in Crossref: 102] [Cited by in F6Publishing: 85] [Article Influence: 20.4] [Reference Citation Analysis]
199 Nusinzon I, Horvath CM. Histone deacetylases as transcriptional activators? Role reversal in inducible gene regulation. Sci STKE 2005;2005:re11. [PMID: 16091625 DOI: 10.1126/stke.2962005re11] [Cited by in Crossref: 21] [Cited by in F6Publishing: 48] [Article Influence: 1.2] [Reference Citation Analysis]
200 Nusinzon I, Horvath CM. Unexpected Roles for Deacetylation in Interferon- and Cytokine-Induced Transcription. Journal of Interferon & Cytokine Research 2005;25:745-8. [DOI: 10.1089/jir.2005.25.745] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 1.1] [Reference Citation Analysis]
201 Bijron JG, Bol GM, Verheijen RH, van Diest PJ. Epigenetic biomarkers in the diagnosis of ovarian cancer. Expert Opin Med Diagn 2012;6:421-38. [PMID: 23480807 DOI: 10.1517/17530059.2012.702105] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
202 Lin RJ, Sternsdorf T, Tini M, Evans RM. Transcriptional regulation in acute promyelocytic leukemia. Oncogene 2001;20:7204-15. [DOI: 10.1038/sj.onc.1204853] [Cited by in Crossref: 121] [Cited by in F6Publishing: 110] [Article Influence: 5.8] [Reference Citation Analysis]
203 Place RF, Noonan EJ, Giardina C. HDACs and the senescent phenotype of WI-38 cells. BMC Cell Biol 2005;6:37. [PMID: 16250917 DOI: 10.1186/1471-2121-6-37] [Cited by in Crossref: 42] [Cited by in F6Publishing: 36] [Article Influence: 2.5] [Reference Citation Analysis]
204 Fischer C, Leithner K, Wohlkoenig C, Quehenberger F, Bertsch A, Olschewski A, Olschewski H, Hrzenjak A. Panobinostat reduces hypoxia-induced cisplatin resistance of non-small cell lung carcinoma cells via HIF-1α destabilization. Mol Cancer 2015;14:4. [PMID: 25608569 DOI: 10.1186/1476-4598-14-4] [Cited by in Crossref: 38] [Cited by in F6Publishing: 39] [Article Influence: 5.4] [Reference Citation Analysis]
205 Fackler MJ, Evron E, Khan SA, Sukumar S. Novel agents for chemoprevention, screening methods, and sampling issues. J Mammary Gland Biol Neoplasia 2003;8:75-89. [PMID: 14587864 DOI: 10.1023/a:1025735405628] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
206 Tambaro FP, Dell'aversana C, Carafa V, Nebbioso A, Radic B, Ferrara F, Altucci L. Histone deacetylase inhibitors: clinical implications for hematological malignancies. Clin Epigenetics 2010;1:25-44. [PMID: 22704087 DOI: 10.1007/s13148-010-0006-2] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
207 Marchion D, Münster P. Development of histone deacetylase inhibitors for cancer treatment. Expert Review of Anticancer Therapy 2014;7:583-98. [DOI: 10.1586/14737140.7.4.583] [Cited by in Crossref: 118] [Cited by in F6Publishing: 97] [Article Influence: 14.8] [Reference Citation Analysis]
208 Parolin C, Calonghi N, Presta E, Boga C, Caruana P, Naldi M, Andrisano V, Masotti L, Sartor G. Mechanism and stereoselectivity of HDAC I inhibition by (R)-9-hydroxystearic acid in colon cancer. Biochim Biophys Acta 2012;1821:1334-40. [PMID: 22814230 DOI: 10.1016/j.bbalip.2012.07.007] [Cited by in Crossref: 26] [Cited by in F6Publishing: 20] [Article Influence: 2.6] [Reference Citation Analysis]
209 Gao D, Xu M, Zhang Y, Du Y, Gao J, Gong Y, Man X, Wu H, Jin J, Xu G, Li Z. Upregulated Histone Deacetylase 1 Expression in Pancreatic Ductal Adenocarcinoma and Specific SiRNA Inhibits the Growth of Cancer Cells. Pancreas 2010;39:994-1001. [DOI: 10.1097/mpa.0b013e3181db0086] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
210 Fatima N, Baqri SSR, Bhattacharya A, Koney NK, Husain K, Abbas A, Ansari RA. Role of Flavonoids as Epigenetic Modulators in Cancer Prevention and Therapy. Front Genet 2021;12:758733. [PMID: 34858475 DOI: 10.3389/fgene.2021.758733] [Reference Citation Analysis]
211 Dinarello CA. Inhibitors of Histone Deacetylases as Anti-inflammatory Drugs. In: Numerof R, Dinarello CA, Asadullah K, editors. Cytokines as Potential Therapeutic Targets for Inflammatory Skin Diseases. Springer Berlin Heidelberg; 2005. pp. 45-60. [DOI: 10.1007/3-540-37673-9_3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Reference Citation Analysis]
212 Naruse Y, Oh-hashi K, Iijima N, Naruse M, Yoshioka H, Tanaka M. Circadian and light-induced transcription of clock gene Per1 depends on histone acetylation and deacetylation. Mol Cell Biol 2004;24:6278-87. [PMID: 15226430 DOI: 10.1128/MCB.24.14.6278-6287.2004] [Cited by in Crossref: 152] [Cited by in F6Publishing: 75] [Article Influence: 8.4] [Reference Citation Analysis]
213 Epping MT, Bernards R. Molecular basis of the anti-cancer effects of histone deacetylase inhibitors. Int J Biochem Cell Biol 2009;41:16-20. [PMID: 18765293 DOI: 10.1016/j.biocel.2008.07.020] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
214 Bajbouj K, Mawrin C, Hartig R, Schulze-Luehrmann J, Wilisch-Neumann A, Roessner A, Schneider-Stock R. P53-dependent antiproliferative and pro-apoptotic effects of trichostatin A (TSA) in glioblastoma cells. J Neurooncol. 2012;107:503-516. [PMID: 22270849 DOI: 10.1007/s11060-011-0791-2] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 2.0] [Reference Citation Analysis]
215 Wilson PM, El-Khoueiry A, Iqbal S, Fazzone W, LaBonte MJ, Groshen S, Yang D, Danenberg KD, Cole S, Kornacki M, Ladner RD, Lenz HJ. A phase I/II trial of vorinostat in combination with 5-fluorouracil in patients with metastatic colorectal cancer who previously failed 5-FU-based chemotherapy. Cancer Chemother Pharmacol. 2010;65:979-988. [PMID: 20062993 DOI: 10.1007/s00280-009-1236-x] [Cited by in Crossref: 40] [Cited by in F6Publishing: 35] [Article Influence: 3.3] [Reference Citation Analysis]
216 Worthley DL, Whitehall VLJ, Le Leu RK, Irahara N, Buttenshaw RL, Mallitt K, Greco SA, Ramsnes I, Winter J, Hu Y, Ogino S, Young GP, Leggett BA. DNA Methylation in the Rectal Mucosa Is Associated with Crypt Proliferation and Fecal Short-Chain Fatty Acids. Dig Dis Sci 2011;56:387-96. [DOI: 10.1007/s10620-010-1312-4] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
217 Mastoraki A, Schizas D, Charalampakis N, Naar L, Ioannidi M, Tsilimigras D, Sotiropoulou M, Moris D, Vassiliu P, Felekouras E. Contribution of Histone Deacetylases in Prognosis and Therapeutic Management of Cholangiocarcinoma. Mol Diagn Ther 2020;24:175-84. [PMID: 32125662 DOI: 10.1007/s40291-020-00454-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
218 Nakayama T, Watanabe M, Yamanaka M, Hirokawa Y, Suzuki H, Ito H, Yatani R, Shiraishi T. The role of epigenetic modifications in retinoic acid receptor beta2 gene expression in human prostate cancers. Lab Invest. 2001;81:1049-1057. [PMID: 11454993 DOI: 10.1038/labinvest.3780316] [Cited by in Crossref: 77] [Cited by in F6Publishing: 56] [Article Influence: 3.7] [Reference Citation Analysis]
219 Selma Dagtas A, Gilbert KM. p21(Cip1) up-regulated during histone deacetylase inhibitor-induced CD4(+) T-cell anergy selectively associates with mitogen-activated protein kinases. Immunology 2010;129:589-99. [PMID: 20102411 DOI: 10.1111/j.1365-2567.2009.03161.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 0.3] [Reference Citation Analysis]
220 Nourani A, Doyon Y, Utley RT, Allard S, Lane WS, Côté J. Role of an ING1 growth regulator in transcriptional activation and targeted histone acetylation by the NuA4 complex. Mol Cell Biol 2001;21:7629-40. [PMID: 11604499 DOI: 10.1128/MCB.21.22.7629-7640.2001] [Cited by in Crossref: 71] [Cited by in F6Publishing: 49] [Article Influence: 3.4] [Reference Citation Analysis]
221 Nakamura T, Kukita T, Shobuike T, Nagata K, Wu Z, Ogawa K, Hotokebuchi T, Kohashi O, Kukita A. Inhibition of histone deacetylase suppresses osteoclastogenesis and bone destruction by inducing IFN-beta production. J Immunol 2005;175:5809-16. [PMID: 16237073 DOI: 10.4049/jimmunol.175.9.5809] [Cited by in Crossref: 78] [Cited by in F6Publishing: 67] [Article Influence: 4.6] [Reference Citation Analysis]
222 Lobjois V, Frongia C, Jozan S, Truchet I, Valette A. Cell cycle and apoptotic effects of SAHA are regulated by the cellular microenvironment in HCT116 multicellular tumour spheroids. Eur J Cancer 2009;45:2402-11. [PMID: 19553104 DOI: 10.1016/j.ejca.2009.05.026] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 1.7] [Reference Citation Analysis]
223 Travaglini L, Vian L, Billi M, Grignani F, Nervi C. Epigenetic reprogramming of breast cancer cells by valproic acid occurs regardless of estrogen receptor status. Int J Biochem Cell Biol 2009;41:225-34. [PMID: 18789398 DOI: 10.1016/j.biocel.2008.08.019] [Cited by in Crossref: 34] [Cited by in F6Publishing: 25] [Article Influence: 2.4] [Reference Citation Analysis]
224 Mishra VK, Wegwitz F, Kosinsky RL, Sen M, Baumgartner R, Wulff T, Siveke JT, Schildhaus HU, Najafova Z, Kari V. Histone deacetylase class-I inhibition promotes epithelial gene expression in pancreatic cancer cells in a BRD4- and MYC-dependent manner. Nucleic Acids Res. 2017;45:6334-6349. [PMID: 28369619 DOI: 10.1093/nar/gkx212] [Cited by in Crossref: 47] [Cited by in F6Publishing: 42] [Article Influence: 9.4] [Reference Citation Analysis]
225 Friedmann I, Atmaca A, Chow K, Jäger E, Weidmann E. Synergistic Effects of Valproic Acid and Mitomycin C in Adenocarcinoma Cell Lines and Fresh Tumor Cells of Patients with Colon Cancer. Journal of Chemotherapy 2013;18:415-20. [DOI: 10.1179/joc.2006.18.4.415] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 1.8] [Reference Citation Analysis]
226 Cunningham CE, MacAuley MJ, Yadav G, Vizeacoumar FS, Freywald A, Vizeacoumar FJ. Targeting the CINful genome: Strategies to overcome tumor heterogeneity. Prog Biophys Mol Biol 2019;147:77-91. [PMID: 30817936 DOI: 10.1016/j.pbiomolbio.2019.02.006] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
227 Laribee RN, Klemsz MJ. Loss of PU.1 Expression Following Inhibition of Histone Deacetylases. J Immunol 2001;167:5160-6. [DOI: 10.4049/jimmunol.167.9.5160] [Cited by in Crossref: 52] [Cited by in F6Publishing: 53] [Article Influence: 2.5] [Reference Citation Analysis]
228 Skov S, Rieneck K, Bovin LF, Skak K, Tomra S, Michelsen BK, Ødum N. Histone deacetylase inhibitors: a new class of immunosuppressors targeting a novel signal pathway essential for CD154 expression. Blood 2003;101:1430-8. [PMID: 12393479 DOI: 10.1182/blood-2002-07-2073] [Cited by in Crossref: 58] [Cited by in F6Publishing: 52] [Article Influence: 2.9] [Reference Citation Analysis]
229 Rasheed W, Bishton M, Johnstone RW, Prince HM. Histone deacetylase inhibitors in lymphoma and solid malignancies. Expert Review of Anticancer Therapy 2014;8:413-32. [DOI: 10.1586/14737140.8.3.413] [Cited by in Crossref: 74] [Cited by in F6Publishing: 65] [Article Influence: 9.3] [Reference Citation Analysis]
230 Hirsch CL, Bonham K. Histone deacetylase inhibitors regulate p21WAF1 gene expression at the post-transcriptional level in HepG2 cells. FEBS Lett. 2004;570:37-40. [PMID: 15251435 DOI: 10.1016/j.febslet.2004.06.018] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 1.4] [Reference Citation Analysis]
231 Rico T, Gilles M, Chauderlier A, Comptdaer T, Magnez R, Chwastyniak M, Drobecq H, Pinet F, Thuru X, Buée L, Galas MC, Lefebvre B. Tau Stabilizes Chromatin Compaction. Front Cell Dev Biol 2021;9:740550. [PMID: 34722523 DOI: 10.3389/fcell.2021.740550] [Reference Citation Analysis]
232 Lane AA, Chabner BA. Histone deacetylase inhibitors in cancer therapy. J Clin Oncol 2009;27:5459-68. [PMID: 19826124 DOI: 10.1200/JCO.2009.22.1291] [Cited by in Crossref: 633] [Cited by in F6Publishing: 335] [Article Influence: 48.7] [Reference Citation Analysis]
233 Gan YH, Zhang S. PTEN/AKT pathway involved in histone deacetylases inhibitor induced cell growth inhibition and apoptosis of oral squamous cell carcinoma cells. Oral Oncol 2009;45:e150-4. [PMID: 19574087 DOI: 10.1016/j.oraloncology.2009.05.563] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 2.2] [Reference Citation Analysis]
234 Sanda T. Transcription Factors as Therapeutic Targets in Lymphoid Malignancies. International Reviews of Immunology 2009;26:305-32. [DOI: 10.1080/08830180701655945] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
235 Jackman DM. Current options for systemic therapy in mesothelioma. Semin Thorac Cardiovasc Surg 2009;21:154-8. [PMID: 19822287 DOI: 10.1053/j.semtcvs.2009.06.010] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
236 Bose P, Dai Y, Grant S. Histone deacetylase inhibitor (HDACI) mechanisms of action: emerging insights. Pharmacol Ther. 2014;143:323-336. [PMID: 24769080 DOI: 10.1016/j.pharmthera.2014.04.004] [Cited by in Crossref: 152] [Cited by in F6Publishing: 143] [Article Influence: 19.0] [Reference Citation Analysis]
237 Stengel KR, Hiebert SW. Class I HDACs Affect DNA Replication, Repair, and Chromatin Structure: Implications for Cancer Therapy. Antioxid Redox Signal 2015;23:51-65. [PMID: 24730655 DOI: 10.1089/ars.2014.5915] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 3.6] [Reference Citation Analysis]
238 Liu J, Gu J, Feng Z, Yang Y, Zhu N, Lu W, Qi F. Both HDAC5 and HDAC6 are required for the proliferation and metastasis of melanoma cells. J Transl Med 2016;14:7. [PMID: 26747087 DOI: 10.1186/s12967-015-0753-0] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 6.0] [Reference Citation Analysis]
239 Gilbert KM, DeLoose A, Valentine JL, Fifer EK. Structure-activity relationship between carboxylic acids and T cell cycle blockade. Life Sci 2006;78:2159-65. [PMID: 16318858 DOI: 10.1016/j.lfs.2005.09.047] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
240 Marks PA. Discovery and development of SAHA as an anticancer agent. Oncogene 2007;26:1351-6. [PMID: 17322921 DOI: 10.1038/sj.onc.1210204] [Cited by in Crossref: 436] [Cited by in F6Publishing: 403] [Article Influence: 29.1] [Reference Citation Analysis]
241 De Marinis Y, Cai M, Bompada P, Atac D, Kotova O, Johansson ME, Garcia-Vaz E, Gomez MF, Laakso M, Groop L. Epigenetic regulation of the thioredoxin-interacting protein (TXNIP) gene by hyperglycemia in kidney. Kidney Int 2016;89:342-53. [PMID: 26806835 DOI: 10.1016/j.kint.2015.12.018] [Cited by in Crossref: 44] [Cited by in F6Publishing: 43] [Article Influence: 8.8] [Reference Citation Analysis]
242 Gabrielli B, Warrener R, Burgess A, Beamish H. Defining the Chemotherapeutic Targets of Histone Deacetylase Inhibitors. Annals of the New York Academy of Sciences 2004;1030:627-35. [DOI: 10.1196/annals.1329.073] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
243 Romanov VS, Pospelov VA, Pospelova TV. Cyclin-dependent kinase inhibitor p21(Waf1): contemporary view on its role in senescence and oncogenesis. Biochemistry (Mosc) 2012;77:575-84. [PMID: 22817456 DOI: 10.1134/S000629791206003X] [Cited by in Crossref: 74] [Cited by in F6Publishing: 58] [Article Influence: 7.4] [Reference Citation Analysis]
244 Meraviglia V, Bocchi L, Sacchetto R, Florio MC, Motta BM, Corti C, Weichenberger CX, Savi M, D'Elia Y, Rosato-Siri MD, Suffredini S, Piubelli C, Pompilio G, Pramstaller PP, Domingues FS, Stilli D, Rossini A. HDAC Inhibition Improves the Sarcoendoplasmic Reticulum Ca2+-ATPase Activity in Cardiac Myocytes. Int J Mol Sci 2018;19:E419. [PMID: 29385061 DOI: 10.3390/ijms19020419] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.8] [Reference Citation Analysis]
245 Brioschi A, Zara GP, Calderoni S, Gasco MR, Mauro A. Cholesterylbutyrate solid lipid nanoparticles as a butyric acid prodrug. Molecules 2008;13:230-54. [PMID: 18305415 DOI: 10.3390/molecules13020230] [Cited by in Crossref: 35] [Cited by in F6Publishing: 31] [Article Influence: 2.5] [Reference Citation Analysis]
246 Heider U, Kaiser M, Sterz J, Zavrski I, Jakob C, Fleissner C, Eucker J, Possinger K, Sezer O. Histone deacetylase inhibitors reduce VEGF production and induce growth suppression and apoptosis in human mantle cell lymphoma. Eur J Haematol 2006;76:42-50. [DOI: 10.1111/j.1600-0609.2005.00546.x] [Cited by in Crossref: 62] [Cited by in F6Publishing: 58] [Article Influence: 3.9] [Reference Citation Analysis]
247 Sasakawa Y, Naoe Y, Inoue T, Sasakawa T, Matsuo M, Manda T, Mutoh S. Effects of FK228, a novel histone deacetylase inhibitor, on tumor growth and expression of p21 and c-myc genes in vivo. Cancer Letters 2003;195:161-8. [DOI: 10.1016/s0304-3835(03)00184-8] [Cited by in Crossref: 32] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
248 Boyle GM, Martyn AC, Parsons PG. Histone deacetylase inhibitors and malignant melanoma. Pigment Cell Res. 2005;18:160-166. [PMID: 15892712 DOI: 10.1111/j.1600-0749.2005.00228.x] [Cited by in Crossref: 44] [Cited by in F6Publishing: 41] [Article Influence: 2.6] [Reference Citation Analysis]
249 Sato A, Asano T, Ito K, Asano T. Ritonavir Interacts With Bortezomib to Enhance Protein Ubiquitination and Histone Acetylation Synergistically in Renal Cancer Cells. Urology 2012;79:966.e13-21. [DOI: 10.1016/j.urology.2011.11.033] [Cited by in Crossref: 12] [Cited by in F6Publishing: 17] [Article Influence: 1.2] [Reference Citation Analysis]
250 Kang JH, Kim MJ, Chang SY, Sim SS, Kim MS, Jo YH. CCAAT box is required for the induction of human thrombospondin-1 gene by trichostatin A. J Cell Biochem 2008;104:1192-203. [PMID: 18275041 DOI: 10.1002/jcb.21697] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
251 Rombouts K, Knittel T, Machesky L, Braet F, Wielant A, Hellemans K, De Bleser P, Gelman I, Ramadori G, Geerts A. Actin filament formation, reorganization and migration are impaired in hepatic stellate cells under influence of trichostatin A, a histone deacetylase inhibitor. Journal of Hepatology 2002;37:788-96. [DOI: 10.1016/s0168-8278(02)00275-1] [Cited by in Crossref: 53] [Cited by in F6Publishing: 21] [Article Influence: 2.7] [Reference Citation Analysis]
252 Killick-Cole CL, Singleton WGB, Bienemann AS, Asby DJ, Wyatt MJ, Boulter LJ, Barua NU, Gill SS. Repurposing the anti-epileptic drug sodium valproate as an adjuvant treatment for diffuse intrinsic pontine glioma. PLoS One 2017;12:e0176855. [PMID: 28542253 DOI: 10.1371/journal.pone.0176855] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
253 Horvat T, Mužinić A, Barišić D, Bosnar MH, Zoldoš V. Epigenetic modulation of the HeLa cell membrane N-glycome. Biochim Biophys Acta 2012;1820:1412-9. [PMID: 22192783 DOI: 10.1016/j.bbagen.2011.12.007] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
254 Kai M, Kanaya N, Wu SV, Mendez C, Nguyen D, Luu T, Chen S. Targeting breast cancer stem cells in triple-negative breast cancer using a combination of LBH589 and salinomycin. Breast Cancer Res Treat 2015;151:281-94. [PMID: 25904215 DOI: 10.1007/s10549-015-3376-5] [Cited by in Crossref: 39] [Cited by in F6Publishing: 38] [Article Influence: 5.6] [Reference Citation Analysis]
255 LaBonte MJ, Wilson PM, Fazzone W, Groshen S, Lenz HJ, Ladner RD. DNA microarray profiling of genes differentially regulated by the histone deacetylase inhibitors vorinostat and LBH589 in colon cancer cell lines. BMC Med Genomics 2009;2:67. [PMID: 19948057 DOI: 10.1186/1755-8794-2-67] [Cited by in Crossref: 65] [Cited by in F6Publishing: 63] [Article Influence: 5.0] [Reference Citation Analysis]
256 Habold C, Poehlmann A, Bajbouj K, Hartig R, Korkmaz KS, Roessner A, Schneider-Stock R. Trichostatin A causes p53 to switch oxidative-damaged colorectal cancer cells from cell cycle arrest into apoptosis. J Cell Mol Med. 2008;12:607-621. [PMID: 18419600 DOI: 10.1111/j.1582-4934.2007.00136.x] [Cited by in Crossref: 44] [Cited by in F6Publishing: 42] [Article Influence: 3.1] [Reference Citation Analysis]
257 Weisberg E, Catley L, Kujawa J, Atadja P, Remiszewski S, Fuerst P, Cavazza C, Anderson K, Griffin JD. Histone deacetylase inhibitor NVP-LAQ824 has significant activity against myeloid leukemia cells in vitro and in vivo. Leukemia 2004;18:1951-63. [DOI: 10.1038/sj.leu.2403519] [Cited by in Crossref: 46] [Cited by in F6Publishing: 38] [Article Influence: 2.6] [Reference Citation Analysis]
258 Flis S, Gnyszka A, Flis K, Spławiński J. MS275 enhances cytotoxicity induced by 5-fluorouracil in the colorectal cancer cells. European Journal of Pharmacology 2010;627:26-32. [DOI: 10.1016/j.ejphar.2009.10.033] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
259 Flower A, Abla O. Resistance to Histone Deacetylase Inhibitors in the Treatment of Lymphoma. In: Xavier AC, Cairo MS, editors. Resistance to Targeted Therapies in Lymphomas. Cham: Springer International Publishing; 2019. pp. 87-110. [DOI: 10.1007/978-3-030-24424-8_5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
260 Eyüpoglu IY, Hahnen E, Buslei R, Siebzehnrübl FA, Savaskan NE, Lüders M, Tränkle C, Wick W, Weller M, Fahlbusch R, Blümcke I. Suberoylanilide hydroxamic acid (SAHA) has potent anti-glioma properties in vitro, ex vivo and in vivo. J Neurochem 2005;93:992-9. [PMID: 15857402 DOI: 10.1111/j.1471-4159.2005.03098.x] [Cited by in Crossref: 87] [Cited by in F6Publishing: 78] [Article Influence: 5.1] [Reference Citation Analysis]
261 Chinnaiyan P, Varambally S, Tomlins SA, Ray S, Huang S, Chinnaiyan AM, Harari PM. Enhancing the antitumor activity of ErbB blockade with histone deacetylase (HDAC) inhibition. Int J Cancer 2006;118:1041-50. [DOI: 10.1002/ijc.21465] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 1.9] [Reference Citation Analysis]
262 Tai HH, Tai GC, Beardmore T. Dynamic histone acetylation of late embryonic genes during seed germination. Plant Mol Biol 2005;59:909-25. [PMID: 16307366 DOI: 10.1007/s11103-005-2081-x] [Cited by in Crossref: 51] [Cited by in F6Publishing: 47] [Article Influence: 3.2] [Reference Citation Analysis]
263 Calonghi N, Cappadone C, Pagnotta E, Boga C, Bertucci C, Fiori J, Tasco G, Casadio R, Masotti L. Histone deacetylase 1: a target of 9-hydroxystearic acid in the inhibition of cell growth in human colon cancer. Journal of Lipid Research 2005;46:1596-603. [DOI: 10.1194/jlr.m400424-jlr200] [Cited by in Crossref: 33] [Cited by in F6Publishing: 9] [Article Influence: 1.9] [Reference Citation Analysis]
264 Glauben R, Sonnenberg E, Zeitz M, Siegmund B. HDAC inhibitors in models of inflammation-related tumorigenesis. Cancer Lett 2009;280:154-9. [PMID: 19101082 DOI: 10.1016/j.canlet.2008.11.019] [Cited by in Crossref: 44] [Cited by in F6Publishing: 39] [Article Influence: 3.1] [Reference Citation Analysis]
265 Rücker FG, Lang KM, Fütterer M, Komarica V, Schmid M, Döhner H, Schlenk RF, Döhner K, Knudsen S, Bullinger L. Molecular dissection of valproic acid effects in acute myeloid leukemia identifies predictive networks. Epigenetics 2016;11:517-25. [PMID: 27309669 DOI: 10.1080/15592294.2016.1187350] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
266 Kanao K, Mikami S, Mizuno R, Shinojima T, Murai M, Oya M. Decreased Acetylation of Histone H3 in Renal Cell Carcinoma: A Potential Target of Histone Deacetylase Inhibitors. Journal of Urology 2008;180:1131-6. [DOI: 10.1016/j.juro.2008.04.136] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 2.3] [Reference Citation Analysis]
267 Kelly WK, Marks PA. Drug Insight: histone deacetylase inhibitors—development of the new targeted anticancer agent suberoylanilide hydroxamic acid. Nat Rev Clin Oncol 2005;2:150-7. [DOI: 10.1038/ncponc0106] [Cited by in Crossref: 238] [Cited by in F6Publishing: 214] [Article Influence: 14.0] [Reference Citation Analysis]
268 Butler LM, Zhou X, Xu WS, Scher HI, Rifkind RA, Marks PA, Richon VM. The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin. Proc Natl Acad Sci U S A 2002;99:11700-5. [PMID: 12189205 DOI: 10.1073/pnas.182372299] [Cited by in Crossref: 388] [Cited by in F6Publishing: 361] [Article Influence: 19.4] [Reference Citation Analysis]
269 Sun WJ, Zhou X, Zheng JH, Lu MD, Nie JY, Yang XJ, Zheng ZQ. Histone acetyltransferases and deacetylases: molecular and clinical implications to gastrointestinal carcinogenesis. Acta Biochim Biophys Sin (Shanghai) 2012;44:80-91. [PMID: 22194016 DOI: 10.1093/abbs/gmr113] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
270 Schizas D, Mastoraki A, Naar L, Tsilimigras DI, Katsaros I, Fragkiadaki V, Karachaliou GS, Arkadopoulos N, Liakakos T, Moris D. Histone Deacetylases (HDACs) in Gastric Cancer: An Update of their Emerging Prognostic and Therapeutic Role. Curr Med Chem 2020;27:6099-111. [PMID: 31309879 DOI: 10.2174/0929867326666190712160842] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 10.0] [Reference Citation Analysis]
271 Steiner FA, Hong JA, Fischette MR, Beer DG, Guo ZS, Chen GA, Weiser TS, Kassis ES, Nguyen DM, Lee S, Trepel JB, Schrump DS. Sequential 5-Aza 2'-deoxycytidine/depsipeptide FK228 treatment induces tissue factor pathway inhibitor 2 (TFPI-2) expression in cancer cells. Oncogene 2005;24:2386-97. [PMID: 15735751 DOI: 10.1038/sj.onc.1208376] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 1.8] [Reference Citation Analysis]
272 Barazzuol L, Jeynes JCG, Merchant MJ, Wéra A, Barry MA, Kirkby KJ, Suzuki M. Radiosensitization of glioblastoma cells using a histone deacetylase inhibitor (SAHA) comparing carbon ions with X-rays. International Journal of Radiation Biology 2014;91:90-8. [DOI: 10.3109/09553002.2014.946111] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 2.6] [Reference Citation Analysis]
273 Katsura T, Iwai S, Ota Y, Shimizu H, Ikuta K, Yura Y. The effects of trichostatin A on the oncolytic ability of herpes simplex virus for oral squamous cell carcinoma cells. Cancer Gene Ther 2009;16:237-45. [PMID: 18949013 DOI: 10.1038/cgt.2008.81] [Cited by in Crossref: 36] [Cited by in F6Publishing: 40] [Article Influence: 2.6] [Reference Citation Analysis]
274 Adimulam T, Arumugam T, Foolchand A, Ghazi T, Chuturgoon AA. The Effect of Organoselenium Compounds on Histone Deacetylase Inhibition and Their Potential for Cancer Therapy. Int J Mol Sci 2021;22:12952. [PMID: 34884764 DOI: 10.3390/ijms222312952] [Reference Citation Analysis]
275 Imesch P, Fink D, Fedier A. Romidepsin reduces histone deacetylase activity, induces acetylation of histones, inhibits proliferation, and activates apoptosis in immortalized epithelial endometriotic cells. Fertil Steril 2010;94:2838-42. [PMID: 20605144 DOI: 10.1016/j.fertnstert.2010.04.052] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 1.8] [Reference Citation Analysis]
276 Karagiannis D, Rampias T. HDAC Inhibitors: Dissecting Mechanisms of Action to Counter Tumor Heterogeneity. Cancers (Basel) 2021;13:3575. [PMID: 34298787 DOI: 10.3390/cancers13143575] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
277 Whitson JM, Noonan EJ, Pookot D, Place RF, Dahiya R. Double stranded-RNA-mediated activation of P21 gene induced apoptosis and cell cycle arrest in renal cell carcinoma. Int J Cancer 2009;125:446-52. [PMID: 19384944 DOI: 10.1002/ijc.24370] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 1.8] [Reference Citation Analysis]
278 Schwartz GK, Shah MA. Targeting the cell cycle: a new approach to cancer therapy. J Clin Oncol. 2005;23:9408-9421. [PMID: 16361640 DOI: 10.1200/jco.2005.01.5594] [Cited by in Crossref: 494] [Cited by in F6Publishing: 198] [Article Influence: 30.9] [Reference Citation Analysis]
279 Tóth KF, Knoch TA, Wachsmuth M, Frank-Stöhr M, Stöhr M, Bacher CP, Müller G, Rippe K. Trichostatin A-induced histone acetylation causes decondensation of interphase chromatin. J Cell Sci 2004;117:4277-87. [PMID: 15292402 DOI: 10.1242/jcs.01293] [Cited by in Crossref: 162] [Cited by in F6Publishing: 148] [Article Influence: 9.0] [Reference Citation Analysis]
280 Close P, Creppe C, Gillard M, Ladang A, Chapelle JP, Nguyen L, Chariot A. The emerging role of lysine acetylation of non-nuclear proteins. Cell Mol Life Sci 2010;67:1255-64. [PMID: 20082207 DOI: 10.1007/s00018-009-0252-7] [Cited by in Crossref: 56] [Cited by in F6Publishing: 55] [Article Influence: 4.7] [Reference Citation Analysis]
281 Stintzing S, Kemmerling R, Kiesslich T, Alinger B, Ocker M, Neureiter D. Myelodysplastic syndrome and histone deacetylase inhibitors: “to be or not to be acetylated”. J Biomed Biotechnol. 2011;2011:214143. [PMID: 21629744 DOI: 10.1155/2011/214143] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
282 Coates SS, Lehnert BE, Sharma S, Kindell SM, Gary RK. Beryllium induces premature senescence in human fibroblasts. J Pharmacol Exp Ther 2007;322:70-9. [PMID: 17395767 DOI: 10.1124/jpet.106.118018] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 1.5] [Reference Citation Analysis]
283 Place RF, Noonan EJ, Giardina C. HDAC inhibition prevents NF-kappa B activation by suppressing proteasome activity: down-regulation of proteasome subunit expression stabilizes I kappa B alpha. Biochem Pharmacol. 2005;70:394-406. [PMID: 15950952 DOI: 10.1016/j.bcp.2005.04.030] [Cited by in Crossref: 127] [Cited by in F6Publishing: 124] [Article Influence: 7.5] [Reference Citation Analysis]
284 Zhang Z, Gong Y, Shi Y, Zhang W, Qin X, Wu X. Valproate promotes survival of retinal ganglion cells in a rat model of optic nerve crush. Neuroscience 2012;224:282-93. [DOI: 10.1016/j.neuroscience.2012.07.056] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 3.2] [Reference Citation Analysis]
285 Riedel SS, Neff T, Bernt KM. Histone profiles in cancer. Pharmacology & Therapeutics 2015;154:87-109. [DOI: 10.1016/j.pharmthera.2015.07.004] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
286 Hsieh YJ, Hwu L, Chen YC, Ke CC, Chen FD, Wang HE, Lin KP, Yeh HH, Chang CW, Liu RS. P21-driven multifusion gene system for evaluating the efficacy of histone deacetylase inhibitors by in vivo molecular imaging and for transcription targeting therapy of cancer mediated by histone deacetylase inhibitor. J Nucl Med 2014;55:678-85. [PMID: 24639460 DOI: 10.2967/jnumed.113.126573] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
287 Davie JR. Inhibition of histone deacetylase activity by butyrate. J Nutr 2003;133:2485S-93S. [PMID: 12840228 DOI: 10.1093/jn/133.7.2485S] [Cited by in Crossref: 747] [Cited by in F6Publishing: 380] [Article Influence: 39.3] [Reference Citation Analysis]
288 Buckley MT, Yoon J, Yee H, Chiriboga L, Liebes L, Ara G, Qian X, Bajorin DF, Sun TT, Wu XR, Osman I. The histone deacetylase inhibitor belinostat (PXD101) suppresses bladder cancer cell growth in vitro and in vivo. J Transl Med 2007;5:49. [PMID: 17935615 DOI: 10.1186/1479-5876-5-49] [Cited by in Crossref: 52] [Cited by in F6Publishing: 47] [Article Influence: 3.5] [Reference Citation Analysis]
289 Tong M, Ding Y, Tai HH. Histone deacetylase inhibitors and transforming growth factor-beta induce 15-hydroxyprostaglandin dehydrogenase expression in human lung adenocarcinoma cells. Biochem Pharmacol. 2006;72:701-709. [PMID: 16844092 DOI: 10.1016/j.bcp.2006.06.004] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 1.5] [Reference Citation Analysis]
290 Kobayashi H, Tan EM, Fleming SE. Acetylation of histones associated with the p21WAF1/CIP1 gene by butyrate is not sufficient for p21WAF1/CIP1 gene transcription in human colorectal adenocarcinoma cells. Int J Cancer 2004;109:207-13. [PMID: 14750171 DOI: 10.1002/ijc.11697] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 1.6] [Reference Citation Analysis]
291 Ahrens TD, Timme S, Hoeppner J, Ostendorp J, Hembach S, Follo M, Hopt UT, Werner M, Busch H, Boerries M. Selective inhibition of esophageal cancer cells by combination of HDAC inhibitors and Azacytidine. Epigenetics. 2015;10:431-445. [PMID: 25923331 DOI: 10.1080/15592294.2015.1039216] [Cited by in Crossref: 41] [Cited by in F6Publishing: 40] [Article Influence: 6.8] [Reference Citation Analysis]
292 Liang Y, Mao Q, Wang L, Xia W, Chen B, Wang H, Li R, Xu L, Jiang F, Dong G. CircIMMP2L promotes esophageal squamous cell carcinoma malignant progression via CtBP1 nuclear retention dependent epigenetic modification. Clin Transl Med 2021;11:e519. [PMID: 34586741 DOI: 10.1002/ctm2.519] [Reference Citation Analysis]
293 Kitazono S, Fujiwara Y, Nakamichi S, Mizugaki H, Nokihara H, Yamamoto N, Yamada Y, Inukai E, Nakamura O, Tamura T. A phase I study of resminostat in Japanese patients with advanced solid tumors. Cancer Chemother Pharmacol 2015;75:1155-61. [PMID: 25847480 DOI: 10.1007/s00280-015-2741-8] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
294 Simone C, Stiegler P, Forcales SV, Bagella L, De Luca A, Sartorelli V, Giordano A, Puri PL. Deacetylase recruitment by the C/H3 domain of the acetyltransferase p300. Oncogene 2004;23:2177-87. [PMID: 14968110 DOI: 10.1038/sj.onc.1207327] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 1.4] [Reference Citation Analysis]
295 Hideshima T, Anderson KC. Preclinical studies of novel targeted therapies. Hematol Oncol Clin North Am 2007;21:1071-91, viii-ix. [PMID: 17996589 DOI: 10.1016/j.hoc.2007.08.013] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.1] [Reference Citation Analysis]
296 Takada Y, Gillenwater A, Ichikawa H, Aggarwal BB. Suberoylanilide Hydroxamic Acid Potentiates Apoptosis, Inhibits Invasion, and Abolishes Osteoclastogenesis by Suppressing Nuclear Factor-κB Activation. Journal of Biological Chemistry 2006;281:5612-22. [DOI: 10.1074/jbc.m507213200] [Cited by in Crossref: 93] [Cited by in F6Publishing: 29] [Article Influence: 5.8] [Reference Citation Analysis]
297 Abe F, Kitadate A, Ikeda S, Yamashita J, Nakanishi H, Takahashi N, Asaka C, Teshima K, Miyagaki T, Sugaya M, Tagawa H. Histone deacetylase inhibitors inhibit metastasis by restoring a tumor suppressive microRNA-150 in advanced cutaneous T-cell lymphoma. Oncotarget 2017;8:7572-85. [PMID: 27935859 DOI: 10.18632/oncotarget.13810] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 3.3] [Reference Citation Analysis]
298 Fraczek JE, Vinken M, Tourwé D, Vanhaecke T, Rogiers V. Synergetic effects of DNA demethylation and histone deacetylase inhibition in primary rat hepatocytes. Invest New Drugs 2012;30:1715-24. [DOI: 10.1007/s10637-011-9659-8] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.0] [Reference Citation Analysis]
299 Zhang X, Wharton W, Yuan Z, Tsai SC, Olashaw N, Seto E. Activation of the growth-differentiation factor 11 gene by the histone deacetylase (HDAC) inhibitor trichostatin A and repression by HDAC3. Mol Cell Biol 2004;24:5106-18. [PMID: 15169878 DOI: 10.1128/MCB.24.12.5106-5118.2004] [Cited by in Crossref: 71] [Cited by in F6Publishing: 39] [Article Influence: 3.9] [Reference Citation Analysis]
300 Blondel A, Benberghout A, Pedeux R, Ricordel C. Exploiting ING2 Epigenetic Modulation as a Therapeutic Opportunity for Non-Small Cell Lung Cancer. Cancers (Basel) 2019;11:E1601. [PMID: 31640185 DOI: 10.3390/cancers11101601] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
301 Noro R, Miyanaga A, Minegishi Y, Okano T, Seike M, Soeno C, Kataoka K, Matsuda K, Yoshimura A, Gemma A. Histone deacetylase inhibitor enhances sensitivity of non-small-cell lung cancer cells to 5-FU/S-1 via down-regulation of thymidylate synthase expression and up-regulation of p21(waf1/cip1) expression. Cancer Sci 2010;101:1424-30. [PMID: 20384633 DOI: 10.1111/j.1349-7006.2010.01559.x] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 2.3] [Reference Citation Analysis]
302 Schaefer EW, Loaiza-Bonilla A, Juckett M, DiPersio JF, Roy V, Slack J, Wu W, Laumann K, Espinoza-Delgado I, Gore SD; Mayo P2C Phase II Consortium. A phase 2 study of vorinostat in acute myeloid leukemia. Haematologica 2009;94:1375-82. [PMID: 19794082 DOI: 10.3324/haematol.2009.009217] [Cited by in Crossref: 81] [Cited by in F6Publishing: 75] [Article Influence: 7.4] [Reference Citation Analysis]
303 Hui KF, Cheung AK, Choi CK, Yeung PL, Middeldorp JM, Lung ML, Tsao SW, Chiang AK. Inhibition of class I histone deacetylases by romidepsin potently induces Epstein-Barr virus lytic cycle and mediates enhanced cell death with ganciclovir. Int J Cancer 2016;138:125-36. [PMID: 26205347 DOI: 10.1002/ijc.29698] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 5.1] [Reference Citation Analysis]
304 Mishra N, Reilly CM, Brown DR, Ruiz P, Gilkeson GS. Histone deacetylase inhibitors modulate renal disease in the MRL-lpr/lpr mouse. J Clin Invest. 2003;111:539-552. [PMID: 12588892 DOI: 10.1172/jci16153] [Cited by in Crossref: 266] [Cited by in F6Publishing: 125] [Article Influence: 14.0] [Reference Citation Analysis]
305 Cai D, Wang Y, Ottmann OG, Barth PJ, Neubauer A, Burchert A. FLT3-ITD–, but not BCR/ABL-transformed cells require concurrent Akt/mTor blockage to undergo apoptosis after histone deacetylase inhibitor treatment. Blood 2006;107:2094-7. [DOI: 10.1182/blood-2005-08-3317] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 1.3] [Reference Citation Analysis]
306 Monks A, Hose CD, Pezzoli P, Kondapaka S, Vansant G, Petersen KD, Sehested M, Monforte J, Shoemaker RH. Gene expression-signature of belinostat in cell lines is specific for histone deacetylase inhibitor treatment, with a corresponding signature in xenografts. Anticancer Drugs 2009;20:682-92. [PMID: 19606018 DOI: 10.1097/CAD.0b013e32832e14e1] [Cited by in Crossref: 17] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
307 Han JW, Ahn SH, Kim YK, Bae GU, Yoon JW, Hong S, Lee HY, Lee YW, Lee HW. Activation of p21(WAF1/Cip1) transcription through Sp1 sites by histone deacetylase inhibitor apicidin: involvement of protein kinase C. J Biol Chem 2001;276:42084-90. [PMID: 11551946 DOI: 10.1074/jbc.M106688200] [Cited by in Crossref: 67] [Cited by in F6Publishing: 21] [Article Influence: 3.2] [Reference Citation Analysis]
308 Sato A, Asano T, Ito K, Sumitomo M, Asano T. Suberoylanilide hydroxamic acid (SAHA) combined with bortezomib inhibits renal cancer growth by enhancing histone acetylation and protein ubiquitination synergistically. BJU Int 2012;109:1258-68. [PMID: 21895936 DOI: 10.1111/j.1464-410X.2011.10533.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 1.5] [Reference Citation Analysis]
309 Kubo M, Kanaya N, Petrossian K, Ye J, Warden C, Liu Z, Nishimura R, Osako T, Okido M, Shimada K, Takahashi M, Chu P, Yuan YC, Chen S. Inhibition of the proliferation of acquired aromatase inhibitor-resistant breast cancer cells by histone deacetylase inhibitor LBH589 (panobinostat). Breast Cancer Res Treat 2013;137:93-107. [PMID: 23160924 DOI: 10.1007/s10549-012-2332-x] [Cited by in Crossref: 34] [Cited by in F6Publishing: 30] [Article Influence: 3.4] [Reference Citation Analysis]
310 Marks PA, Richon VM, Breslow R, Rifkind RA. Histone deacetylase inhibitors as new cancer drugs. Curr Opin Oncol. 2001;13:477-483. [PMID: 11673688 DOI: 10.1097/00001622-200111000-00010] [Cited by in Crossref: 389] [Cited by in F6Publishing: 357] [Article Influence: 18.5] [Reference Citation Analysis]
311 Su X, Zhang L, Lucas DM, Davis ME, Knapp AR, Green-Church KB, Marcucci G, Parthun MR, Byrd JC, Freitas MA. Histone H4 acetylation dynamics determined by stable isotope labeling with amino acids in cell culture and mass spectrometry. Anal Biochem 2007;363:22-34. [PMID: 17286952 DOI: 10.1016/j.ab.2006.12.031] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 0.9] [Reference Citation Analysis]
312 Wegener D, Deubzer HE, Oehme I, Milde T, Hildmann C, Schwienhorst A, Witt O. HKI 46F08, a novel potent histone deacetylase inhibitor, exhibits antitumoral activity against embryonic childhood cancer cells. Anticancer Drugs. 2008;19:849-857. [PMID: 18765999 DOI: 10.1097/CAD.0b013e32830efbeb] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
313 Zhang Z, Karam J, Frenkel E, Sagalowsky A, Hsieh JT. The application of epigenetic modifiers on the treatment of prostate and bladder cancer. Urol Oncol 2006;24:152-60. [PMID: 16520279 DOI: 10.1016/j.urolonc.2005.11.004] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.2] [Reference Citation Analysis]
314 Ahn MY, Jung JH, Na YJ, Kim HS. A natural histone deacetylase inhibitor, Psammaplin A, induces cell cycle arrest and apoptosis in human endometrial cancer cells. Gynecol Oncol. 2008;108:27-33. [PMID: 17920664 DOI: 10.1016/j.ygyno.2007.08.098] [Cited by in Crossref: 64] [Cited by in F6Publishing: 62] [Article Influence: 4.3] [Reference Citation Analysis]
315 Han S, Fukazawa T, Yamatsuji T, Matsuoka J, Miyachi H, Maeda Y, Durbin M, Naomoto Y. Anti-tumor effect in human lung cancer by a combination treatment of novel histone deacetylase inhibitors: SL142 or SL325 and retinoic acids. PLoS One 2010;5:e13834. [PMID: 21079797 DOI: 10.1371/journal.pone.0013834] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
316 Martín-subero JI, Esteller M. Epigenetic Mechanisms in Cancer Development. In: Coleman WB, Tsongalis GJ, editors. The Molecular Basis of Human Cancer. New York: Springer; 2017. pp. 263-75. [DOI: 10.1007/978-1-59745-458-2_16] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
317 Tsubaki J, Hwa V, Twigg SM, Rosenfeld RG. Differential activation of the IGF binding protein-3 promoter by butyrate in prostate cancer cells. Endocrinology 2002;143:1778-88. [PMID: 11956160 DOI: 10.1210/endo.143.5.8766] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 1.3] [Reference Citation Analysis]
318 Chen R, Zhang M, Zhou Y, Guo W, Yi M, Zhang Z, Ding Y, Wang Y. The application of histone deacetylases inhibitors in glioblastoma. J Exp Clin Cancer Res 2020;39:138. [PMID: 32682428 DOI: 10.1186/s13046-020-01643-6] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 6.5] [Reference Citation Analysis]
319 Sun M, Song L, Zhou T, Gillespie GY, Jope RS. The role of DDX3 in regulating Snail. Biochim Biophys Acta. 2011;1813:438-447. [PMID: 21237216 DOI: 10.1016/j.bbamcr.2011.01.003] [Cited by in Crossref: 43] [Cited by in F6Publishing: 44] [Article Influence: 3.9] [Reference Citation Analysis]
320 Fortunati N, Bertino S, Costantino L, Bosco O, Vercellinatto I, Catalano MG, Boccuzzi G. Valproic acid is a selective antiproliferative agent in estrogen-sensitive breast cancer cells. Cancer Letters 2008;259:156-64. [DOI: 10.1016/j.canlet.2007.10.006] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 2.5] [Reference Citation Analysis]
321 Pal-Bhadra M, Ramaiah MJ, Reddy TL, Krishnan A, Pushpavalli SN, Babu KS, Tiwari AK, Rao JM, Yadav JS, Bhadra U. Plant HDAC inhibitor chrysin arrest cell growth and induce p21WAF1 by altering chromatin of STAT response element in A375 cells. BMC Cancer 2012;12:180. [PMID: 22591439 DOI: 10.1186/1471-2407-12-180] [Cited by in Crossref: 34] [Cited by in F6Publishing: 35] [Article Influence: 3.4] [Reference Citation Analysis]
322 Fan J, Lou B, Chen W, Zhang J, Lin S, Lv FF, Chen Y. Down-regulation of HDAC5 inhibits growth of human hepatocellular carcinoma by induction of apoptosis and cell cycle arrest. Tumour Biol. 2014; Aug 17. [Epub ahead of print]. [PMID: 25129440 DOI: 10.1007/s13277-014-2358-2] [Cited by in Crossref: 38] [Cited by in F6Publishing: 37] [Article Influence: 4.8] [Reference Citation Analysis]
323 Lee KS, Lee MG, Kwon YS, Nam KS. Arctigenin Enhances the Cytotoxic Effect of Doxorubicin in MDA-MB-231 Breast Cancer Cells. Int J Mol Sci 2020;21:E2997. [PMID: 32340377 DOI: 10.3390/ijms21082997] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
324 Kristeleit R, Fong P, Aherne GW, de Bono J. Histone Deacetylase Inhibitors: Emerging Anticancer Therapeutic Agents? Clinical Lung Cancer 2005;7:S19-30. [DOI: 10.3816/clc.2005.s.004] [Cited by in Crossref: 20] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
325 Keshelava N, Houghton PJ, Morton CL, Lock RB, Carol H, Keir ST, Maris JM, Reynolds CP, Gorlick R, Kolb EA, Wu J, Smith MA. Initial testing (stage 1) of vorinostat (SAHA) by the pediatric preclinical testing program. Pediatr Blood Cancer 2009;53:505-8. [PMID: 19418547 DOI: 10.1002/pbc.21988] [Cited by in Crossref: 43] [Cited by in F6Publishing: 42] [Article Influence: 3.3] [Reference Citation Analysis]
326 Hrabeta J, Stiborova M, Adam V, Kizek R, Eckschlager T. Histone deacetylase inhibitors in cancer therapy. A review. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2014;158:161-9. [PMID: 24263215 DOI: 10.5507/bp.2013.085] [Cited by in Crossref: 40] [Cited by in F6Publishing: 32] [Article Influence: 4.4] [Reference Citation Analysis]
327 Esteller M. Cancer epigenomics: DNA methylomes and histone-modification maps. Nat Rev Genet. 2007;8:286-298. [PMID: 17339880 DOI: 10.1038/nrg2005] [Cited by in Crossref: 1413] [Cited by in F6Publishing: 1268] [Article Influence: 94.2] [Reference Citation Analysis]
328 Fiegler N, Textor S, Arnold A, Rölle A, Oehme I, Breuhahn K, Moldenhauer G, Witzens-Harig M, Cerwenka A. Downregulation of the activating NKp30 ligand B7-H6 by HDAC inhibitors impairs tumor cell recognition by NK cells. Blood 2013;122:684-93. [PMID: 23801635 DOI: 10.1182/blood-2013-02-482513] [Cited by in Crossref: 81] [Cited by in F6Publishing: 80] [Article Influence: 9.0] [Reference Citation Analysis]
329 Fraga MF, Ballestar E, Villar-Garea A, Boix-Chornet M, Espada J, Schotta G, Bonaldi T, Haydon C, Ropero S, Petrie K. Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat Genet. 2005;37:391-400. [PMID: 15765097 DOI: 10.1038/ng1531] [Cited by in Crossref: 1238] [Cited by in F6Publishing: 1095] [Article Influence: 72.8] [Reference Citation Analysis]
330 Sawas A, O’connor OA. Belinostat for the treatment of T-cell lymphoma. Expert Opinion on Orphan Drugs 2015;3:219-27. [DOI: 10.1517/21678707.2015.997209] [Reference Citation Analysis]
331 Kim YK, Han J, Woo YN, Chun JK, Yoo JY, Cho E, Hong S, Lee HY, Lee Y, Lee H. Expression of p21WAF1/Cip1 through Sp1 sites by histone deacetylase inhibitor apicidin requires PI 3-kinase–PKCε signaling pathway. Oncogene 2003;22:6023-31. [DOI: 10.1038/sj.onc.1206875] [Cited by in Crossref: 44] [Cited by in F6Publishing: 40] [Article Influence: 2.3] [Reference Citation Analysis]
332 Acharya MR, Sparreboom A, Venitz J, Figg WD. Rational development of histone deacetylase inhibitors as anticancer agents: a review. Mol Pharmacol. 2005;68:917-932. [PMID: 15955865 DOI: 10.1124/mol.105.014167] [Cited by in Crossref: 163] [Cited by in F6Publishing: 154] [Article Influence: 9.6] [Reference Citation Analysis]
333 Takahashi S, Harigae H, Kaku M, Sasaki T, Licht JD. Flt3 mutation activates p21WAF1/CIP1 gene expression through the action of STAT5. Biochem Biophys Res Commun. 2004;316:85-92. [PMID: 15003515 DOI: 10.1016/j.bbrc.2004.02.018] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 1.4] [Reference Citation Analysis]
334 Yang H, Xu W, Li Y, Lan P, Zhang J, Zhang Y, Zhang C. Superior activity of a new histone deacetylase inhibitor (ZYJ-34c) in inhibiting growth of human leukemia cells by inducing p21WAF1 expression and cell cycle arrest. Anticancer Drugs 2014;25:767-77. [PMID: 24686006 DOI: 10.1097/CAD.0000000000000101] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
335 Lee J, Choy ML, Marks PA. Mechanisms of Resistance to Histone Deacetylase Inhibitors. Histone Deacetylase Inhibitors as Cancer Therapeutics. Elsevier; 2012. pp. 39-86. [DOI: 10.1016/b978-0-12-394387-3.00002-1] [Cited by in Crossref: 63] [Cited by in F6Publishing: 37] [Article Influence: 6.3] [Reference Citation Analysis]
336 Zhang Y, Adachi M, Kawamura R, Zou HC, Imai K, Hareyama M, Shinomura Y. Bmf contributes to histone deacetylase inhibitor-mediated enhancing effects on apoptosis after ionizing radiation. Apoptosis 2006;11:1349-57. [PMID: 16830229 DOI: 10.1007/s10495-006-8266-1] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.1] [Reference Citation Analysis]
337 Pulukuri SM, Gorantla B, Rao JS. Inhibition of histone deacetylase activity promotes invasion of human cancer cells through activation of urokinase plasminogen activator. J Biol Chem 2007;282:35594-603. [PMID: 17923479 DOI: 10.1074/jbc.M705867200] [Cited by in Crossref: 38] [Cited by in F6Publishing: 23] [Article Influence: 2.5] [Reference Citation Analysis]
338 Duque-Afonso J, Yalcin A, Berg T, Abdelkarim M, Heidenreich O, Lübbert M. The HDAC class I-specific inhibitor entinostat (MS-275) effectively relieves epigenetic silencing of the LAT2 gene mediated by AML1/ETO. Oncogene 2011;30:3062-72. [PMID: 21577204 DOI: 10.1038/onc.2011.32] [Cited by in Crossref: 38] [Cited by in F6Publishing: 33] [Article Influence: 3.5] [Reference Citation Analysis]
339 Marks PA, Richon VM, Miller T, Kelly WK. Histone deacetylase inhibitors. Adv Cancer Res. 2004;91:137-168. [PMID: 15327890 DOI: 10.1016/s0065-230x(04)91004-4] [Cited by in Crossref: 355] [Cited by in F6Publishing: 123] [Article Influence: 19.7] [Reference Citation Analysis]
340 Nam ST, Hwang JH, Kim DH, Park MJ, Lee IH, Nam HJ, Kang JK, Kim SK, Hwang JS, Chung HK, Shong M, Lee CH, Kim H. Role of NADH: quinone oxidoreductase-1 in the tight junctions of colonic epithelial cells. BMB Rep 2014;47:494-9. [PMID: 24393524 DOI: 10.5483/bmbrep.2014.47.9.196] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 1.9] [Reference Citation Analysis]
341 Rada-Iglesias A, Enroth S, Ameur A, Koch CM, Clelland GK, Respuela-Alonso P, Wilcox S, Dovey OM, Ellis PD, Langford CF. Butyrate mediates decrease of histone acetylation centered on transcription start sites and down-regulation of associated genes. Genome Res. 2007;17:708-719. [PMID: 17567991 DOI: 10.1101/gr.5540007] [Cited by in Crossref: 99] [Cited by in F6Publishing: 86] [Article Influence: 6.6] [Reference Citation Analysis]
342 Ugur HC, Ramakrishna N, Bello L, Menon LG, Kim SK, Black PM, Carroll RS. Continuous intracranial administration of suberoylanilide hydroxamic acid (SAHA) inhibits tumor growth in an orthotopic glioma model. J Neurooncol 2007;83:267-75. [PMID: 17310267 DOI: 10.1007/s11060-007-9337-z] [Cited by in Crossref: 46] [Cited by in F6Publishing: 43] [Article Influence: 3.1] [Reference Citation Analysis]
343 Hasegawa H, Yamada Y, Tsukasaki K, Mori N, Tsuruda K, Sasaki D, Usui T, Osaka A, Atogami S, Ishikawa C, Machijima Y, Sawada S, Hayashi T, Miyazaki Y, Kamihira S. LBH589, a deacetylase inhibitor, induces apoptosis in adult T-cell leukemia/lymphoma cells via activation of a novel RAIDD-caspase-2 pathway. Leukemia 2011;25:575-87. [PMID: 21242994 DOI: 10.1038/leu.2010.315] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 2.9] [Reference Citation Analysis]
344 Rascle A, Johnston JA, Amati B. Deacetylase activity is required for recruitment of the basal transcription machinery and transactivation by STAT5. Mol Cell Biol 2003;23:4162-73. [PMID: 12773560 DOI: 10.1128/MCB.23.12.4162-4173.2003] [Cited by in Crossref: 108] [Cited by in F6Publishing: 39] [Article Influence: 5.7] [Reference Citation Analysis]
345 Ocker M. Deacetylase inhibitors - focus on non-histone targets and effects. World J Biol Chem 2010; 1(5): 55-61 [PMID: 21540990 DOI: 10.4331/wjbc.v1.i5.55] [Cited by in CrossRef: 42] [Cited by in F6Publishing: 43] [Article Influence: 3.5] [Reference Citation Analysis]
346 Fang Z, Fu Y, Liang Y, Li Z, Zhang W, Jin J, Yang Y, Zha X. Increased expression of integrin beta1 subunit enhances p21WAF1/Cip1 transcription through the Sp1 sites and p300-mediated histone acetylation in human hepatocellular carcinoma cells. J Cell Biochem 2007;101:654-64. [PMID: 17211849 DOI: 10.1002/jcb.21223] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
347 Sasakawa Y, Naoe Y, Noto T, Inoue T, Sasakawa T, Matsuo M, Manda T, Mutoh S. Antitumor efficacy of FK228, a novel histone deacetylase inhibitor, depends on the effect on expression of angiogenesis factors. Biochem Pharmacol 2003;66:897-906. [PMID: 12963476 DOI: 10.1016/s0006-2952(03)00411-8] [Cited by in Crossref: 57] [Cited by in F6Publishing: 20] [Article Influence: 3.0] [Reference Citation Analysis]
348 Sun PC, Tzao C, Chen BH, Liu CW, Yu CP, Jin JS. Suberoylanilide hydroxamic acid induces apoptosis and sub-G1 arrest of 320 HSR colon cancer cells. J Biomed Sci. 2010;17:76. [PMID: 20846458 DOI: 10.1186/1423-0127-17-76] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
349 Kim YK, Lee EK, Kang JK, Kim JA, You J, Park JH, Seo D, Hwang JW, Kim S, Lee HY, Lee HW, Han J. Activation of NF-κB by HDAC inhibitor apicidin through Sp1-dependent de novo protein synthesis: its implication for resistance to apoptosis. Cell Death Differ 2006;13:2033-41. [DOI: 10.1038/sj.cdd.4401915] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 1.8] [Reference Citation Analysis]
350 Ryu JK, Lee WJ, Lee KH, Hwang JH, Kim YT, Yoon YB, Kim CY. SK-7041, a new histone deacetylase inhibitor, induces G2-M cell cycle arrest and apoptosis in pancreatic cancer cell lines. Cancer Lett. 2006;237:143-154. [PMID: 16009488 DOI: 10.1016/j.canlet.2005.05.040] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 1.3] [Reference Citation Analysis]
351 Mai A, Altucci L. Epi-drugs to fight cancer: from chemistry to cancer treatment, the road ahead. Int J Biochem Cell Biol. 2009;41:199-213. [PMID: 18790076 DOI: 10.1016/j.biocel.2008.08.020] [Cited by in Crossref: 138] [Cited by in F6Publishing: 130] [Article Influence: 9.9] [Reference Citation Analysis]
352 Han R, Nusbaum O, Chen X, Zhu Y. Valeric Acid Suppresses Liver Cancer Development by Acting as a Novel HDAC Inhibitor. Mol Ther Oncolytics 2020;19:8-18. [PMID: 33024815 DOI: 10.1016/j.omto.2020.08.017] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
353 Bates SE, Zhan Z, Steadman K, Obrzut T, Luchenko V, Frye R, Robey RW, Turner M, Gardner ER, Figg WD, Steinberg SM, Ling A, Fojo T, To KW, Piekarz RL. Laboratory correlates for a phase II trial of romidepsin in cutaneous and peripheral T-cell lymphoma. Br J Haematol 2010;148:256-67. [PMID: 19874311 DOI: 10.1111/j.1365-2141.2009.07954.x] [Cited by in Crossref: 54] [Cited by in F6Publishing: 54] [Article Influence: 4.2] [Reference Citation Analysis]
354 Jose A, Chaitanya MVNL, Kannan E, Madhunapantula SV. Tricaproin Isolated From Simarouba glauca Inhibits the Growth of Human Colorectal Carcinoma Cell Lines by Targeting Class-1 Histone Deacetylases. Front Pharmacol 2018;9:127. [PMID: 29593526 DOI: 10.3389/fphar.2018.00127] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
355 Hassler MR, Schiefer AI, Egger G. Combating the epigenome: epigenetic drugs against non-Hodgkin's lymphoma. Epigenomics 2013;5:397-415. [PMID: 23895653 DOI: 10.2217/epi.13.39] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
356 Gilbert KM, Boger SR, Price P, Fifer EK. T cell tolerance induced by histone deacetylase inhibitor is mediated by P21cip1. Immunopharmacol Immunotoxicol 2005;27:545-64. [PMID: 16435576 DOI: 10.1080/08923970500416749] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 0.4] [Reference Citation Analysis]
357 Levine A, Huang Y, Drisaldi B, Griffin EA Jr, Pollak DD, Xu S, Yin D, Schaffran C, Kandel DB, Kandel ER. Molecular mechanism for a gateway drug: epigenetic changes initiated by nicotine prime gene expression by cocaine. Sci Transl Med 2011;3:107ra109. [PMID: 22049069 DOI: 10.1126/scitranslmed.3003062] [Cited by in Crossref: 164] [Cited by in F6Publishing: 154] [Article Influence: 16.4] [Reference Citation Analysis]
358 Ryu H, Lee J, Olofsson BA, Mwidau A, Dedeoglu A, Escudero M, Flemington E, Azizkhan-Clifford J, Ferrante RJ, Ratan RR. Histone deacetylase inhibitors prevent oxidative neuronal death independent of expanded polyglutamine repeats via an Sp1-dependent pathway. Proc Natl Acad Sci U S A 2003;100:4281-6. [PMID: 12640146 DOI: 10.1073/pnas.0737363100] [Cited by in F6Publishing: 191] [Reference Citation Analysis]
359 O’grady S, Lawless MW. Liver Cancer (Hepatocellular Carcinoma). Epigenetic Cancer Therapy. Elsevier; 2015. pp. 269-88. [DOI: 10.1016/b978-0-12-800206-3.00012-4] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
360 Lillehammer T, Engesaeter BO, Prasmickaite L, Maelandsmo GM, Fodstad O, Engebraaten O. Combined treatment with Ad-hTRAIL and DTIC or SAHA is associated with increased mitochondrial-mediated apoptosis in human melanoma cell lines. J Gene Med 2007;9:440-51. [PMID: 17410615 DOI: 10.1002/jgm.1036] [Cited by in Crossref: 34] [Cited by in F6Publishing: 38] [Article Influence: 2.3] [Reference Citation Analysis]
361 Krueger KE, Srivastava S. Posttranslational protein modifications: current implications for cancer detection, prevention, and therapeutics. Mol Cell Proteomics 2006;5:1799-810. [PMID: 16844681 DOI: 10.1074/mcp.R600009-MCP200] [Cited by in Crossref: 161] [Cited by in F6Publishing: 72] [Article Influence: 10.1] [Reference Citation Analysis]
362 Wang WX, Tian LQ, Huang Q, Wu XB, Zeng ZJ. Effects of 10-Hydroxy-2-decenoic acid on the development of honey bee ( Apis mellifera ) larvae. Journal of Apicultural Research 2015;53:171-6. [DOI: 10.3896/ibra.1.53.1.19] [Cited by in Crossref: 9] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
363 Hristov AC, Tejasvi T, A Wilcox R. Cutaneous T-cell lymphomas: 2021 update on diagnosis, risk-stratification, and management. Am J Hematol 2021. [PMID: 34297414 DOI: 10.1002/ajh.26299] [Reference Citation Analysis]
364 Wilcox RA. Cutaneous T-cell lymphoma: 2017 update on diagnosis, risk-stratification, and management. Am J Hematol 2017;92:1085-102. [PMID: 28872191 DOI: 10.1002/ajh.24876] [Cited by in Crossref: 64] [Cited by in F6Publishing: 56] [Article Influence: 12.8] [Reference Citation Analysis]
365 Song Y, Shiota M, Tamiya S, Kuroiwa K, Naito S, Tsuneyoshi M. The significance of strong histone deacetylase 1 expression in the progression of prostate cancer. Histopathology. 2011;58:773-780. [PMID: 21438903 DOI: 10.1111/j.1365-2559.2011.03797.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
366 Janiga J, Kentley J, Nabhan C, Abdulla F. Current systemic therapeutic options for advanced mycosis fungoides and Sézary syndrome. Leuk Lymphoma 2018;59:562-77. [PMID: 29308723 DOI: 10.1080/10428194.2017.1347650] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
367 Sadri-Vakili G, Cha JH. Mechanisms of disease: Histone modifications in Huntington's disease. Nat Clin Pract Neurol 2006;2:330-8. [PMID: 16932577 DOI: 10.1038/ncpneuro0199] [Cited by in Crossref: 90] [Cited by in F6Publishing: 80] [Article Influence: 5.6] [Reference Citation Analysis]
368 Balch C, Huang TH, Brown R, Nephew KP. The epigenetics of ovarian cancer drug resistance and resensitization. Am J Obstet Gynecol 2004;191:1552-72. [PMID: 15547525 DOI: 10.1016/j.ajog.2004.05.025] [Cited by in Crossref: 106] [Cited by in F6Publishing: 84] [Article Influence: 5.9] [Reference Citation Analysis]
369 Carew JS, Giles FJ, Nawrocki ST. Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy. Cancer Lett 2008;269:7-17. [PMID: 18462867 DOI: 10.1016/j.canlet.2008.03.037] [Cited by in Crossref: 296] [Cited by in F6Publishing: 287] [Article Influence: 21.1] [Reference Citation Analysis]
370 Vasilatou D, Papageorgiou SG, Dimitriadis G, Pappa V. Epigenetic alterations and microRNAs: new players in the pathogenesis of myelodysplastic syndromes. Epigenetics 2013;8:561-70. [PMID: 23760524 DOI: 10.4161/epi.24897] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 2.6] [Reference Citation Analysis]
371 Smith KT, Martin-Brown SA, Florens L, Washburn MP, Workman JL. Deacetylase inhibitors dissociate the histone-targeting ING2 subunit from the Sin3 complex. Chem Biol 2010;17:65-74. [PMID: 20142042 DOI: 10.1016/j.chembiol.2009.12.010] [Cited by in Crossref: 60] [Cited by in F6Publishing: 57] [Article Influence: 5.0] [Reference Citation Analysis]
372 Genevois AL, Ichim G, Coissieux MM, Lambert MP, Lavial F, Goldschneider D, Jarrosson-Wuilleme L, Lepinasse F, Gouysse G, Herceg Z. Dependence receptor TrkC is a putative colon cancer tumor suppressor. Proc Natl Acad Sci USA. 2013;110:3017-3022. [PMID: 23341610 DOI: 10.1073/pnas.1212333110] [Cited by in Crossref: 40] [Cited by in F6Publishing: 40] [Article Influence: 4.4] [Reference Citation Analysis]
373 Du C, Huang D, Peng Y, Yao Y, Zhao Y, Yang Y, Wang H, Cao L, Zhu WG, Gu J. 5-Fluorouracil targets histone acetyltransferases p300/CBP in the treatment of colorectal cancer. Cancer Lett 2017;400:183-93. [PMID: 28465257 DOI: 10.1016/j.canlet.2017.04.033] [Cited by in Crossref: 25] [Cited by in F6Publishing: 31] [Article Influence: 5.0] [Reference Citation Analysis]
374 Sharma S, Chauhan R, Paliwal S, Dwivedi J. 2-D QSAR model development for α-amino suberic acid derivatives as a novel anticancer agent. Med Chem Res 2013;22:1517-27. [DOI: 10.1007/s00044-012-0145-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
375 Blasco F, Penuelas S, Cascallo M, Hernandez JL, Alemany C, Masa M, Calbo J, Soler M, Nicolas M, Perez-Torras S. Expression profiles of a human pancreatic cancer cell line upon induction of apoptosis search for modulators in cancer therapy. Oncology. 2004;67:277-290. [PMID: 15557790 DOI: 10.1159/000081329] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 0.7] [Reference Citation Analysis]
376 Mao P, He W, Mai X, Feng L, Li N, Liao Y, Zhu C, Li J, Chen T, Liu S, Zhang Q, He L. Synthesis and biological evaluation of aminobenzamides containing purine moiety as class I histone deacetylases inhibitors. Bioorganic & Medicinal Chemistry 2021. [DOI: 10.1016/j.bmc.2021.116599] [Reference Citation Analysis]
377 Chowdhury S, Howell GM, Teggart CA, Chowdhury A, Person JJ, Bowers DM, Brattain MG. Histone deacetylase inhibitor belinostat represses survivin expression through reactivation of transforming growth factor beta (TGFbeta) receptor II leading to cancer cell death. J Biol Chem 2011;286:30937-48. [PMID: 21757750 DOI: 10.1074/jbc.M110.212035] [Cited by in Crossref: 30] [Cited by in F6Publishing: 19] [Article Influence: 2.7] [Reference Citation Analysis]
378 Tanaka N, Patel AA, Tang L, Silver NL, Lindemann A, Takahashi H, Jaksik R, Rao X, Kalu NN, Chen TC, Wang J, Frederick MJ, Johnson F, Gleber-Netto FO, Fu S, Kimmel M, Wang J, Hittelman WN, Pickering CR, Myers JN, Osman AA. Replication Stress Leading to Apoptosis within the S-phase Contributes to Synergism between Vorinostat and AZD1775 in HNSCC Harboring High-Risk TP53 Mutation. Clin Cancer Res 2017;23:6541-54. [PMID: 28790110 DOI: 10.1158/1078-0432.CCR-17-0947] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 3.4] [Reference Citation Analysis]
379 Jung YS, Qian Y, Chen X. Examination of the expanding pathways for the regulation of p21 expression and activity. Cell Signal. 2010;22:1003-1012. [PMID: 20100570 DOI: 10.1016/j.cellsig.2010.01.013] [Cited by in Crossref: 265] [Cited by in F6Publishing: 248] [Article Influence: 22.1] [Reference Citation Analysis]
380 Oyelere AK, Chen PC, Guerrant W, Mwakwari SC, Hood R, Zhang Y, Fan Y. Non-peptide macrocyclic histone deacetylase inhibitors. J Med Chem 2009;52:456-68. [PMID: 19093884 DOI: 10.1021/jm801128g] [Cited by in Crossref: 51] [Cited by in F6Publishing: 51] [Article Influence: 3.9] [Reference Citation Analysis]
381 Almeida LO, Guimarães DM, Martins MD, Martins MAT, Warner KA, Nör JE, Castilho RM, Squarize CH. Unlocking the chromatin of adenoid cystic carcinomas using HDAC inhibitors sensitize cancer stem cells to cisplatin and induces tumor senescence. Stem Cell Res 2017;21:94-105. [PMID: 28426972 DOI: 10.1016/j.scr.2017.04.003] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 4.2] [Reference Citation Analysis]
382 Natarajan U, Venkatesan T, Rathinavelu A. Effect of the HDAC Inhibitor on Histone Acetylation and Methyltransferases in A2780 Ovarian Cancer Cells. Medicina (Kaunas) 2021;57:456. [PMID: 34066975 DOI: 10.3390/medicina57050456] [Reference Citation Analysis]
383 Glauben R, Batra A, Fedke I, Zeitz M, Lehr HA, Leoni F, Mascagni P, Fantuzzi G, Dinarello CA, Siegmund B. Histone hyperacetylation is associated with amelioration of experimental colitis in mice. J Immunol 2006;176:5015-22. [PMID: 16585598 DOI: 10.4049/jimmunol.176.8.5015] [Cited by in Crossref: 204] [Cited by in F6Publishing: 189] [Article Influence: 12.8] [Reference Citation Analysis]
384 Smith KT, Workman JL. Histone deacetylase inhibitors: anticancer compounds. Int J Biochem Cell Biol. 2009;41:21-25. [PMID: 18845268 DOI: 10.1016/j.biocel.2008.09.008] [Cited by in Crossref: 67] [Cited by in F6Publishing: 64] [Article Influence: 4.8] [Reference Citation Analysis]
385 Parbin S, Shilpi A, Kar S, Pradhan N, Sengupta D, Deb M, Rath SK, Patra SK. Insights into the molecular interactions of thymoquinone with histone deacetylase: evaluation of the therapeutic intervention potential against breast cancer. Mol Biosyst 2016;12:48-58. [PMID: 26540192 DOI: 10.1039/c5mb00412h] [Cited by in Crossref: 21] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
386 Saha B, Parks RJ. Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid Suppresses Human Adenovirus Gene Expression and Replication. J Virol 2019;93:e00088-19. [PMID: 30944181 DOI: 10.1128/JVI.00088-19] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
387 Ji H, Zhou Y, Zhuang X, Zhu Y, Wu Z, Lu Y, Li S, Zeng Y, Lu QR, Huo Y, Shi Y, Bu H. HDAC3 Deficiency Promotes Liver Cancer through a Defect in H3K9ac/H3K9me3 Transition. Cancer Res 2019;79:3676-88. [PMID: 31097476 DOI: 10.1158/0008-5472.CAN-18-3767] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
388 Richon VM. Cancer biology: mechanism of antitumour action of vorinostat (suberoylanilide hydroxamic acid), a novel histone deacetylase inhibitor. Br J Cancer 2006;95:S2-6. [DOI: 10.1038/sj.bjc.6603463] [Cited by in Crossref: 139] [Cited by in F6Publishing: 58] [Article Influence: 8.7] [Reference Citation Analysis]
389 Kurihara Y, Suzuki T, Sakaue M, Murayama O, Miyazaki Y, Onuki A, Aoki T, Saito M, Fujii Y, Hisasue M, Tanaka K, Takizawa T. Valproic acid, a histone deacetylase inhibitor, decreases proliferation of and induces specific neurogenic differentiation of canine adipose tissue-derived stem cells. J Vet Med Sci 2014;76:15-23. [PMID: 23986119 DOI: 10.1292/jvms.13-0219] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
390 Um S, Lee H, Zhang Q, Kim HY, Lee JH, Seo BM. Valproic Acid Modulates the Multipotency in Periodontal Ligament Stem Cells via p53-Mediated Cell Cycle. Tissue Eng Regen Med 2017;14:153-62. [PMID: 30603472 DOI: 10.1007/s13770-017-0027-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
391 Burgess A, Ruefli A, Beamish H, Warrener R, Saunders N, Johnstone R, Gabrielli B. Histone deacetylase inhibitors specifically kill nonproliferating tumour cells. Oncogene 2004;23:6693-701. [DOI: 10.1038/sj.onc.1207893] [Cited by in Crossref: 99] [Cited by in F6Publishing: 83] [Article Influence: 5.5] [Reference Citation Analysis]
392 Meisel A, Harms C, Yildirim F, Bösel J, Kronenberg G, Harms U, Fink KB, Endres M. Inhibition of histone deacetylation protects wild-type but not gelsolin-deficient neurons from oxygen/glucose deprivation. J Neurochem 2006;98:1019-31. [PMID: 16895577 DOI: 10.1111/j.1471-4159.2006.04016.x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 32] [Article Influence: 1.8] [Reference Citation Analysis]
393 Yang H, Lan P, Hou Z, Guan Y, Zhang J, Xu W, Tian Z, Zhang C. Histone deacetylase inhibitor SAHA epigenetically regulates miR-17-92 cluster and MCM7 to upregulate MICA expression in hepatoma. Br J Cancer. 2015;112:112-121. [PMID: 25393367 DOI: 10.1038/bjc.2014.547] [Cited by in Crossref: 67] [Cited by in F6Publishing: 71] [Article Influence: 8.4] [Reference Citation Analysis]
394 Hitchler MJ, Domann FE. Metabolic defects provide a spark for the epigenetic switch in cancer. Free Radic Biol Med 2009;47:115-27. [PMID: 19362589 DOI: 10.1016/j.freeradbiomed.2009.04.010] [Cited by in Crossref: 64] [Cited by in F6Publishing: 60] [Article Influence: 4.9] [Reference Citation Analysis]
395 Giannini G, Cabri W, Fattorusso C, Rodriquez M. Histone deacetylase inhibitors in the treatment of cancer: overview and perspectives. Future Med Chem 2012;4:1439-60. [PMID: 22857533 DOI: 10.4155/fmc.12.80] [Cited by in Crossref: 108] [Cited by in F6Publishing: 110] [Article Influence: 10.8] [Reference Citation Analysis]
396 Zhang J, Ouyang W, Li J, Zhang D, Yu Y, Wang Y, Li X, Huang C. Suberoylanilide hydroxamic acid (SAHA) inhibits EGF-induced cell transformation via reduction of cyclin D1 mRNA stability. Toxicol Appl Pharmacol 2012;263:218-24. [PMID: 22749963 DOI: 10.1016/j.taap.2012.06.012] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 1.8] [Reference Citation Analysis]
397 Almenara J, Rosato R, Grant S. Synergistic induction of mitochondrial damage and apoptosis in human leukemia cells by flavopiridol and the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA). Leukemia 2002;16:1331-43. [DOI: 10.1038/sj.leu.2402535] [Cited by in Crossref: 102] [Cited by in F6Publishing: 79] [Article Influence: 5.1] [Reference Citation Analysis]
398 Chueh AC, Tse JW, Tögel L, Mariadason JM. Mechanisms of histone deacetylase inhibitor-regulated gene expression in cancer cells. Antioxid Redox Signal. 2015;23:66-84. [PMID: 24512308 DOI: 10.1089/ars.2014.5863] [Cited by in Crossref: 37] [Cited by in F6Publishing: 36] [Article Influence: 4.6] [Reference Citation Analysis]
399 Takai N, Kawamata N, Gui D, Said JW, Miyakawa I, Koeffler HP. Human ovarian carcinoma cells: histone deacetylase inhibitors exhibit antiproliferative activity and potently induce apoptosis. Cancer 2004;101:2760-70. [PMID: 15536623 DOI: 10.1002/cncr.20709] [Cited by in Crossref: 83] [Cited by in F6Publishing: 76] [Article Influence: 4.6] [Reference Citation Analysis]
400 Saijo K, Katoh T, Shimodaira H, Oda A, Takahashi O, Ishioka C. Romidepsin (FK228) and its analogs directly inhibit phosphatidylinositol 3-kinase activity and potently induce apoptosis as histone deacetylase/phosphatidylinositol 3-kinase dual inhibitors. Cancer Sci 2012;103:1994-2001. [PMID: 22924958 DOI: 10.1111/cas.12002] [Cited by in Crossref: 34] [Cited by in F6Publishing: 29] [Article Influence: 3.4] [Reference Citation Analysis]
401 Wang H, Liu YC, Zhu CY, Yan F, Wang MZ, Chen XS, Wang XK, Pang BX, Li YH, Liu DH, Gao CJ, Liu SJ, Dou LP. Chidamide increases the sensitivity of refractory or relapsed acute myeloid leukemia cells to anthracyclines via regulation of the HDAC3 -AKT-P21-CDK2 signaling pathway. J Exp Clin Cancer Res 2020;39:278. [PMID: 33298132 DOI: 10.1186/s13046-020-01792-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
402 Ahn MY, Lee J, Na YJ, Choi WS, Lee BM, Kang KW, Kim HS. Mechanism of apicidin-induced cell cycle arrest and apoptosis in Ishikawa human endometrial cancer cells. Chemico-Biological Interactions 2009;179:169-77. [DOI: 10.1016/j.cbi.2008.11.011] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 1.8] [Reference Citation Analysis]
403 Di Giorgio E, Gagliostro E, Brancolini C. Selective class IIa HDAC inhibitors: myth or reality. Cell Mol Life Sci 2015;72:73-86. [PMID: 25189628 DOI: 10.1007/s00018-014-1727-8] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 3.3] [Reference Citation Analysis]
404 Pinto JT, Lee JI, Sinha R, MacEwan ME, Cooper AJ. Chemopreventive mechanisms of α-keto acid metabolites of naturally occurring organoselenium compounds. Amino Acids 2011;41:29-41. [PMID: 20383543 DOI: 10.1007/s00726-010-0578-3] [Cited by in Crossref: 41] [Cited by in F6Publishing: 40] [Article Influence: 3.4] [Reference Citation Analysis]
405 Brusa G, Zuffa E, Mancini M, Benvenuti M, Calonghi N, Barbieri E, Santucci MA. P210 Bcr-abl tyrosine kinase interaction with histone deacetylase 1 modifies histone H4 acetylation and chromatin structure of chronic myeloid leukaemia haematopoietic progenitors. Br J Haematol 2006;132:359-69. [PMID: 16409301 DOI: 10.1111/j.1365-2141.2005.05873.x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 1.1] [Reference Citation Analysis]
406 Orlowski C, Mah LJ, Vasireddy RS, El-Osta A, Karagiannis TC. Double-strand breaks and the concept of short- and long-term epigenetic memory. Chromosoma 2011;120:129-49. [PMID: 21174214 DOI: 10.1007/s00412-010-0305-6] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
407 Kitadate A, Ikeda S, Teshima K, Ito M, Toyota I, Hasunuma N, Takahashi N, Miyagaki T, Sugaya M, Tagawa H. MicroRNA-16 mediates the regulation of a senescence-apoptosis switch in cutaneous T-cell and other non-Hodgkin lymphomas. Oncogene 2016;35:3692-704. [PMID: 26640145 DOI: 10.1038/onc.2015.435] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 4.0] [Reference Citation Analysis]
408 Butler LM, Liapis V, Bouralexis S, Welldon K, Hay S, Thai LM, Labrinidis A, Tilley WD, Findlay DM, Evdokiou A. The histone deacetylase inhibitor, suberoylanilide hydroxamic acid, overcomes resistance of human breast cancer cells to Apo2L/TRAIL. Int J Cancer 2006;119:944-54. [DOI: 10.1002/ijc.21939] [Cited by in Crossref: 57] [Cited by in F6Publishing: 47] [Article Influence: 3.6] [Reference Citation Analysis]
409 Ernst P, Heidel FH. Molecular Mechanisms of Senescence and Implications for the Treatment of Myeloid Malignancies. Cancers (Basel) 2021;13:612. [PMID: 33557090 DOI: 10.3390/cancers13040612] [Reference Citation Analysis]
410 Arunkumar A, Vijayababu MR, Gunadharini N, Krishnamoorthy G, Arunakaran J. Induction of apoptosis and histone hyperacetylation by diallyl disulfide in prostate cancer cell line PC-3. Cancer Lett 2007;251:59-67. [PMID: 17150304 DOI: 10.1016/j.canlet.2006.11.001] [Cited by in Crossref: 31] [Cited by in F6Publishing: 23] [Article Influence: 1.9] [Reference Citation Analysis]
411 Spiller SE, Ravanpay AC, Hahn AW, Olson JM. Suberoylanilide hydroxamic acid is effective in preclinical studies of medulloblastoma. J Neurooncol 2006;79:259-70. [DOI: 10.1007/s11060-006-9142-0] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 2.2] [Reference Citation Analysis]
412 Hanigan TW, Danes JM, Taha TY, Frasor J, Petukhov PA. Histone deacetylase inhibitor-based chromatin precipitation for identification of targeted genomic loci. J Biol Methods 2018;5:e88. [PMID: 29682593 DOI: 10.14440/jbm.2018.216] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
413 Tzao C, Jin JS, Chen BH, Chung HY, Chang CC, Hsu TY, Sun GH. Anticancer effects of suberoylanilide hydroxamic acid in esophageal squamous cancer cells in vitro and in vivo. Dis Esophagus 2014;27:693-702. [PMID: 24033428 DOI: 10.1111/dote.12127] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
414 Ishihama K, Yamakawa M, Semba S, Takeda H, Kawata S, Kimura S, Kimura W. Expression of HDAC1 and CBP/p300 in human colorectal carcinomas. J Clin Pathol. 2007;60:1205-1210. [PMID: 17720775 DOI: 10.1136/jcp.2005.029165] [Cited by in Crossref: 104] [Cited by in F6Publishing: 97] [Article Influence: 6.9] [Reference Citation Analysis]
415 Joanna F, van Grunsven LA, Mathieu V, Sarah S, Sarah D, Karin V, Tamara V, Vera R. Histone deacetylase inhibition and the regulation of cell growth with particular reference to liver pathobiology. J Cell Mol Med 2009;13:2990-3005. [PMID: 19583816 DOI: 10.1111/j.1582-4934.2009.00831.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
416 Pang M, Zhuang S. Histone deacetylase: a potential therapeutic target for fibrotic disorders. J Pharmacol Exp Ther 2010;335:266-72. [PMID: 20719940 DOI: 10.1124/jpet.110.168385] [Cited by in Crossref: 117] [Cited by in F6Publishing: 109] [Article Influence: 9.8] [Reference Citation Analysis]
417 Neri P, Bahlis NJ, Lonial S. Panobinostat for the treatment of multiple myeloma. Expert Opinion on Investigational Drugs 2012;21:733-47. [DOI: 10.1517/13543784.2012.668883] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 2.7] [Reference Citation Analysis]
418 Skarpidi E, Cao H, Heltweg B, White BF, Marhenke RL, Jung M, Stamatoyannopoulos G. Hydroxamide derivatives of short-chain fatty acids are potent inducers of human fetal globin gene expression. Experimental Hematology 2003;31:197-203. [DOI: 10.1016/s0301-472x(02)01030-5] [Cited by in Crossref: 19] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
419 Grant S, Roberts JD. The use of cyclin-dependent kinase inhibitors alone or in combination with established cytotoxic drugs in cancer chemotherapy. Drug Resist Updat. 2003;6:15-26. [PMID: 12654284 DOI: 10.1016/S1368-7646(02)00141-3] [Cited by in Crossref: 36] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
420 Manal M, Chandrasekar M, Gomathi Priya J, Nanjan M. Inhibitors of histone deacetylase as antitumor agents: A critical review. Bioorganic Chemistry 2016;67:18-42. [DOI: 10.1016/j.bioorg.2016.05.005] [Cited by in Crossref: 124] [Cited by in F6Publishing: 103] [Article Influence: 20.7] [Reference Citation Analysis]
421 Huang Y, Wu R, Su ZY, Guo Y, Zheng X, Yang CS, Kong AN. A naturally occurring mixture of tocotrienols inhibits the growth of human prostate tumor, associated with epigenetic modifications of cyclin-dependent kinase inhibitors p21 and p27. J Nutr Biochem 2017;40:155-63. [PMID: 27889685 DOI: 10.1016/j.jnutbio.2016.10.019] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 3.8] [Reference Citation Analysis]
422 Sun C, Li H, Shi M, Liu Q, Bai J, Zheng J. Diverse roles of C-terminal Hsp70-interacting protein (CHIP) in tumorigenesis. J Cancer Res Clin Oncol 2014;140:189-97. [DOI: 10.1007/s00432-013-1571-5] [Cited by in Crossref: 30] [Cited by in F6Publishing: 24] [Article Influence: 3.3] [Reference Citation Analysis]
423 Chung EJ, Lee MJ, Lee S, Trepel JB. Assays for pharmacodynamic analysis of histone deacetylase inhibitors. Expert Opin Drug Metab Toxicol 2006;2:213-30. [PMID: 16866608 DOI: 10.1517/17425255.2.2.213] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
424 Bowman MD, Schmink JR, Mcgowan CM, Kormos CM, Leadbeater NE. Scale-Up of Microwave-Promoted Reactions to the Multigram Level Using a Sealed-Vessel Microwave Apparatus. Org Process Res Dev 2008;12:1078-88. [DOI: 10.1021/op8001239] [Cited by in Crossref: 45] [Cited by in F6Publishing: 30] [Article Influence: 3.2] [Reference Citation Analysis]
425 Zhou B, Margariti A, Xu Q. The Role of Epigenetics in Cardiovascular Disease. Epigenetics in Human Disease. Elsevier; 2012. pp. 395-414. [DOI: 10.1016/b978-0-12-388415-2.00020-2] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
426 Ying J, Srivastava G, Gao Z, Zhang X, Murray P, Ambinder R, Tao Q. Promoter hypermethylation of the cyclin-dependent kinase inhibitor (CDKI) gene p21WAF1/CIP1/SDI1 is rare in various lymphomas and carcinomas. Blood 2004;103:743-6. [DOI: 10.1182/blood-2003-09-3193] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 1.3] [Reference Citation Analysis]
427 Dou C, Li N, Ding N, Liu C, Yang X, Kang F, Cao Z, Quan H, Hou T, Xu J, Dong S. HDAC2 regulates FoxO1 during RANKL-induced osteoclastogenesis. Am J Physiol Cell Physiol 2016;310:C780-7. [PMID: 26962001 DOI: 10.1152/ajpcell.00351.2015] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 3.2] [Reference Citation Analysis]
428 Ozyerli-Goknar E, Bagci-Onder T. Epigenetic Deregulation of Apoptosis in Cancers. Cancers (Basel) 2021;13:3210. [PMID: 34199020 DOI: 10.3390/cancers13133210] [Reference Citation Analysis]
429 Fukushige S, Horii A. Road to early detection of pancreatic cancer: Attempts to utilize epigenetic biomarkers. Cancer Lett. 2014;342:231-237. [PMID: 22450751 DOI: 10.1016/j.canlet.2012.03.022] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 2.7] [Reference Citation Analysis]
430 Mitani Y, Oue N, Hamai Y, Aung PP, Matsumura S, Nakayama H, Kamata N, Yasui W. Histone H3 acetylation is associated with reduced p21(WAF1/CIP1) expression by gastric carcinoma. J Pathol. 2005;205:65-73. [PMID: 15586362 DOI: 10.1002/path.1684] [Cited by in Crossref: 51] [Cited by in F6Publishing: 45] [Article Influence: 3.0] [Reference Citation Analysis]
431 Peltonen K, Kiviharju TM, Järvinen PM, Ra R, Laiho M. Melanoma cell lines are susceptible to histone deacetylase inhibitor TSA provoked cell cycle arrest and apoptosis. Pigment Cell Res 2005;18:196-202. [PMID: 15892716 DOI: 10.1111/j.1600-0749.2005.00225.x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 1.5] [Reference Citation Analysis]
432 Bubna AK. Vorinostat-An Overview. Indian J Dermatol. 2015;60:419. [PMID: 26288427 DOI: 10.4103/0019-5154.160511] [Cited by in Crossref: 50] [Cited by in F6Publishing: 46] [Article Influence: 7.1] [Reference Citation Analysis]
433 Sigalotti L, Fratta E, Coral S, Cortini E, Covre A, Nicolay HJ, Anzalone L, Pezzani L, Di Giacomo AM, Fonsatti E, Colizzi F, Altomonte M, Calabrò L, Maio M. Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications. J Cell Physiol 2007;212:330-44. [PMID: 17458893 DOI: 10.1002/jcp.21066] [Cited by in Crossref: 95] [Cited by in F6Publishing: 97] [Article Influence: 6.3] [Reference Citation Analysis]
434 Chen YX, Fang JY, Zhu HY, Lu R, Cheng ZH, Qiu DK. Histone acetylation regulates p21WAF1 expression in human colon cancer cell lines. World J Gastroenterol 2004; 10(18): 2643-2646 [PMID: 15309711 DOI: 10.3748/wjg.v10.i18.2643] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 23] [Article Influence: 1.3] [Reference Citation Analysis]
435 Kaliszczak M, Trousil S, Åberg O, Perumal M, Nguyen QD, Aboagye EO. A novel small molecule hydroxamate preferentially inhibits HDAC6 activity and tumour growth. Br J Cancer 2013;108:342-50. [PMID: 23322205 DOI: 10.1038/bjc.2012.576] [Cited by in Crossref: 44] [Cited by in F6Publishing: 40] [Article Influence: 4.9] [Reference Citation Analysis]
436 Senese S, Zaragoza K, Minardi S, Muradore I, Ronzoni S, Passafaro A, Bernard L, Draetta GF, Alcalay M, Seiser C, Chiocca S. Role for histone deacetylase 1 in human tumor cell proliferation. Mol Cell Biol 2007;27:4784-95. [PMID: 17470557 DOI: 10.1128/MCB.00494-07] [Cited by in Crossref: 168] [Cited by in F6Publishing: 99] [Article Influence: 11.2] [Reference Citation Analysis]
437 Sonnemann J, Gänge J, Pilz S, Stötzer C, Ohlinger R, Belau A, Lorenz G, Beck JF. Comparative evaluation of the treatment efficacy of suberoylanilide hydroxamic acid (SAHA) and paclitaxel in ovarian cancer cell lines and primary ovarian cancer cells from patients. BMC Cancer 2006;6:183. [PMID: 16834771 DOI: 10.1186/1471-2407-6-183] [Cited by in Crossref: 46] [Cited by in F6Publishing: 45] [Article Influence: 2.9] [Reference Citation Analysis]
438 Backs J, Olson EN. Control of cardiac growth by histone acetylation/deacetylation. Circ Res 2006;98:15-24. [PMID: 16397154 DOI: 10.1161/01.RES.0000197782.21444.8f] [Cited by in Crossref: 313] [Cited by in F6Publishing: 174] [Article Influence: 19.6] [Reference Citation Analysis]
439 Laribee RN, Klemsz MJ. Histone H4 HDAC activity is necessary for expression of the PU.1 gene. Biochim Biophys Acta 2005;1730:226-34. [PMID: 16139904 DOI: 10.1016/j.bbaexp.2005.08.003] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
440 He L, Jhong JH, Chen Q, Huang KY, Strittmatter K, Kreuzer J, DeRan M, Wu X, Lee TY, Slavov N, Haas W, Marneros AG. Global characterization of macrophage polarization mechanisms and identification of M2-type polarization inhibitors. Cell Rep 2021;37:109955. [PMID: 34731634 DOI: 10.1016/j.celrep.2021.109955] [Reference Citation Analysis]
441 Catley L, Weisberg E, Tai YT, Atadja P, Remiszewski S, Hideshima T, Mitsiades N, Shringarpure R, LeBlanc R, Chauhan D. NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma. Blood. 2003;102:2615-2622. [PMID: 12816865 DOI: 10.1182/blood-2003-01-0233] [Cited by in Crossref: 173] [Cited by in F6Publishing: 148] [Article Influence: 9.1] [Reference Citation Analysis]
442 Nan X, Hyndman L, Agbi N, Porteous DJ, Boyd AC. Potent stimulation of gene expression by histone deacetylase inhibitors on transiently transfected DNA. Biochem Biophys Res Commun 2004;324:348-54. [PMID: 15465025 DOI: 10.1016/j.bbrc.2004.09.055] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 0.7] [Reference Citation Analysis]
443 Kim JS, Lee S, Lee T, Lee YW, Trepel JB. Transcriptional activation of p21(WAF1/CIP1) by apicidin, a novel histone deacetylase inhibitor. Biochem Biophys Res Commun. 2001;281:866-871. [PMID: 11237739 DOI: 10.1006/bbrc.2001.4434] [Cited by in Crossref: 35] [Cited by in F6Publishing: 34] [Article Influence: 1.7] [Reference Citation Analysis]
444 Yi X, Wei W, Wang SY, Du ZY, Xu YJ, Yu XD. Histone deacetylase inhibitor SAHA induces ERalpha degradation in breast cancer MCF-7 cells by CHIP-mediated ubiquitin pathway and inhibits survival signaling. Biochem Pharmacol 2008;75:1697-705. [PMID: 18342836 DOI: 10.1016/j.bcp.2007.10.035] [Cited by in Crossref: 38] [Cited by in F6Publishing: 37] [Article Influence: 2.5] [Reference Citation Analysis]
445 Gan L, Ni PY, Ge Y, Xiao YF, Sun CY, Deng L, Zhang W, Wu SS, Liu Y, Jiang W, Xin HB. Histone deacetylases regulate gonadotropin-releasing hormone I gene expression via modulating Otx2-driven transcriptional activity. PLoS One 2012;7:e39770. [PMID: 22761896 DOI: 10.1371/journal.pone.0039770] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
446 Joung KE, Min KN, Kim DK, Sheen YY. Anti-Cancer Effect of IN-2001 in T47D Human Breast Cancer. Biomol Ther (Seoul) 2012;20:81-8. [PMID: 24116279 DOI: 10.4062/biomolther.2012.20.1.081] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
447 Watson JA, McKenna DJ, Maxwell P, Diamond J, Arthur K, McKelvey-Martin VJ, Hamilton PW. Hyperacetylation in prostate cancer induces cell cycle aberrations, chromatin reorganization and altered gene expression profiles. J Cell Mol Med 2010;14:1668-82. [PMID: 19583812 DOI: 10.1111/j.1582-4934.2009.00835.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
448 Zhang C, Yang C, Feldman MJ, Wang H, Pang Y, Maggio DM, Zhu D, Nesvick CL, Dmitriev P, Bullova P, Chittiboina P, Brady RO, Pacak K, Zhuang Z. Vorinostat suppresses hypoxia signaling by modulating nuclear translocation of hypoxia inducible factor 1 alpha. Oncotarget 2017;8:56110-25. [PMID: 28915577 DOI: 10.18632/oncotarget.18125] [Cited by in Crossref: 35] [Cited by in F6Publishing: 29] [Article Influence: 7.0] [Reference Citation Analysis]
449 Bange J, Zwick E, Ullrich A. Molecular targets for breast cancer therapy and prevention. Nat Med 2001;7:548-52. [PMID: 11329054 DOI: 10.1038/87872] [Cited by in Crossref: 184] [Cited by in F6Publishing: 159] [Article Influence: 8.8] [Reference Citation Analysis]
450 Maruyama T, Yamamoto S, Qiu J, Ueda Y, Suzuki T, Nojima M, Shima H. Apoptosis of bladder cancer by sodium butyrate and cisplatin. Journal of Infection and Chemotherapy 2012;18:288-95. [DOI: 10.1007/s10156-011-0322-2] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
451 Chun P. Histone deacetylase inhibitors in hematological malignancies and solid tumors. Arch Pharm Res 2015;38:933-49. [PMID: 25653088 DOI: 10.1007/s12272-015-0571-1] [Cited by in Crossref: 69] [Cited by in F6Publishing: 57] [Article Influence: 9.9] [Reference Citation Analysis]
452 Mehta A, Ravinder, Onteru SK, Singh D. HDAC inhibitor prevents LPS mediated inhibition of CYP19A1 expression and 17β-estradiol production in granulosa cells. Molecular and Cellular Endocrinology 2015;414:73-81. [DOI: 10.1016/j.mce.2015.07.002] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.7] [Reference Citation Analysis]
453 Zhang XD, Gillespie SK, Borrow JM, Hersey P. The histone deacetylase inhibitor suberic bishydroxamate: a potential sensitizer of melanoma to TNF-related apoptosis-inducing ligand (TRAIL) induced apoptosis. Biochemical Pharmacology 2003;66:1537-45. [DOI: 10.1016/s0006-2952(03)00509-4] [Cited by in Crossref: 75] [Cited by in F6Publishing: 23] [Article Influence: 3.9] [Reference Citation Analysis]
454 Li G, Tian Y, Zhu WG. The Roles of Histone Deacetylases and Their Inhibitors in Cancer Therapy. Front Cell Dev Biol 2020;8:576946. [PMID: 33117804 DOI: 10.3389/fcell.2020.576946] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
455 Masgras I, Carrera S, de Verdier PJ, Brennan P, Majid A, Makhtar W, Tulchinsky E, Jones GD, Roninson IB, Macip S. Reactive oxygen species and mitochondrial sensitivity to oxidative stress determine induction of cancer cell death by p21. J Biol Chem. 2012;287:9845-9854. [PMID: 22311974 DOI: 10.1074/jbc.m111.250357] [Cited by in Crossref: 57] [Cited by in F6Publishing: 30] [Article Influence: 5.7] [Reference Citation Analysis]
456 Young JC, Wu S, Hansteen G, Du C, Sambucetti L, Remiszewski S, O’Farrell AM, Hill B, Lavau C, Murray LJ. Inhibitors of histone deacetylases promote hematopoietic stem cell self-renewal. Cytotherapy. 2004;6:328-336. [PMID: 16146885 DOI: 10.1080/14653240410004899] [Cited by in Crossref: 51] [Cited by in F6Publishing: 46] [Article Influence: 3.2] [Reference Citation Analysis]
457 Aparicio A. The Potential of Histone Deacetylase Inhibitors in Lung Cancer. Clinical Lung Cancer 2006;7:309-12. [DOI: 10.3816/clc.2006.n.011] [Cited by in Crossref: 4] [Article Influence: 0.3] [Reference Citation Analysis]
458 Munkacsi AB, Hammond N, Schneider RT, Senanayake DS, Higaki K, Lagutin K, Bloor SJ, Ory DS, Maue RA, Chen FW, Hernandez-Ono A, Dahlson N, Repa JJ, Ginsberg HN, Ioannou YA, Sturley SL. Normalization of Hepatic Homeostasis in the Npc1nmf164 Mouse Model of Niemann-Pick Type C Disease Treated with the Histone Deacetylase Inhibitor Vorinostat. J Biol Chem 2017;292:4395-410. [PMID: 28031458 DOI: 10.1074/jbc.M116.770578] [Cited by in Crossref: 19] [Cited by in F6Publishing: 12] [Article Influence: 3.2] [Reference Citation Analysis]
459 Di Padova M, Bruno T, De Nicola F, Iezzi S, D'Angelo C, Gallo R, Nicosia D, Corbi N, Biroccio A, Floridi A, Passananti C, Fanciulli M. Che-1 arrests human colon carcinoma cell proliferation by displacing HDAC1 from the p21WAF1/CIP1 promoter. J Biol Chem 2003;278:36496-504. [PMID: 12847090 DOI: 10.1074/jbc.M306694200] [Cited by in Crossref: 33] [Cited by in F6Publishing: 17] [Article Influence: 1.7] [Reference Citation Analysis]
460 Zhang Y, Li N, Caron C, Matthias G, Hess D, Khochbin S, Matthias P. HDAC-6 interacts with and deacetylates tubulin and microtubules in vivo. EMBO J 2003;22:1168-79. [PMID: 12606581 DOI: 10.1093/emboj/cdg115] [Cited by in Crossref: 495] [Cited by in F6Publishing: 481] [Article Influence: 26.1] [Reference Citation Analysis]
461 Rosato RR, Grant S. Histone deacetylase inhibitors in clinical development. Expert Opinion on Investigational Drugs 2005;13:21-38. [DOI: 10.1517/13543784.13.1.21] [Cited by in Crossref: 85] [Cited by in F6Publishing: 69] [Article Influence: 5.0] [Reference Citation Analysis]
462 Mercurio C, Minucci S, Pelicci PG. Histone deacetylases and epigenetic therapies of hematological malignancies. Pharmacol Res 2010;62:18-34. [PMID: 20219679 DOI: 10.1016/j.phrs.2010.02.010] [Cited by in Crossref: 94] [Cited by in F6Publishing: 88] [Article Influence: 7.8] [Reference Citation Analysis]
463 Xu W, Ngo L, Perez G, Dokmanovic M, Marks PA. Intrinsic apoptotic and thioredoxin pathways in human prostate cancer cell response to histone deacetylase inhibitor. Proc Natl Acad Sci U S A 2006;103:15540-5. [PMID: 17030815 DOI: 10.1073/pnas.0607518103] [Cited by in Crossref: 134] [Cited by in F6Publishing: 122] [Article Influence: 8.4] [Reference Citation Analysis]
464 Goh M, Chen F, Paulsen MT, Yeager AM, Dyer ES, Ljungman M. Phenylbutyrate attenuates the expression of Bcl-X(L), DNA-PK, caveolin-1, and VEGF in prostate cancer cells. Neoplasia 2001;3:331-8. [PMID: 11571633 DOI: 10.1038/sj.neo.7900165] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 1.3] [Reference Citation Analysis]
465 Grant S, Easley C, Kirkpatrick P. Vorinostat. Nat Rev Drug Discov 2007;6:21-2. [PMID: 17269160 DOI: 10.1038/nrd2227] [Cited by in Crossref: 311] [Cited by in F6Publishing: 288] [Article Influence: 20.7] [Reference Citation Analysis]
466 Mahalingam D, Mita A, Mita MM, Nawrocki ST, Giles FJ. Targeted therapy for advanced non-small cell lung cancers: historical perspective, current practices, and future development. Curr Probl Cancer. 2009;33:73-111. [PMID: 19409299 DOI: 10.1016/j.currproblcancer.2009.03.001] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
467 Tong X, Yin L, Giardina C. Butyrate suppresses Cox-2 activation in colon cancer cells through HDAC inhibition. Biochemical and Biophysical Research Communications 2004;317:463-71. [DOI: 10.1016/j.bbrc.2004.03.066] [Cited by in Crossref: 73] [Cited by in F6Publishing: 72] [Article Influence: 4.1] [Reference Citation Analysis]
468 Song Q, Li M, Fan C, Liu Y, Zheng L, Bao Y, Sun L, Yu C, Song Z, Sun Y, Wang G, Huang Y, Li Y. A novel benzamine lead compound of histone deacetylase inhibitor ZINC24469384 can suppresses HepG2 cells proliferation by upregulating NR1H4. Sci Rep 2019;9:2350. [PMID: 30787420 DOI: 10.1038/s41598-019-39487-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
469 Melnick AM, Adelson K, Licht JD. The theoretical basis of transcriptional therapy of cancer: can it be put into practice? J Clin Oncol 2005;23:3957-70. [PMID: 15867201 DOI: 10.1200/JCO.2005.14.498] [Cited by in Crossref: 24] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
470 Zhang Y, Adachi M, Kawamura R, Imai K. Bmf is a possible mediator in histone deacetylase inhibitors FK228 and CBHA-induced apoptosis. Cell Death Differ 2006;13:129-40. [PMID: 15947789 DOI: 10.1038/sj.cdd.4401686] [Cited by in Crossref: 82] [Cited by in F6Publishing: 78] [Article Influence: 5.1] [Reference Citation Analysis]
471 Sodeifian G, Saadati Ardestani N, Sajadian SA, Golmohammadi MR, Fazlali A. Prediction of Solubility of Sodium Valproate in Supercritical Carbon Dioxide: Experimental Study and Thermodynamic Modeling. J Chem Eng Data 2020;65:1747-60. [DOI: 10.1021/acs.jced.9b01069] [Cited by in Crossref: 17] [Cited by in F6Publishing: 5] [Article Influence: 8.5] [Reference Citation Analysis]
472 Deubzer H, Busche B, Rönndahl G, Eikel D, Michaelis M, Cinatl J, Schulze S, Nau H, Witt O. Novel valproic acid derivatives with potent differentiation-inducing activity in myeloid leukemia cells. Leukemia Research 2006;30:1167-75. [DOI: 10.1016/j.leukres.2006.01.009] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
473 Hernández-Borja F, Mercado-Sánchez I, Alcaraz Y, García-Revilla MA, Villegas Gómez C, Ordaz-Rosado D, Santos-Martínez N, García-Becerra R, Vazquez MA. Exploring novel capping framework: high substituent pyridine-hydroxamic acid derivatives as potential antiproliferative agents. Daru 2021. [PMID: 34297326 DOI: 10.1007/s40199-021-00406-8] [Reference Citation Analysis]
474 Wang L, Tao R, Hancock WW. Using histone deacetylase inhibitors to enhance Foxp3(+) regulatory T-cell function and induce allograft tolerance. Immunol Cell Biol 2009;87:195-202. [PMID: 19172156 DOI: 10.1038/icb.2008.106] [Cited by in Crossref: 67] [Cited by in F6Publishing: 63] [Article Influence: 5.2] [Reference Citation Analysis]
475 Mckinsey TA, Olson EN. Cardiac histone acetylation – therapeutic opportunities abound. Trends in Genetics 2004;20:206-13. [DOI: 10.1016/j.tig.2004.02.002] [Cited by in Crossref: 103] [Cited by in F6Publishing: 91] [Article Influence: 5.7] [Reference Citation Analysis]
476 Romero OA, Vilarrubi A, Alburquerque-Bejar JJ, Gomez A, Andrades A, Trastulli D, Pros E, Setien F, Verdura S, Farré L, Martín-Tejera JF, Llabata P, Oaknin A, Saigi M, Piulats JM, Matias-Guiu X, Medina PP, Vidal A, Villanueva A, Sanchez-Cespedes M. SMARCA4 deficient tumours are vulnerable to KDM6A/UTX and KDM6B/JMJD3 blockade. Nat Commun 2021;12:4319. [PMID: 34262032 DOI: 10.1038/s41467-021-24618-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
477 Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 2006;5:769-84. [DOI: 10.1038/nrd2133] [Cited by in Crossref: 2086] [Cited by in F6Publishing: 1940] [Article Influence: 130.4] [Reference Citation Analysis]
478 Espino PS, Drobic B, Dunn KL, Davie JR. Histone modifications as a platform for cancer therapy. J Cell Biochem. 2005;94:1088-1102. [PMID: 15723344 DOI: 10.1002/jcb.20387] [Cited by in Crossref: 44] [Cited by in F6Publishing: 37] [Article Influence: 2.6] [Reference Citation Analysis]
479 Wang ZT, Chen ZJ, Jiang GM, Wu YM, Liu T, Yi YM, Zeng J, Du J, Wang HS. Histone deacetylase inhibitors suppress mutant p53 transcription via HDAC8/YY1 signals in triple negative breast cancer cells. Cell Signal 2016;28:506-15. [PMID: 26876786 DOI: 10.1016/j.cellsig.2016.02.006] [Cited by in Crossref: 44] [Cited by in F6Publishing: 43] [Article Influence: 7.3] [Reference Citation Analysis]
480 Zain J, O'Connor OA. Targeting histone deacetyalses in the treatment of B- and T-cell malignancies. Invest New Drugs 2010;28 Suppl 1:S58-78. [PMID: 21132350 DOI: 10.1007/s10637-010-9591-3] [Cited by in Crossref: 37] [Cited by in F6Publishing: 39] [Article Influence: 3.1] [Reference Citation Analysis]
481 McLaughlin F, Finn P, La Thangue NB. The cell cycle, chromatin and cancer: mechanism-based therapeutics come of age. Drug Discov Today. 2003;8:793-802. [PMID: 12946642 DOI: 10.1016/s1359-6446(03)02792-2] [Cited by in Crossref: 41] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
482 Slattery EL, Speck JD, Warchol ME. Epigenetic influences on sensory regeneration: histone deacetylases regulate supporting cell proliferation in the avian utricle. J Assoc Res Otolaryngol 2009;10:341-53. [PMID: 19340485 DOI: 10.1007/s10162-009-0166-y] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 2.0] [Reference Citation Analysis]
483 Reddy ND, Shoja M, Biswas S, Nayak PG, Kumar N, Rao CM. An appraisal of cinnamyl sulfonamide hydroxamate derivatives (HDAC inhibitors) for anti-cancer, anti-angiogenic and anti-metastatic activities in human cancer cells. Chemico-Biological Interactions 2016;253:112-24. [DOI: 10.1016/j.cbi.2016.05.008] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
484 Fiskus W, Rao R, Fernandez P, Herger B, Yang Y, Chen J, Kolhe R, Mandawat A, Wang Y, Joshi R, Eaton K, Lee P, Atadja P, Peiper S, Bhalla K. Molecular and biologic characterization and drug sensitivity of pan-histone deacetylase inhibitor-resistant acute myeloid leukemia cells. Blood 2008;112:2896-905. [PMID: 18660379 DOI: 10.1182/blood-2007-10-116319] [Cited by in Crossref: 65] [Cited by in F6Publishing: 59] [Article Influence: 4.6] [Reference Citation Analysis]
485 Romanski A, Schwarz K, Keller M, Wietbrauk S, Vogel A, Roos J, Oancea C, Brill B, Krämer OH, Serve H, Ruthardt M, Bug G. Deacetylase inhibitors modulate proliferation and self-renewal properties of leukemic stem and progenitor cells. Cell Cycle 2012;11:3219-26. [PMID: 22895185 DOI: 10.4161/cc.21565] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 1.8] [Reference Citation Analysis]
486 Dickinson M, Cheah C, Prince HM. Current Epigenetic Therapy for T-Cell Lymphoma. In: Foss F, editor. T-Cell Lymphomas. Totowa: Humana Press; 2013. pp. 279-96. [DOI: 10.1007/978-1-62703-170-7_16] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
487 Gabrielli B, Brown M. Histone deacetylase inhibitors disrupt the mitotic spindle assembly checkpoint by targeting histone and nonhistone proteins. Adv Cancer Res 2012;116:1-37. [PMID: 23088867 DOI: 10.1016/B978-0-12-394387-3.00001-X] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
488 Su RC, Becker AB, Kozyrskyj AL, Hayglass KT. Epigenetic regulation of established human type 1 versus type 2 cytokine responses. J Allergy Clin Immunol 2008;121:57-63.e3. [PMID: 17980413 DOI: 10.1016/j.jaci.2007.09.004] [Cited by in Crossref: 57] [Cited by in F6Publishing: 53] [Article Influence: 3.8] [Reference Citation Analysis]
489 Piekarz RL, Sackett DL, Bates SE. Histone Deacetylase Inhibitors and Demethylating Agents: Clinical Development of Histone Deacetylase Inhibitors for Cancer Therapy. The Cancer Journal 2007;13:30-9. [DOI: 10.1097/ppo.0b013e31803c73cc] [Cited by in Crossref: 42] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
490 Worthley DL, Le Leu RK, Whitehall VL, Conlon M, Christophersen C, Belobrajdic D, Mallitt KA, Hu Y, Irahara N, Ogino S, Leggett BA, Young GP. A human, double-blind, placebo-controlled, crossover trial of prebiotic, probiotic, and synbiotic supplementation: effects on luminal, inflammatory, epigenetic, and epithelial biomarkers of colorectal cancer. Am J Clin Nutr 2009;90:578-86. [PMID: 19640954 DOI: 10.3945/ajcn.2009.28106] [Cited by in Crossref: 85] [Cited by in F6Publishing: 78] [Article Influence: 6.5] [Reference Citation Analysis]
491 Sanchez-Gonzalez B, Yang H, Bueso-Ramos C, Hoshino K, Quintas-Cardama A, Richon VM, Garcia-Manero G. Antileukemia activity of the combination of an anthracycline with a histone deacetylase inhibitor. Blood 2006;108:1174-82. [PMID: 16675713 DOI: 10.1182/blood-2005-09-008086] [Cited by in Crossref: 66] [Cited by in F6Publishing: 59] [Article Influence: 4.1] [Reference Citation Analysis]
492 Choi SW, Friso S. Epigenetics: A New Bridge between Nutrition and Health. Adv Nutr 2010;1:8-16. [PMID: 22043447 DOI: 10.3945/an.110.1004] [Cited by in Crossref: 323] [Cited by in F6Publishing: 244] [Article Influence: 26.9] [Reference Citation Analysis]
493 Cain JE, McCaw A, Jayasekara WS, Rossello FJ, Marini KD, Irving AT, Kansara M, Thomas DM, Ashley DM, Watkins DN. Sustained Low-Dose Treatment with the Histone Deacetylase Inhibitor LBH589 Induces Terminal Differentiation of Osteosarcoma Cells. Sarcoma 2013;2013:608964. [PMID: 23533324 DOI: 10.1155/2013/608964] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 2.2] [Reference Citation Analysis]
494 Zhao L, Chen CN, Hajji N, Oliver E, Cotroneo E, Wharton J, Wang D, Li M, McKinsey TA, Stenmark KR, Wilkins MR. Histone deacetylation inhibition in pulmonary hypertension: therapeutic potential of valproic acid and suberoylanilide hydroxamic acid. Circulation 2012;126:455-67. [PMID: 22711276 DOI: 10.1161/CIRCULATIONAHA.112.103176] [Cited by in Crossref: 164] [Cited by in F6Publishing: 93] [Article Influence: 16.4] [Reference Citation Analysis]
495 Wozniak MB, Villuendas R, Bischoff JR, Aparicio CB, Martínez Leal JF, de La Cueva P, Rodriguez ME, Herreros B, Martin-Perez D, Longo MI, Herrera M, Piris MA, Ortiz-Romero PL. Vorinostat interferes with the signaling transduction pathway of T-cell receptor and synergizes with phosphoinositide-3 kinase inhibitors in cutaneous T-cell lymphoma. Haematologica 2010;95:613-21. [PMID: 20133897 DOI: 10.3324/haematol.2009.013870] [Cited by in Crossref: 68] [Cited by in F6Publishing: 70] [Article Influence: 5.7] [Reference Citation Analysis]
496 Nalawansha DA, Gomes ID, Wambua MK, Pflum MKH. HDAC Inhibitor-Induced Mitotic Arrest Is Mediated by Eg5/KIF11 Acetylation. Cell Chem Biol 2017;24:481-492.e5. [PMID: 28392145 DOI: 10.1016/j.chembiol.2017.03.008] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
497 Price N, Reddy GK, Peck S, Jain VK. Highlights From: 40th Annual Meeting of the American Society of Clinical Oncology; June 2004 New Orleans, Louisiana. Clinical Lymphoma 2004;5:74-80. [DOI: 10.1016/s1526-9655(11)70059-8] [Cited by in Crossref: 2] [Article Influence: 0.1] [Reference Citation Analysis]
498 Li Y, Woster PM. Discovery of a new class of histone deacetylase inhibitors with a novel zinc binding group. Medchemcomm 2015;6:613-8. [PMID: 26005563 DOI: 10.1039/C4MD00401A] [Cited by in Crossref: 20] [Cited by in F6Publishing: 5] [Article Influence: 2.9] [Reference Citation Analysis]
499 Nebbioso A, Clarke N, Voltz E, Germain E, Ambrosino C, Bontempo P, Alvarez R, Schiavone EM, Ferrara F, Bresciani F. Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells. Nat Med. 2005;11:77-84. [PMID: 15619633 DOI: 10.1038/nm1161] [Cited by in Crossref: 415] [Cited by in F6Publishing: 333] [Article Influence: 23.1] [Reference Citation Analysis]
500 Li X, Yang H, Huang S, Qiu Y. Histone deacetylase 1 and p300 can directly associate with chromatin and compete for binding in a mutually exclusive manner. PLoS One 2014;9:e94523. [PMID: 24722339 DOI: 10.1371/journal.pone.0094523] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
501 Brunetto AT, Ang JE, Lal R, Olmos D, Molife LR, Kristeleit R, Parker A, Casamayor I, Olaleye M, Mais A, Hauns B, Strobel V, Hentsch B, de Bono JS. First-in-human, pharmacokinetic and pharmacodynamic phase I study of Resminostat, an oral histone deacetylase inhibitor, in patients with advanced solid tumors. Clin Cancer Res 2013;19:5494-504. [PMID: 24065624 DOI: 10.1158/1078-0432.CCR-13-0735] [Cited by in Crossref: 37] [Cited by in F6Publishing: 15] [Article Influence: 4.1] [Reference Citation Analysis]
502 Mitsiades N, Mitsiades CS, Richardson PG, McMullan C, Poulaki V, Fanourakis G, Schlossman R, Chauhan D, Munshi NC, Hideshima T, Richon VM, Marks PA, Anderson KC. Molecular sequelae of histone deacetylase inhibition in human malignant B cells. Blood 2003;101:4055-62. [PMID: 12531799 DOI: 10.1182/blood-2002-11-3514] [Cited by in Crossref: 234] [Cited by in F6Publishing: 198] [Article Influence: 12.3] [Reference Citation Analysis]
503 Marks PA. Histone deacetylase inhibitors: a chemical genetics approach to understanding cellular functions. Biochim Biophys Acta 2010;1799:717-25. [PMID: 20594930 DOI: 10.1016/j.bbagrm.2010.05.008] [Cited by in Crossref: 124] [Cited by in F6Publishing: 117] [Article Influence: 10.3] [Reference Citation Analysis]
504 Richon VM, Garcia-Vargas J, Hardwick JS. Development of vorinostat: current applications and future perspectives for cancer therapy. Cancer Lett 2009;280:201-10. [PMID: 19181442 DOI: 10.1016/j.canlet.2009.01.002] [Cited by in Crossref: 118] [Cited by in F6Publishing: 112] [Article Influence: 9.1] [Reference Citation Analysis]
505 Said TK, Moraes RC, Sinha R, Medina D. Mechanisms of suberoylanilide hydroxamic acid inhibition of mammary cell growth. Breast Cancer Res. 2001;3:122-133. [PMID: 11250759 DOI: 10.1186/bcr284] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 0.6] [Reference Citation Analysis]
506 Marks PA, Breslow R. Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug. Nat Biotechnol. 2007;25:84-90. [PMID: 17211407 DOI: 10.1038/nbt1272] [Cited by in Crossref: 837] [Cited by in F6Publishing: 767] [Article Influence: 55.8] [Reference Citation Analysis]
507 Liu R, Wang L, Chen G, Katoh H, Chen C, Liu Y, Zheng P. FOXP3 up-regulates p21 expression by site-specific inhibition of histone deacetylase 2/histone deacetylase 4 association to the locus. Cancer Res 2009;69:2252-9. [PMID: 19276356 DOI: 10.1158/0008-5472.CAN-08-3717] [Cited by in Crossref: 74] [Cited by in F6Publishing: 56] [Article Influence: 5.7] [Reference Citation Analysis]
508 Williams SM, Golden-Mason L, Ferguson BS, Schuetze KB, Cavasin MA, Demos-Davies K, Yeager ME, Stenmark KR, McKinsey TA. Class I HDACs regulate angiotensin II-dependent cardiac fibrosis via fibroblasts and circulating fibrocytes. J Mol Cell Cardiol 2014;67:112-25. [PMID: 24374140 DOI: 10.1016/j.yjmcc.2013.12.013] [Cited by in Crossref: 110] [Cited by in F6Publishing: 102] [Article Influence: 12.2] [Reference Citation Analysis]
509 Wilcox RA. Cutaneous T-cell lymphoma: 2011 update on diagnosis, risk-stratification, and management. Am J Hematol 2011;86:928-48. [DOI: 10.1002/ajh.22139] [Cited by in Crossref: 48] [Cited by in F6Publishing: 42] [Article Influence: 4.4] [Reference Citation Analysis]
510 Shi Y, Fu Y, Zhang X, Zhao G, Yao Y, Guo Y, Ma G, Bai S, Li H. Romidepsin (FK228) regulates the expression of the immune checkpoint ligand PD-L1 and suppresses cellular immune functions in colon cancer. Cancer Immunol Immunother 2021;70:61-73. [PMID: 32632663 DOI: 10.1007/s00262-020-02653-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
511 López-camarillo C, Gallardo-rincón D, Álvarez-sánchez ME, Marchat LA. Pharmaco-epigenomics: On the Road of Translation Medicine. In: Ruiz-garcia E, Astudillo-de la Vega H, editors. Translational Research and Onco-Omics Applications in the Era of Cancer Personal Genomics. Cham: Springer International Publishing; 2019. pp. 31-42. [DOI: 10.1007/978-3-030-24100-1_3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
512 Sutheesophon K, Nishimura N, Kobayashi Y, Furukawa Y, Kawano M, Itoh K, Kano Y, Ishii H, Furukawa Y. Involvement of the tumor necrosis factor (TNF)/TNF receptor system in leukemic cell apoptosis induced by histone deacetylase inhibitor depsipeptide (FK228). J Cell Physiol 2005;203:387-97. [DOI: 10.1002/jcp.20235] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 2.1] [Reference Citation Analysis]
513 Russo SM, Ove R. Molecular targets as therapeutic strategies in the management of breast cancer. Expert Opinion on Therapeutic Targets 2005;7:543-57. [DOI: 10.1517/14728222.7.4.543] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
514 Muscal JA, Scorsone KA, Zhang L, Ecsedy JA, Berg SL. Additive effects of vorinostat and MLN8237 in pediatric leukemia, medulloblastoma, and neuroblastoma cell lines. Invest New Drugs 2013;31:39-45. [PMID: 22669335 DOI: 10.1007/s10637-012-9831-9] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 2.7] [Reference Citation Analysis]
515 Liu Y, Denlinger CE, Rundall BK, Smith PW, Jones DR. Suberoylanilide Hydroxamic Acid Induces Akt-mediated Phosphorylation of p300, Which Promotes Acetylation and Transcriptional Activation of RelA/p65. J Biol Chem 2006;281:31359-68. [DOI: 10.1074/jbc.m604478200] [Cited by in Crossref: 56] [Cited by in F6Publishing: 38] [Article Influence: 3.5] [Reference Citation Analysis]
516 Camphausen K, Tofilon PJ. Inhibition of Histone Deacetylation: A Strategy for Tumor Radiosensitization. JCO 2007;25:4051-6. [DOI: 10.1200/jco.2007.11.6202] [Cited by in Crossref: 114] [Cited by in F6Publishing: 59] [Article Influence: 7.6] [Reference Citation Analysis]
517 You D, Richardson JR, Aleksunes LM. Epigenetic Regulation of Multidrug Resistance Protein 1 and Breast Cancer Resistance Protein Transporters by Histone Deacetylase Inhibition. Drug Metab Dispos 2020;48:459-80. [PMID: 32193359 DOI: 10.1124/dmd.119.089953] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
518 Verstegen REM, Kostadinova AI, Merenciana Z, Garssen J, Folkerts G, Hendriks RW, Willemsen LEM. Dietary Fibers: Effects, Underlying Mechanisms and Possible Role in Allergic Asthma Management. Nutrients 2021;13:4153. [PMID: 34836408 DOI: 10.3390/nu13114153] [Reference Citation Analysis]
519 Yeh BW, Li WM, Li CC, Kang WY, Huang CN, Hour TC, Liu ZM, Wu WJ, Huang HS. Histone deacetylase inhibitor trichostatin A resensitizes gemcitabine resistant urothelial carcinoma cells via suppression of TG-interacting factor. Toxicol Appl Pharmacol 2016;290:98-106. [PMID: 26589485 DOI: 10.1016/j.taap.2015.11.007] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
520 Guimarães DM, Almeida LO, Martins MD, Warner KA, Silva AR, Vargas PA, Nunes FD, Squarize CH, Nör JE, Castilho RM. Sensitizing mucoepidermoid carcinomas to chemotherapy by targeted disruption of cancer stem cells. Oncotarget 2016;7:42447-60. [PMID: 27285758 DOI: 10.18632/oncotarget.9884] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 5.3] [Reference Citation Analysis]
521 Kumari A, Cacan E, Greer SF, Garnett-Benson C. Turning T cells on: epigenetically enhanced expression of effector T-cell costimulatory molecules on irradiated human tumor cells. J Immunother Cancer 2013;1:17. [PMID: 24829753 DOI: 10.1186/2051-1426-1-17] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
522 Lernoux M, Schnekenburger M, Dicato M, Diederich M. Epigenetic mechanisms underlying the therapeutic effects of HDAC inhibitors in chronic myeloid leukemia. Biochem Pharmacol 2020;173:113698. [PMID: 31706847 DOI: 10.1016/j.bcp.2019.113698] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
523 Karthik S, Sankar R, Varunkumar K, Ravikumar V. Romidepsin induces cell cycle arrest, apoptosis, histone hyperacetylation and reduces matrix metalloproteinases 2 and 9 expression in bortezomib sensitized non-small cell lung cancer cells. Biomed Pharmacother. 2014;68:327-334. [PMID: 24485799 DOI: 10.1016/j.biopha.2014.01.002] [Cited by in Crossref: 49] [Cited by in F6Publishing: 49] [Article Influence: 6.1] [Reference Citation Analysis]
524 Wang H, Lim Z, Zhou Y, Ng M, Lu T, Lee K, Sangthongpitag K, Goh KC, Wang X, Wu X, Khng HH, Goh SK, Ong WC, Bonday Z, Sun ET. Acylurea connected straight chain hydroxamates as novel histone deacetylase inhibitors: Synthesis, SAR, and in vivo antitumor activity. Bioorganic & Medicinal Chemistry Letters 2010;20:3314-21. [DOI: 10.1016/j.bmcl.2010.04.041] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
525 Zhou H, Jiang S, Chen J, Su SB. Suberoylanilide hydroxamic acid suppresses inflammation-induced neovascularization. Can J Physiol Pharmacol 2014;92:879-85. [PMID: 25272091 DOI: 10.1139/cjpp-2014-0117] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
526 Amnekar RV, Khan SA, Rashid M, Khade B, Thorat R, Gera P, Shrikhande SV, Smoot DT, Ashktorab H, Gupta S. Histone deacetylase inhibitor pre-treatment enhances the efficacy of DNA-interacting chemotherapeutic drugs in gastric cancer. World J Gastroenterol 2020; 26(6): 598-613 [PMID: 32103870 DOI: 10.3748/wjg.v26.i6.598] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
527 Jang YG, Ko EB, Choi KC. Gallic acid, a phenolic acid, hinders the progression of prostate cancer by inhibition of histone deacetylase 1 and 2 expression. J Nutr Biochem 2020;84:108444. [PMID: 32615369 DOI: 10.1016/j.jnutbio.2020.108444] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
528 Uecker A, Sicker M, Beckers T, Mahboobi S, Hägerstrand D, Ostman A, Böhmer FD. Chimeric tyrosine kinase-HDAC inhibitors as antiproliferative agents. Anticancer Drugs 2010;21:759-65. [PMID: 20613486 DOI: 10.1097/CAD.0b013e32833ccf25] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
529 Min KN, Joung KE, Kim DK, Sheen YY. Anti-Cancer Effect of IN-2001 in MDA-MB-231 Human Breast Cancer. Biomol Ther (Seoul) 2012;20:313-9. [PMID: 24130929 DOI: 10.4062/biomolther.2012.20.3.313] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
530 Yildirim F, Gertz K, Kronenberg G, Harms C, Fink KB, Meisel A, Endres M. Inhibition of histone deacetylation protects wildtype but not gelsolin-deficient mice from ischemic brain injury. Exp Neurol 2008;210:531-42. [PMID: 18234195 DOI: 10.1016/j.expneurol.2007.11.031] [Cited by in Crossref: 76] [Cited by in F6Publishing: 81] [Article Influence: 5.1] [Reference Citation Analysis]
531 Yoshida C, Melo JV. Biology of Chronic Myeloid Leukemia and Possible Therapeutic Approaches to Imatinib-Resistant Disease. International Journal of Hematology 2004;79:420-33. [DOI: 10.1532/ijh97.04032] [Cited by in Crossref: 35] [Cited by in F6Publishing: 6] [Article Influence: 1.9] [Reference Citation Analysis]
532 Grant S. The novel histone deacetylase inhibitor NVP-LAQ824: an addition to the therapeutic armamentarium in leukemia? Leukemia 2004;18:1931-3. [DOI: 10.1038/sj.leu.2403522] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
533 Chiarella AM, Lu D, Hathaway NA. Epigenetic Control of a Local Chromatin Landscape. Int J Mol Sci 2020;21:E943. [PMID: 32023873 DOI: 10.3390/ijms21030943] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
534 Jiang GM, Wang HS, Zhang F, Zhang KS, Liu ZC, Fang R, Wang H, Cai SH, Du J. Histone deacetylase inhibitor induction of epithelial-mesenchymal transitions via up-regulation of Snail facilitates cancer progression. Biochim Biophys Acta 2013;1833:663-71. [PMID: 23246564 DOI: 10.1016/j.bbamcr.2012.12.002] [Cited by in Crossref: 47] [Cited by in F6Publishing: 61] [Article Influence: 4.7] [Reference Citation Analysis]
535 Lin CR, Cheng JK, Wu CH, Chen KH, Liu CK. Epigenetic suppression of potassium-chloride co-transporter 2 expression in inflammatory pain induced by complete Freund's adjuvant (CFA). Eur J Pain 2017;21:309-21. [PMID: 27506893 DOI: 10.1002/ejp.925] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
536 Simboeck E, Sawicka A, Zupkovitz G, Senese S, Winter S, Dequiedt F, Ogris E, Di Croce L, Chiocca S, Seiser C. A phosphorylation switch regulates the transcriptional activation of cell cycle regulator p21 by histone deacetylase inhibitors. J Biol Chem 2010;285:41062-73. [PMID: 20952396 DOI: 10.1074/jbc.M110.184481] [Cited by in Crossref: 46] [Cited by in F6Publishing: 32] [Article Influence: 3.8] [Reference Citation Analysis]
537 Rasheed WK, Johnstone RW, Prince HM. Histone deacetylase inhibitors in cancer therapy. Expert Opin Investig Drugs 2007;16:659-78. [PMID: 17461739 DOI: 10.1517/13543784.16.5.659] [Cited by in Crossref: 168] [Cited by in F6Publishing: 146] [Article Influence: 11.2] [Reference Citation Analysis]
538 Cramer SA, Adjei IM, Labhasetwar V. Advancements in the delivery of epigenetic drugs. Expert Opin Drug Deliv 2015;12:1501-12. [PMID: 25739728 DOI: 10.1517/17425247.2015.1021678] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
539 Wu Y, Guo SW. Histone deacetylase inhibitors trichostatin A and valproic acid induce cell cycle arrest and p21 expression in immortalized human endometrial stromal cells. Eur J Obstet Gynecol Reprod Biol. 2008;137:198-203. [PMID: 17376583 DOI: 10.1016/j.ejogrb.2007.02.014] [Cited by in Crossref: 44] [Cited by in F6Publishing: 41] [Article Influence: 2.9] [Reference Citation Analysis]
540 Degen M, Alexander B, Choudhury M, Eshghi M, Konno S. Alternative therapeutic approach to renal-cell carcinoma: induction of apoptosis with combination of vitamin K3 and D-fraction. J Endourol 2013;27:1499-503. [PMID: 24341344 DOI: 10.1089/end.2013.0207] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
541 Chung Y, Lee M, Wang A, Yao L. A therapeutic strategy uses histone deacetylase inhibitors to modulate the expression of genes involved in the pathogenesis of rheumatoid arthritis. Molecular Therapy 2003;8:707-17. [DOI: 10.1016/s1525-0016(03)00235-1] [Cited by in Crossref: 179] [Cited by in F6Publishing: 58] [Article Influence: 9.4] [Reference Citation Analysis]
542 Clarke JD, Hsu A, Yu Z, Dashwood RH, Ho E. Differential effects of sulforaphane on histone deacetylases, cell cycle arrest and apoptosis in normal prostate cells versus hyperplastic and cancerous prostate cells. Mol Nutr Food Res. 2011;55:999-1009. [PMID: 21374800 DOI: 10.1002/mnfr.201000547] [Cited by in Crossref: 123] [Cited by in F6Publishing: 118] [Article Influence: 11.2] [Reference Citation Analysis]
543 Nambiar MP, Warke VG, Fisher CU, Tsokos GC. Effect of trichostatin A on human T cells resembles signaling abnormalities in T cells of patients with systemic lupus erythematosus: a new mechanism for TCR zeta chain deficiency and abnormal signaling. J Cell Biochem 2002;85:459-69. [PMID: 11967985 DOI: 10.1002/jcb.10160] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 1.7] [Reference Citation Analysis]
544 Li Y, Daniel M, Tollefsbol TO. Epigenetic regulation of caloric restriction in aging. BMC Med 2011;9:98. [PMID: 21867551 DOI: 10.1186/1741-7015-9-98] [Cited by in Crossref: 111] [Cited by in F6Publishing: 88] [Article Influence: 10.1] [Reference Citation Analysis]
545 Mills J, Hricik T, Siddiqi S, Matushansky I. Chromatin structure predicts epigenetic therapy responsiveness in sarcoma. Mol Cancer Ther 2011;10:313-24. [PMID: 21216937 DOI: 10.1158/1535-7163.MCT-10-0724] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
546 Donadelli M, Costanzo C, Faggioli L, Scupoli MT, Moore PS, Bassi C, Scarpa A, Palmieri M. Trichostatin A, an inhibitor of histone deacetylases, strongly suppresses growth of pancreatic adenocarcinoma cells. Mol Carcinog. 2003;38:59-69. [PMID: 14502645 DOI: 10.1002/mc.10145] [Cited by in Crossref: 71] [Cited by in F6Publishing: 67] [Article Influence: 3.7] [Reference Citation Analysis]
547 Ocker M, Alajati A, Ganslmayer M, Zopf S, Lüders M, Neureiter D, Hahn EG, Schuppan D, Herold C. The histone-deacetylase inhibitor SAHA potentiates proapoptotic effects of 5-fluorouracil and irinotecan in hepatoma cells. J Cancer Res Clin Oncol. 2005;131:385-394. [PMID: 15754201 DOI: 10.1007/s00432-004-0664-6] [Cited by in Crossref: 53] [Cited by in F6Publishing: 53] [Article Influence: 3.1] [Reference Citation Analysis]
548 Kerr JS, Galloway S, Lagrutta A, Armstrong M, Miller T, Richon VM, Andrews PA. Nonclinical safety assessment of the histone deacetylase inhibitor vorinostat. Int J Toxicol 2010;29:3-19. [PMID: 19903873 DOI: 10.1177/1091581809352111] [Cited by in Crossref: 44] [Cited by in F6Publishing: 42] [Article Influence: 3.4] [Reference Citation Analysis]
549 Gardian G, Browne SE, Choi DK, Klivenyi P, Gregorio J, Kubilus JK, Ryu H, Langley B, Ratan RR, Ferrante RJ, Beal MF. Neuroprotective effects of phenylbutyrate in the N171-82Q transgenic mouse model of Huntington's disease. J Biol Chem 2005;280:556-63. [PMID: 15494404 DOI: 10.1074/jbc.M410210200] [Cited by in Crossref: 314] [Cited by in F6Publishing: 153] [Article Influence: 17.4] [Reference Citation Analysis]
550 Marks P, Rifkind RA, Richon VM, Breslow R, Miller T, Kelly WK. Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer. 2001;1:194-202. [PMID: 11902574 DOI: 10.1038/35106079] [Cited by in Crossref: 1343] [Cited by in F6Publishing: 1219] [Article Influence: 67.2] [Reference Citation Analysis]
551 Hodges-Gallagher L, Valentine CD, Bader SE, Kushner PJ. Inhibition of histone deacetylase enhances the anti-proliferative action of antiestrogens on breast cancer cells and blocks tamoxifen-induced proliferation of uterine cells. Breast Cancer Res Treat 2007;105:297-309. [PMID: 17186358 DOI: 10.1007/s10549-006-9459-6] [Cited by in Crossref: 74] [Cited by in F6Publishing: 66] [Article Influence: 4.6] [Reference Citation Analysis]
552 Goldstein LJ, Zhao F, Wang M, Swaby RF, Sparano JA, Meropol NJ, Bhalla KN, Pellegrino CM, Katherine Alpaugh R, Falkson CI, Klein P, Sledge GW. A Phase I/II study of suberoylanilide hydroxamic acid (SAHA) in combination with trastuzumab (Herceptin) in patients with advanced metastatic and/or local chest wall recurrent HER2-amplified breast cancer: a trial of the ECOG-ACRIN Cancer Research Group (E1104). Breast Cancer Res Treat 2017;165:375-82. [PMID: 28623430 DOI: 10.1007/s10549-017-4310-9] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.6] [Reference Citation Analysis]
553 Gao H, Lou S, Hong H, Ge Q, Zhao H. Autophagy Inhibition Potentiates the Anticancer Effects of a Bendamustine Derivative NL-101 in Acute T Lymphocytic Leukemia. Biomed Res Int 2020;2020:1520651. [PMID: 32149078 DOI: 10.1155/2020/1520651] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
554 Richa S, Dey P, Park C, Yang J, Son JY, Park JH, Lee SH, Ahn MY, Kim IS, Moon HR, Kim HS. A New Histone Deacetylase Inhibitor, MHY4381, Induces Apoptosis via Generation of Reactive Oxygen Species in Human Prostate Cancer Cells. Biomol Ther (Seoul) 2020;28:184-94. [PMID: 31476841 DOI: 10.4062/biomolther.2019.074] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
555 Mannaerts I, Eysackers N, Onyema OO, Van Beneden K, Valente S, Mai A, Odenthal M, van Grunsven LA. Class II HDAC inhibition hampers hepatic stellate cell activation by induction of microRNA-29. PLoS One. 2013;8:e55786. [PMID: 23383282 DOI: 10.1371/journal.pone.0055786] [Cited by in Crossref: 45] [Cited by in F6Publishing: 48] [Article Influence: 5.0] [Reference Citation Analysis]
556 Fernández-rodríguez C, Salar A, Navarro A, Gimeno E, Pairet S, Camacho L, Ferraro M, Serrano S, Besses C, Bellosillo B, Sanchez-gonzalez B. Anti-tumor activity of the combination of bendamustine with vorinostat in diffuse large B-cell lymphoma cells. Leukemia & Lymphoma 2015;57:692-9. [DOI: 10.3109/10428194.2015.1063143] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
557 Nguyen AH, Elliott IA, Wu N, Matsumura C, Vogelauer M, Attar N, Dann A, Ghukasyan R, Toste PA, Patel SG, Williams JL, Li L, Dawson DW, Radu C, Kurdistani SK, Donahue TR. Histone deacetylase inhibitors provoke a tumor supportive phenotype in pancreatic cancer associated fibroblasts. Oncotarget 2017;8:19074-88. [PMID: 27894105 DOI: 10.18632/oncotarget.13572] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
558 Hatziapostolou M, Iliopoulos D. Epigenetic aberrations during oncogenesis. Cell Mol Life Sci. 2011;68:1681-1702. [PMID: 21249513 DOI: 10.1007/s00018-010-0624-z] [Cited by in Crossref: 112] [Cited by in F6Publishing: 104] [Article Influence: 10.2] [Reference Citation Analysis]
559 Dai C, Holland EC. Astrocyte Differentiation States and Glioma Formation: . The Cancer Journal 2003;9:72-81. [DOI: 10.1097/00130404-200303000-00002] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 1.6] [Reference Citation Analysis]
560 Akhavan-Niaki H, Samadani AA. DNA methylation and cancer development: molecular mechanism. Cell Biochem Biophys. 2013;67:501-513. [PMID: 23508887 DOI: 10.1007/s12013-013-9555-2] [Cited by in Crossref: 79] [Cited by in F6Publishing: 82] [Article Influence: 9.9] [Reference Citation Analysis]
561 Bauman J, Shaheen M, Verschraegen CF, Belinsky SA, Houman Fekrazad M, Lee FC, Rabinowitz I, Ravindranathan M, Jones DV Jr. A Phase I Protocol of Hydralazine and Valproic Acid in Advanced, Previously Treated Solid Cancers. Transl Oncol 2014:S1936-5233(14)00020-5. [PMID: 24746712 DOI: 10.1016/j.tranon.2014.03.001] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.5] [Reference Citation Analysis]
562 Wissing MD, Mendonca J, Kortenhorst MS, Kaelber NS, Gonzalez M, Kim E, Hammers H, van Diest PJ, Carducci MA, Kachhap SK. Targeting prostate cancer cell lines with polo-like kinase 1 inhibitors as a single agent and in combination with histone deacetylase inhibitors. FASEB J 2013;27:4279-93. [PMID: 23884428 DOI: 10.1096/fj.12-222893] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 2.4] [Reference Citation Analysis]
563 Ruefli AA, Bernhard D, Tainton KM, Kofler R, Smyth MJ, Johnstone RW. Suberoylanilide hydroxamic acid (SAHA) overcomes multidrug resistance and induces cell death in P-glycoprotein-expressing cells. Int J Cancer. 2002;99:292-298. [PMID: 11979447 DOI: 10.1002/ijc.10327] [Cited by in Crossref: 53] [Cited by in F6Publishing: 45] [Article Influence: 2.7] [Reference Citation Analysis]
564 Drobic B, Dunn KL, Espino PS, Davie JR. Abnormalities of chromatin in tumor cells. EXS 2006;:25-47. [PMID: 16383013 DOI: 10.1007/3-7643-7378-4_2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 11] [Article Influence: 0.2] [Reference Citation Analysis]
565 Chuang MJ, Wu ST, Tang SH, Lai XM, Lai HC, Hsu KH, Sun KH, Sun GH, Chang SY, Yu DS. The HDAC inhibitor LBH589 induces ERK-dependent prometaphase arrest in prostate cancer via HDAC6 inactivation and down-regulation. PLoS One. 2013;8:e73401. [PMID: 24023871 DOI: 10.1371/journal.pone.0073401] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 2.8] [Reference Citation Analysis]
566 Walsh L, Gallagher WM, O’connor DP, Ní Chonghaile T. Diagnostic and Therapeutic Implications of Histone Epigenetic Modulators in Breast Cancer. Expert Review of Molecular Diagnostics 2016;16:541-51. [DOI: 10.1586/14737159.2016.1156534] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
567 Li J, Gong C, Feng X, Zhou X, Xu X, Xie L, Wang R, Zhang D, Wang H, Deng P, Zhou M, Ji N, Zhou Y, Wang Y, Wang Z, Liao G, Geng N, Chu L, Qian Z, Wang Z, Chen Q. Biodegradable thermosensitive hydrogel for SAHA and DDP delivery: therapeutic effects on oral squamous cell carcinoma xenografts. PLoS One 2012;7:e33860. [PMID: 22529899 DOI: 10.1371/journal.pone.0033860] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 2.7] [Reference Citation Analysis]
568 Yang J, Ikezoe T, Nishioka C, Ni L, Koeffler HP, Yokoyama A. Inhibition of mTORC1 by RAD001 (everolimus) potentiates the effects of 1,25-dihydroxyvitamin D3 to induce growth arrest and differentiation of AML cells in vitro and in vivo. Experimental Hematology 2010;38:666-76. [DOI: 10.1016/j.exphem.2010.03.020] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 2.5] [Reference Citation Analysis]
569 Voss SR, Ponomareva LV, Dwaraka VB, Pardue KE, Baddar NWAH, Rodgers AK, Woodcock MR, Qiu Q, Crowner A, Blichmann D, Khatri S, Thorson JS. HDAC Regulates Transcription at the Outset of Axolotl Tail Regeneration. Sci Rep 2019;9:6751. [PMID: 31043677 DOI: 10.1038/s41598-019-43230-6] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
570 Besse L, Kraus M, Besse A, Bader J, Silzle T, Mehrling T, Driessen C. The first-in-class alkylating HDAC inhibitor EDO-S101 is highly synergistic with proteasome inhibition against multiple myeloma through activation of multiple pathways. Blood Cancer J 2017;7:e589. [PMID: 28753594 DOI: 10.1038/bcj.2017.69] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
571 Sato A, Asano T, Ito K, Asano T. Vorinostat and bortezomib synergistically cause ubiquitinated protein accumulation in prostate cancer cells. J Urol 2012;188:2410-8. [PMID: 23088964 DOI: 10.1016/j.juro.2012.07.108] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 2.1] [Reference Citation Analysis]
572 Urbinati G, Marsaud V, Plassat V, Fattal E, Lesieur S, Renoir J. Liposomes loaded with histone deacetylase inhibitors for breast cancer therapy. International Journal of Pharmaceutics 2010;397:184-93. [DOI: 10.1016/j.ijpharm.2010.06.046] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 2.2] [Reference Citation Analysis]
573 Gameiro SR, Malamas AS, Tsang KY, Ferrone S, Hodge JW. Inhibitors of histone deacetylase 1 reverse the immune evasion phenotype to enhance T-cell mediated lysis of prostate and breast carcinoma cells. Oncotarget 2016;7:7390-402. [PMID: 26862729 DOI: 10.18632/oncotarget.7180] [Cited by in Crossref: 45] [Cited by in F6Publishing: 45] [Article Influence: 7.5] [Reference Citation Analysis]
574 Glaser KB, Li J, Staver MJ, Wei R, Albert DH, Davidsen SK. Role of Class I and Class II histone deacetylases in carcinoma cells using siRNA. Biochemical and Biophysical Research Communications 2003;310:529-36. [DOI: 10.1016/j.bbrc.2003.09.043] [Cited by in Crossref: 165] [Cited by in F6Publishing: 149] [Article Influence: 8.7] [Reference Citation Analysis]
575 Paller CJ, Wissing MD, Mendonca J, Sharma A, Kim E, Kim HS, Kortenhorst MS, Gerber S, Rosen M, Shaikh F, Zahurak ML, Rudek MA, Hammers H, Rudin CM, Carducci MA, Kachhap SK. Combining the pan-aurora kinase inhibitor AMG 900 with histone deacetylase inhibitors enhances antitumor activity in prostate cancer. Cancer Med 2014;3:1322-35. [PMID: 24989836 DOI: 10.1002/cam4.289] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
576 Takahashi S, McConnell MJ, Harigae H, Kaku M, Sasaki T, Melnick AM, Licht JD. The Flt3 internal tandem duplication mutant inhibits the function of transcriptional repressors by blocking interactions with SMRT. Blood 2004;103:4650-8. [PMID: 14982881 DOI: 10.1182/blood-2003-08-2759] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 1.3] [Reference Citation Analysis]
577 Mühlenberg T, Zhang Y, Wagner AJ, Grabellus F, Bradner J, Taeger G, Lang H, Taguchi T, Schuler M, Fletcher JA. Inhibitors of deacetylases suppress oncogenic KIT signaling, acetylate HSP90, and induce apoptosis in gastrointestinal stromal tumors. Cancer Res. 2009;69:6941-6950. [PMID: 19706776 DOI: 10.1158/0008-5472.can-08-4004] [Cited by in Crossref: 63] [Cited by in F6Publishing: 42] [Article Influence: 4.8] [Reference Citation Analysis]
578 Prebet T, Vey N. Vorinostat in acute myeloid leukemia and myelodysplastic syndromes. Expert Opin Investig Drugs 2011;20:287-95. [PMID: 21192773 DOI: 10.1517/13543784.2011.542750] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 2.3] [Reference Citation Analysis]
579 Sharma P, Kumar S, Kundu GC. Transcriptional regulation of human osteopontin promoter by histone deacetylase inhibitor, trichostatin A in cervical cancer cells. Mol Cancer 2010;9:178. [PMID: 20609221 DOI: 10.1186/1476-4598-9-178] [Cited by in Crossref: 39] [Cited by in F6Publishing: 40] [Article Influence: 3.3] [Reference Citation Analysis]
580 Hanigan TW, Aboukhatwa SM, Taha TY, Frasor J, Petukhov PA. Divergent JNK Phosphorylation of HDAC3 in Triple-Negative Breast Cancer Cells Determines HDAC Inhibitor Binding and Selectivity. Cell Chem Biol 2017;24:1356-1367.e8. [PMID: 28943357 DOI: 10.1016/j.chembiol.2017.08.015] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 3.2] [Reference Citation Analysis]
581 Mottet D, Pirotte S, Lamour V, Hagedorn M, Javerzat S, Bikfalvi A, Bellahcène A, Verdin E, Castronovo V. HDAC4 represses p21(WAF1/Cip1) expression in human cancer cells through a Sp1-dependent, p53-independent mechanism. Oncogene 2009;28:243-56. [PMID: 18850004 DOI: 10.1038/onc.2008.371] [Cited by in Crossref: 109] [Cited by in F6Publishing: 99] [Article Influence: 7.8] [Reference Citation Analysis]
582 Hrzenjak A, Kremser ML, Strohmeier B, Moinfar F, Zatloukal K, Denk H. SAHA induces caspase-independent, autophagic cell death of endometrial stromal sarcoma cells by influencing the mTOR pathway. J Pathol 2008;216:495-504. [PMID: 18850582 DOI: 10.1002/path.2434] [Cited by in Crossref: 72] [Cited by in F6Publishing: 71] [Article Influence: 5.1] [Reference Citation Analysis]
583 Marks PA. The clinical development of histone deacetylase inhibitors as targeted anticancer drugs. Expert Opin Investig Drugs. 2010;19:1049-1066. [PMID: 20687783 DOI: 10.1517/13543784.2010.510514] [Cited by in Crossref: 202] [Cited by in F6Publishing: 190] [Article Influence: 18.4] [Reference Citation Analysis]
584 Nagaki Y, Motoyama S, Yamaguchi T, Hoshizaki M, Sato Y, Sato T, Koizumi Y, Wakita A, Kawakita Y, Imai K, Nanjo H, Watanabe H, Imai Y, Minamiya Y, Kuba K. m6 A demethylase ALKBH5 promotes proliferation of esophageal squamous cell carcinoma associated with poor prognosis. Genes Cells 2020;25:547-61. [PMID: 32449584 DOI: 10.1111/gtc.12792] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
585 Malinen M, Saramäki A, Ropponen A, Degenhardt T, Väisänen S, Carlberg C. Distinct HDACs regulate the transcriptional response of human cyclin-dependent kinase inhibitor genes to Trichostatin A and 1alpha,25-dihydroxyvitamin D3. Nucleic Acids Res. 2008;36:121-132. [PMID: 17999998 DOI: 10.1093/nar/gkm913] [Cited by in Crossref: 48] [Cited by in F6Publishing: 45] [Article Influence: 3.2] [Reference Citation Analysis]
586 Ouyang D, Zhang Y, Xu L, Li J, Zha Q, He X. Histone deacetylase inhibitor valproic acid sensitizes B16F10 melanoma cells to cucurbitacin B treatment. Acta Biochim Biophys Sin (Shanghai) 2011;43:487-95. [PMID: 21628505 DOI: 10.1093/abbs/gmr032] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 2.2] [Reference Citation Analysis]
587 Mathew OP, Ranganna K, Mathew J, Zhu M, Yousefipour Z, Selvam C, Milton SG. Cellular Effects of Butyrate on Vascular Smooth Muscle Cells are Mediated through Disparate Actions on Dual Targets, Histone Deacetylase (HDAC) Activity and PI3K/Akt Signaling Network. Int J Mol Sci 2019;20:E2902. [PMID: 31197106 DOI: 10.3390/ijms20122902] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
588 Thomas CY, Theodorescu D. Molecular markers of prognosis and novel therapeutic strategies for urothelial cell carcinomas. World J Urol 2006;24:565-78. [DOI: 10.1007/s00345-006-0119-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
589 Buglio D, Georgakis GV, Hanabuchi S, Arima K, Khaskhely NM, Liu YJ, Younes A. Vorinostat inhibits STAT6-mediated TH2 cytokine and TARC production and induces cell death in Hodgkin lymphoma cell lines. Blood 2008;112:1424-33. [PMID: 18541724 DOI: 10.1182/blood-2008-01-133769] [Cited by in Crossref: 126] [Cited by in F6Publishing: 116] [Article Influence: 9.0] [Reference Citation Analysis]
590 Huang H, Liu N, Yang C, Liao S, Guo H, Zhao K, Li X, Liu S, Guan L, Liu C, Xu L, Zhang C, Song W, Li B, Tang P, Dou QP, Liu J. HDAC inhibitor L-carnitine and proteasome inhibitor bortezomib synergistically exert anti-tumor activity in vitro and in vivo. PLoS One 2012;7:e52576. [PMID: 23285100 DOI: 10.1371/journal.pone.0052576] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 1.9] [Reference Citation Analysis]
591 Richon VM, Zhou X, Rifkind RA, Marks PA. Histone Deacetylase Inhibitors: Development of Suberoylanilide Hydroxamic Acid (SAHA) for the Treatment of Cancers. Blood Cells, Molecules, and Diseases 2001;27:260-4. [DOI: 10.1006/bcmd.2000.0376] [Cited by in Crossref: 68] [Cited by in F6Publishing: 61] [Article Influence: 3.2] [Reference Citation Analysis]
592 Miller CP, Singh MM, Rivera-Del Valle N, Manton CA, Chandra J. Therapeutic strategies to enhance the anticancer efficacy of histone deacetylase inhibitors. J Biomed Biotechnol 2011;2011:514261. [PMID: 21765634 DOI: 10.1155/2011/514261] [Cited by in Crossref: 42] [Cited by in F6Publishing: 45] [Article Influence: 3.8] [Reference Citation Analysis]
593 Im JY, Park H, Kang KW, Choi WS, Kim HS. Modulation of cell cycles and apoptosis by apicidin in estrogen receptor (ER)-positive and-negative human breast cancer cells. Chemico-Biological Interactions 2008;172:235-44. [DOI: 10.1016/j.cbi.2008.01.007] [Cited by in Crossref: 34] [Cited by in F6Publishing: 26] [Article Influence: 2.4] [Reference Citation Analysis]
594 Záškodová D, Řezáčová M, Vávrová J, Vokurková D, Tichý A. Effect of Valproic Acid, a Histone Deacetylase Inhibitor, on Cell Death and Molecular Changes Caused by Low-Dose Irradiation. Annals of the New York Academy of Sciences 2006;1091:385-98. [DOI: 10.1196/annals.1378.082] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
595 Jones LK, Saha V. Chromatin modification, leukaemia and implications for therapy. Br J Haematol 2002;118:714-27. [PMID: 12181038 DOI: 10.1046/j.1365-2141.2002.03586.x] [Cited by in Crossref: 36] [Cited by in F6Publishing: 25] [Article Influence: 1.8] [Reference Citation Analysis]
596 Mrakovcic M, Kleinheinz J, Fröhlich LF. p53 at the Crossroads between Different Types of HDAC Inhibitor-Mediated Cancer Cell Death. Int J Mol Sci 2019;20:E2415. [PMID: 31096697 DOI: 10.3390/ijms20102415] [Cited by in Crossref: 22] [Cited by in F6Publishing: 26] [Article Influence: 7.3] [Reference Citation Analysis]
597 Guo SQ, Zhang YZ. Histone deacetylase inhibition: an important mechanism in the treatment of lymphoma. Cancer Biol Med 2012;9:85-9. [PMID: 23691460 DOI: 10.3969/j.issn.2095-3941.2012.02.001] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
598 Huang H, Liu N, Guo H, Liao S, Li X, Yang C, Liu S, Song W, Liu C, Guan L. L-carnitine is an endogenous HDAC inhibitor selectively inhibiting cancer cell growth in vivo and in vitro. PLoS One. 2012;7:e49062. [PMID: 23139833 DOI: 10.1371/journal.pone.0049062] [Cited by in Crossref: 54] [Cited by in F6Publishing: 50] [Article Influence: 5.4] [Reference Citation Analysis]
599 Shim JS, Kim DH, Kwon HJ. Plakoglobin is a new target gene of histone deacetylase in human fibrosarcoma HT1080 cells. Oncogene 2004;23:1704-11. [PMID: 14661058 DOI: 10.1038/sj.onc.1207289] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 0.7] [Reference Citation Analysis]
600 Langley B, D'Annibale MA, Suh K, Ayoub I, Tolhurst A, Bastan B, Yang L, Ko B, Fisher M, Cho S, Beal MF, Ratan RR. Pulse inhibition of histone deacetylases induces complete resistance to oxidative death in cortical neurons without toxicity and reveals a role for cytoplasmic p21(waf1/cip1) in cell cycle-independent neuroprotection. J Neurosci 2008;28:163-76. [PMID: 18171934 DOI: 10.1523/JNEUROSCI.3200-07.2008] [Cited by in Crossref: 105] [Cited by in F6Publishing: 86] [Article Influence: 7.5] [Reference Citation Analysis]
601 Cortez CC, Jones PA. Chromatin, cancer and drug therapies. Mutat Res 2008;647:44-51. [PMID: 18691602 DOI: 10.1016/j.mrfmmm.2008.07.006] [Cited by in Crossref: 50] [Cited by in F6Publishing: 44] [Article Influence: 3.6] [Reference Citation Analysis]
602 Kwon MJ, Shin YK. Epigenetic regulation of cancer-associated genes in ovarian cancer. Int J Mol Sci 2011;12:983-1008. [PMID: 21541038 DOI: 10.3390/ijms12020983] [Cited by in Crossref: 44] [Cited by in F6Publishing: 37] [Article Influence: 4.0] [Reference Citation Analysis]
603 Beck HC. Mass spectrometry in epigenetic research. Methods Mol Biol 2010;593:263-82. [PMID: 19957154 DOI: 10.1007/978-1-60327-194-3_13] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
604 Sebova K, Fridrichova I. Epigenetic tools in potential anticancer therapy. Anticancer Drugs 2010;21:565-77. [PMID: 20436342 DOI: 10.1097/CAD.0b013e32833a4352] [Cited by in Crossref: 22] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
605 Marks PA, Dokmanovic M. Histone deacetylase inhibitors: discovery and development as anticancer agents. Expert Opin Investig Drugs. 2005;14:1497-1511. [PMID: 16307490 DOI: 10.1517/13543784.14.12.1497] [Cited by in Crossref: 216] [Cited by in F6Publishing: 204] [Article Influence: 13.5] [Reference Citation Analysis]
606 Esrick EB, McConkey M, Lin K, Frisbee A, Ebert BL. Inactivation of HDAC1 or HDAC2 induces gamma globin expression without altering cell cycle or proliferation. Am J Hematol 2015;90:624-8. [PMID: 25808664 DOI: 10.1002/ajh.24019] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
607 Blattmann C, Oertel S, Ehemann V, Thiemann M, Huber PE, Bischof M, Witt O, Deubzer HE, Kulozik AE, Debus J, Weber KJ. Enhancement of radiation response in osteosarcoma and rhabdomyosarcoma cell lines by histone deacetylase inhibition. Int J Radiat Oncol Biol Phys 2010;78:237-45. [PMID: 20646843 DOI: 10.1016/j.ijrobp.2010.03.010] [Cited by in Crossref: 70] [Cited by in F6Publishing: 68] [Article Influence: 5.8] [Reference Citation Analysis]
608 Nihal M, Roelke CT, Wood GS. Anti-melanoma effects of vorinostat in combination with polyphenolic antioxidant (-)-epigallocatechin-3-gallate (EGCG). Pharm Res 2010;27:1103-14. [PMID: 20232120 DOI: 10.1007/s11095-010-0054-5] [Cited by in Crossref: 38] [Cited by in F6Publishing: 33] [Article Influence: 3.2] [Reference Citation Analysis]
609 Zhang L, Qiu Z, Hu Y, Yang F, Yan S, Zhao L, Li B, He S, Huang M, Li J, Li L. ABA treatment of germinating maize seeds induces VP1 gene expression and selective promoter-associated histone acetylation. Physiol Plant 2011;143:287-96. [PMID: 21679193 DOI: 10.1111/j.1399-3054.2011.01496.x] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 2.7] [Reference Citation Analysis]
610 Diyabalanage HV, Granda ML, Hooker JM. Combination therapy: histone deacetylase inhibitors and platinum-based chemotherapeutics for cancer. Cancer Lett 2013;329:1-8. [PMID: 23032720 DOI: 10.1016/j.canlet.2012.09.018] [Cited by in Crossref: 58] [Cited by in F6Publishing: 54] [Article Influence: 5.8] [Reference Citation Analysis]
611 Tanji N, Ozawa A, Kikugawa T, Miura N, Sasaki T, Azuma K, Yokoyama M. Potential of histone deacetylase inhibitors for bladder cancer treatment. Expert Review of Anticancer Therapy 2014;11:959-65. [DOI: 10.1586/era.10.230] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
612 Mackmull MT, Iskar M, Parca L, Singer S, Bork P, Ori A, Beck M. Histone deacetylase inhibitors (HDACi) cause the selective depletion of bromodomain containing proteins (BCPs). Mol Cell Proteomics. 2015;14:1350-1360. [PMID: 25755299 DOI: 10.1074/mcp.m114.042499] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
613 Wächter S, Damanakis AI, Elxnat M, Roth S, Wunderlich A, Verburg FA, Fellinger SA, Bartsch DK, Di Fazio P. Epigenetic Modifications in Thyroid Cancer Cells Restore NIS and Radio-Iodine Uptake and Promote Cell Death. J Clin Med 2018;7:E61. [PMID: 29561759 DOI: 10.3390/jcm7040061] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
614 Zhang C, Richon V, Ni X, Talpur R, Duvic M. Selective induction of apoptosis by histone deacetylase inhibitor SAHA in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action. J Invest Dermatol 2005;125:1045-52. [PMID: 16297208 DOI: 10.1111/j.0022-202X.2005.23925.x] [Cited by in Crossref: 180] [Cited by in F6Publishing: 79] [Article Influence: 11.3] [Reference Citation Analysis]
615 Zheng X, Hou H, Zhang H, Yue M, Hu Y, Li L. Histone acetylation is involved in GA-mediated 45S rDNA decondensation in maize aleurone layers. Plant Cell Rep 2018;37:115-23. [PMID: 28939922 DOI: 10.1007/s00299-017-2207-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
616 Wise LD, Spence S, Saldutti LP, Kerr JS. Assessment of female and male fertility in Sprague-Dawley rats administered vorinostat, a histone deacetylase inhibitor. Birth Defects Res B Dev Reprod Toxicol 2008;83:19-26. [PMID: 18092367 DOI: 10.1002/bdrb.20139] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
617 Myzak MC, Dashwood WM, Orner GA, Ho E, Dashwood RH. Sulforaphane inhibits histone deacetylase in vivo and suppresses tumorigenesis in Apc-minus mice. FASEB J. 2006;20:506-508. [PMID: 16407454 DOI: 10.1096/fj.05-4785fje] [Cited by in Crossref: 245] [Cited by in F6Publishing: 213] [Article Influence: 15.3] [Reference Citation Analysis]
618 Hajji N, Joseph B. Epigenetic regulation of cell life and death decisions and deregulation in cancer. Essays Biochem 2010;48:121-46. [PMID: 20822491 DOI: 10.1042/bse0480121] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
619 Akimova T, Beier UH, Liu Y, Wang L, Hancock WW. Histone/protein deacetylases and T-cell immune responses. Blood. 2012;119:2443-2451. [PMID: 22246031 DOI: 10.1182/blood-2011-10-292003] [Cited by in Crossref: 93] [Cited by in F6Publishing: 85] [Article Influence: 9.3] [Reference Citation Analysis]
620 Savio M, Coppa T, Cazzalini O, Perucca P, Necchi D, Nardo T, Stivala LA, Prosperi E. Degradation of p21CDKN1A after DNA damage is independent of type of lesion, and is not required for DNA repair. DNA Repair (Amst) 2009;8:778-85. [PMID: 19321391 DOI: 10.1016/j.dnarep.2009.02.005] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
621 Esteller M. The necessity of a human epigenome project. Carcinogenesis. 2006;27:1121-1125. [PMID: 16699174 DOI: 10.1093/carcin/bgl033] [Cited by in Crossref: 110] [Cited by in F6Publishing: 92] [Article Influence: 6.9] [Reference Citation Analysis]
622 Lauffer BE, Mintzer R, Fong R, Mukund S, Tam C, Zilberleyb I, Flicke B, Ritscher A, Fedorowicz G, Vallero R, Ortwine DF, Gunzner J, Modrusan Z, Neumann L, Koth CM, Lupardus PJ, Kaminker JS, Heise CE, Steiner P. Histone deacetylase (HDAC) inhibitor kinetic rate constants correlate with cellular histone acetylation but not transcription and cell viability. J Biol Chem 2013;288:26926-43. [PMID: 23897821 DOI: 10.1074/jbc.M113.490706] [Cited by in Crossref: 230] [Cited by in F6Publishing: 88] [Article Influence: 25.6] [Reference Citation Analysis]
623 Zhou W, Chen X, He K, Xiao J, Duan X, Huang R, Xia Z, He J, Zhang J, Xiang G. Histone deacetylase inhibitor screening identifies HC toxin as the most effective in intrahepatic cholangiocarcinoma cells. Oncol Rep 2016;35:2535-42. [PMID: 26935789 DOI: 10.3892/or.2016.4636] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
624 Calonghi N, Boga C, Telese D, Bordoni S, Sartor G, Torsello C, Micheletti G. Synthesis of 9-Hydroxystearic Acid Derivatives and Their Antiproliferative Activity on HT 29 Cancer Cells. Molecules 2019;24:E3714. [PMID: 31619025 DOI: 10.3390/molecules24203714] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
625 Bosch I, Xhaja K, Estevez L, Raines G, Melichar H, Warke RV, Fournier MV, Ennis FA, Rothman AL. Increased production of interleukin-8 in primary human monocytes and in human epithelial and endothelial cell lines after dengue virus challenge. J Virol 2002;76:5588-97. [PMID: 11991987 DOI: 10.1128/jvi.76.11.5588-5597.2002] [Cited by in Crossref: 106] [Cited by in F6Publishing: 51] [Article Influence: 5.3] [Reference Citation Analysis]
626 Warrener R, Beamish H, Burgess A, Waterhouse NJ, Giles N, Fairlie DP, Gabrielli B. Tumor cell‐specific cytotoxicity by targeting cell cycle checkpoints. FASEB j 2003;17:1-21. [DOI: 10.1096/fj.02-1003fje] [Cited by in Crossref: 104] [Cited by in F6Publishing: 100] [Article Influence: 5.5] [Reference Citation Analysis]
627 Ferrante RJ, Kubilus JK, Lee J, Ryu H, Beesen A, Zucker B, Smith K, Kowall NW, Ratan RR, Luthi-Carter R, Hersch SM. Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington's disease mice. J Neurosci 2003;23:9418-27. [PMID: 14561870 [PMID: 14561870 DOI: 10.1523/jneurosci.23-28-09418.2003] [Cited by in Crossref: 482] [Article Influence: 25.4] [Reference Citation Analysis]
628 Nalawansha DA, Zhang Y, Herath K, Pflum MKH. HDAC1 Substrate Profiling Using Proteomics-Based Substrate Trapping. ACS Chem Biol 2018;13:3315-24. [PMID: 30421914 DOI: 10.1021/acschembio.8b00737] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
629 Dagtas AS, Edens RE, Gilbert KM. Histone deacetylase inhibitor uses p21(Cip1) to maintain anergy in CD4+ T cells. Int Immunopharmacol 2009;9:1289-97. [PMID: 19664724 DOI: 10.1016/j.intimp.2009.07.012] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
630 Liang YL, Fu Y, Chen SG, Cai XM, Su JM, Jin JW, Ma DZ, Li ZX, Zhang W, Zha X. Integrin beta1 subunit overexpressed in the SMMC-7721 cells regulates the promoter activity of p21(CIP1) and enhances its transcription. FEBS Lett 2004;558:107-13. [PMID: 14759525 DOI: 10.1016/S0014-5793(03)01469-8] [Cited by in Crossref: 11] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
631 Ropero S, Ballestar E, Alaminos M, Arango D, Schwartz S Jr, Esteller M. Transforming pathways unleashed by a HDAC2 mutation in human cancer. Oncogene 2008;27:4008-12. [PMID: 18264134 DOI: 10.1038/onc.2008.31] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 1.8] [Reference Citation Analysis]
632 Schröder C, Khatri R, Petry SF, Linn T. Class I and II Histone Deacetylase Inhibitor LBH589 Promotes Endocrine Differentiation in Bone Marrow Derived Human Mesenchymal Stem Cells and Suppresses Uncontrolled Proliferation. Exp Clin Endocrinol Diabetes 2021;129:357-64. [PMID: 32052390 DOI: 10.1055/a-1103-1900] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
633 Chang F, Steelman LS, Lee JT, Shelton JG, Navolanic PM, Blalock WL, Franklin RA, Mccubrey JA. Signal transduction mediated by the Ras/Raf/MEK/ERK pathway from cytokine receptors to transcription factors: potential targeting for therapeutic intervention. Leukemia 2003;17:1263-93. [DOI: 10.1038/sj.leu.2402945] [Cited by in Crossref: 458] [Cited by in F6Publishing: 436] [Article Influence: 24.1] [Reference Citation Analysis]
634 Kostyniuk CL, Dehm SM, Batten D, Bonham K. The ubiquitous and tissue specific promoters of the human SRC gene are repressed by inhibitors of histone deacetylases. Oncogene 2002;21:6340-7. [DOI: 10.1038/sj.onc.1205787] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 1.6] [Reference Citation Analysis]
635 Chen C, Sung J, Cohen M, Chowdhury WH, Sachs MD, Li Y, Lakshmanan Y, Yung BYM, Lupold SE, Rodriguez R. Valproic Acid Inhibits Invasiveness in Bladder Cancer but Not in Prostate Cancer Cells. J Pharmacol Exp Ther 2006;319:533-42. [DOI: 10.1124/jpet.106.106658] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 1.9] [Reference Citation Analysis]
636 Eckschlager T, Plch J, Stiborova M, Hrabeta J. Histone Deacetylase Inhibitors as Anticancer Drugs. Int J Mol Sci. 2017;18. [PMID: 28671573 DOI: 10.3390/ijms18071414] [Cited by in Crossref: 468] [Cited by in F6Publishing: 434] [Article Influence: 93.6] [Reference Citation Analysis]
637 Guerrant W, Patil V, Canzoneri JC, Oyelere AK. Dual targeting of histone deacetylase and topoisomerase II with novel bifunctional inhibitors. J Med Chem 2012;55:1465-77. [PMID: 22260166 DOI: 10.1021/jm200799p] [Cited by in Crossref: 99] [Cited by in F6Publishing: 89] [Article Influence: 9.9] [Reference Citation Analysis]
638 Glenn MP, Kahnberg P, Boyle GM, Hansford KA, Hans D, Martyn AC, Parsons PG, Fairlie DP. Antiproliferative and Phenotype-Transforming Antitumor Agents Derived from Cysteine. J Med Chem 2004;47:2984-94. [DOI: 10.1021/jm030222i] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 1.3] [Reference Citation Analysis]
639 Kang MR, Kang JS, Han SB, Kim JH, Kim DM, Lee K, Lee CW, Lee KH, Lee CH, Han G. A novel delta-lactam-based histone deacetylase inhibitor, KBH-A42, induces cell cycle arrest and apoptosis in colon cancer cells. Biochem Pharmacol. 2009;78:486-494. [PMID: 19445901 DOI: 10.1016/j.bcp.2009.05.010] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.3] [Reference Citation Analysis]
640 Luu T, Frankel P, Beumer JH, Lim D, Cristea M, Appleman LJ, Lenz HJ, Gandara DR, Kiesel BF, Piekarz RL, Newman EM. Phase I trial of belinostat in combination with 13-cis-retinoic acid in advanced solid tumor malignancies: a California Cancer Consortium NCI/CTEP sponsored trial. Cancer Chemother Pharmacol 2019;84:1201-8. [PMID: 31522242 DOI: 10.1007/s00280-019-03955-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
641 Mehnert JM, Kelly WK. Histone deacetylase inhibitors: biology and mechanism of action. Cancer J 2007;13:23-9. [PMID: 17464243 DOI: 10.1097/PPO.0b013e31803c72ba] [Cited by in Crossref: 71] [Cited by in F6Publishing: 34] [Article Influence: 4.7] [Reference Citation Analysis]
642 Leone G, D'Alò F, Zardo G, Voso MT, Nervi C. Epigenetic treatment of myelodysplastic syndromes and acute myeloid leukemias. Curr Med Chem 2008;15:1274-87. [PMID: 18537607 DOI: 10.2174/092986708784534947] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 2.1] [Reference Citation Analysis]
643 Giannopoulou AF, Velentzas AD, Konstantakou EG, Avgeris M, Katarachia SA, Papandreou NC, Kalavros NI, Mpakou VE, Iconomidou V, Anastasiadou E, Kostakis IK, Papassideri IS, Voutsinas GE, Scorilas A, Stravopodis DJ. Revisiting Histone Deacetylases in Human Tumorigenesis: The Paradigm of Urothelial Bladder Cancer. Int J Mol Sci 2019;20:E1291. [PMID: 30875794 DOI: 10.3390/ijms20061291] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 6.7] [Reference Citation Analysis]
644 Blaheta RA, Cinatl J Jr. Anti-tumor mechanisms of valproate: a novel role for an old drug. Med Res Rev 2002;22:492-511. [PMID: 12210556 DOI: 10.1002/med.10017] [Cited by in Crossref: 182] [Cited by in F6Publishing: 161] [Article Influence: 9.1] [Reference Citation Analysis]
645 Boutillier AL, Trinh E, Loeffler JP. Selective E2F-dependent gene transcription is controlled by histone deacetylase activity during neuronal apoptosis. J Neurochem 2003;84:814-28. [PMID: 12562525 DOI: 10.1046/j.1471-4159.2003.01581.x] [Cited by in Crossref: 72] [Cited by in F6Publishing: 75] [Article Influence: 3.8] [Reference Citation Analysis]
646 Mishra N, Brown DR, Olorenshaw IM, Kammer GM. Trichostatin A reverses skewed expression of CD154, interleukin-10, and interferon-gamma gene and protein expression in lupus T cells. Proc Natl Acad Sci U S A 2001;98:2628-33. [PMID: 11226290 DOI: 10.1073/pnas.051507098] [Cited by in Crossref: 139] [Cited by in F6Publishing: 117] [Article Influence: 6.6] [Reference Citation Analysis]
647 Jain S, Zain J, O'Connor O. Novel therapeutic agents for cutaneous T-Cell lymphoma. J Hematol Oncol 2012;5:24. [PMID: 22594538 DOI: 10.1186/1756-8722-5-24] [Cited by in Crossref: 38] [Cited by in F6Publishing: 35] [Article Influence: 3.8] [Reference Citation Analysis]
648 Perucca P, Cazzalini O, Mortusewicz O, Necchi D, Savio M, Nardo T, Stivala LA, Leonhardt H, Cardoso MC, Prosperi E. Spatiotemporal dynamics of p21CDKN1A protein recruitment to DNA-damage sites and interaction with proliferating cell nuclear antigen. Journal of Cell Science 2006;119:1517-27. [DOI: 10.1242/jcs.02868] [Cited by in Crossref: 38] [Cited by in F6Publishing: 39] [Article Influence: 2.4] [Reference Citation Analysis]
649 Pandolfi PP. Transcription therapy for cancer. Oncogene 2001;20:3116-27. [DOI: 10.1038/sj.onc.1204299] [Cited by in Crossref: 121] [Cited by in F6Publishing: 121] [Article Influence: 5.8] [Reference Citation Analysis]
650 Iwahashi S, Shimada M, Utsunomiya T, Morine Y, Imura S, Ikemoto T, Mori H, Hanaoka J, Sugimoto K, Saito Y. Histone deacetylase inhibitor augments anti-tumor effect of gemcitabine and pegylated interferon-α on pancreatic cancer cells. Int J Clin Oncol 2011;16:671-8. [DOI: 10.1007/s10147-011-0246-y] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 1.7] [Reference Citation Analysis]
651 Hu S, Liu L, Chang EB, Wang JY, Raufman JP. Butyrate inhibits pro-proliferative miR-92a by diminishing c-Myc-induced miR-17-92a cluster transcription in human colon cancer cells. Mol Cancer. 2015;14:180. [PMID: 26463716 DOI: 10.1186/s12943-015-0450-x] [Cited by in Crossref: 80] [Cited by in F6Publishing: 75] [Article Influence: 11.4] [Reference Citation Analysis]
652 Li GC, Zhang X, Pan TJ, Chen Z, Ye ZQ. Histone deacetylase inhibitor trichostatin A inhibits the growth of bladder cancer cells through induction of p21WAF1 and G1 cell cycle arrest. Int J Urol 2006;13:581-6. [PMID: 16771729 DOI: 10.1111/j.1442-2042.2006.01344.x] [Cited by in Crossref: 41] [Cited by in F6Publishing: 35] [Article Influence: 2.6] [Reference Citation Analysis]
653 Stypula-Cyrus Y, Damania D, Kunte DP, Cruz MD, Subramanian H, Roy HK, Backman V. HDAC up-regulation in early colon field carcinogenesis is involved in cell tumorigenicity through regulation of chromatin structure. PLoS One 2013;8:e64600. [PMID: 23724067 DOI: 10.1371/journal.pone.0064600] [Cited by in Crossref: 84] [Cited by in F6Publishing: 66] [Article Influence: 9.3] [Reference Citation Analysis]
654 Palmieri D, Lockman PR, Thomas FC, Hua E, Herring J, Hargrave E, Johnson M, Flores N, Qian Y, Vega-Valle E, Taskar KS, Rudraraju V, Mittapalli RK, Gaasch JA, Bohn KA, Thorsheim HR, Liewehr DJ, Davis S, Reilly JF, Walker R, Bronder JL, Feigenbaum L, Steinberg SM, Camphausen K, Meltzer PS, Richon VM, Smith QR, Steeg PS. Vorinostat inhibits brain metastatic colonization in a model of triple-negative breast cancer and induces DNA double-strand breaks. Clin Cancer Res 2009;15:6148-57. [PMID: 19789319 DOI: 10.1158/1078-0432.CCR-09-1039] [Cited by in Crossref: 104] [Cited by in F6Publishing: 66] [Article Influence: 8.0] [Reference Citation Analysis]
655 Lyberg K, Ali HA, Grootens J, Kjellander M, Tirfing M, Arock M, Hägglund H, Nilsson G, Ungerstedt J. Histone deacetylase inhibitor SAHA mediates mast cell death and epigenetic silencing of constitutively active D816V KIT in systemic mastocytosis. Oncotarget 2017;8:9647-59. [PMID: 28038453 DOI: 10.18632/oncotarget.14181] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
656 Vinodhkumar R, Song YS, Devaki T. Romidepsin (depsipeptide) induced cell cycle arrest, apoptosis and histone hyperacetylation in lung carcinoma cells (A549) are associated with increase in p21 and hypophosphorylated retinoblastoma proteins expression. Biomed Pharmacother 2008;62:85-93. [PMID: 17644301 DOI: 10.1016/j.biopha.2007.06.002] [Cited by in Crossref: 28] [Cited by in F6Publishing: 21] [Article Influence: 1.9] [Reference Citation Analysis]
657 Szyf M. Epigenetic therapeutics in autoimmune disease. Clin Rev Allergy Immunol. 2010;39:62-77. [PMID: 19644776 DOI: 10.1007/s12016-009-8172-8] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 2.7] [Reference Citation Analysis]
658 Carraway HE, Sawalha Y, Gojo I, Lee MJ, Lee S, Tomita Y, Yuno A, Greer J, Smith BD, Pratz KW, Levis MJ, Gore SD, Ghosh N, Dezern A, Blackford AL, Baer MR, Gore L, Piekarz R, Trepel JB, Karp JE. Phase 1 study of the histone deacetylase inhibitor entinostat plus clofarabine for poor-risk Philadelphia chromosome-negative (newly diagnosed older adults or adults with relapsed refractory disease) acute lymphoblastic leukemia or biphenotypic leukemia. Leuk Res 2021;110:106707. [PMID: 34563945 DOI: 10.1016/j.leukres.2021.106707] [Reference Citation Analysis]
659 Tischler JL, Abuaita B, Cuthpert SC, Fage C, Murphy K, Saxe A, Furr EB, Hedrick J, Meyers J, Snare D, Zand AR. Simple inhibitors of histone deacetylase activity that combine features of short-chain fatty acid and hydroxamic acid inhibitors. J Enzyme Inhib Med Chem 2008;23:549-55. [PMID: 18608778 DOI: 10.1080/14756360701715703] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
660 Grant C, Rahman F, Piekarz R, Peer C, Frye R, Robey RW, Gardner ER, Figg WD, Bates SE. Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors. Expert Rev Anticancer Ther. 2010;10:997-1008. [PMID: 20645688 DOI: 10.1586/era.10.88] [Cited by in Crossref: 156] [Cited by in F6Publishing: 147] [Article Influence: 13.0] [Reference Citation Analysis]
661 Kang MR, Kang JS, Yang JW, Kim BG, Kim JA, Jo YN, Lee K, Lee CW, Lee KH, Yun J, Kim HM, Han G, Kang JS, Park SK. Gene expression profiling of KBH-A42, a novel histone deacetylase inhibitor, in human leukemia and bladder cancer cell lines. Oncol Lett 2012;3:113-8. [PMID: 22740865 DOI: 10.3892/ol.2011.430] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
662 Zhou Y, Pan D, Shan S, Zhu J, Zhang K, Yue X, Nie L, Wan J, Lu X, Zhang W, Ning Z. Non-toxic dose chidamide synergistically enhances platinum-induced DNA damage responses and apoptosis in Non-Small-Cell lung cancer cells. Biomedicine & Pharmacotherapy 2014;68:483-91. [DOI: 10.1016/j.biopha.2014.03.011] [Cited by in Crossref: 36] [Cited by in F6Publishing: 36] [Article Influence: 4.5] [Reference Citation Analysis]
663 Bhalla S, Balasubramanian S, David K, Sirisawad M, Buggy J, Mauro L, Prachand S, Miller R, Gordon LI, Evens AM. PCI-24781 induces caspase and reactive oxygen species-dependent apoptosis through NF-kappaB mechanisms and is synergistic with bortezomib in lymphoma cells. Clin Cancer Res. 2009;15:3354-3365. [PMID: 19417023 DOI: 10.1158/1078-0432.ccr-08-2365] [Cited by in Crossref: 70] [Cited by in F6Publishing: 40] [Article Influence: 5.4] [Reference Citation Analysis]
664 Peng S, Zhao S, Yan F, Cheng J, Huang L, Chen H, Liu Q, Ji X, Yuan Z. HDAC2 selectively regulates FOXO3a-mediated gene transcription during oxidative stress-induced neuronal cell death. J Neurosci. 2015;35:1250-1259. [PMID: 25609639 DOI: 10.1523/jneurosci.2444-14.2015] [Cited by in Crossref: 58] [Cited by in F6Publishing: 49] [Article Influence: 8.3] [Reference Citation Analysis]
665 Waterborg JH, Kapros T. Kinetic analysis of histone acetylation turnover and Trichostatin A induced hyper- and hypoacetylation in alfalfa. Biochem Cell Biol 2002;80:279-93. [DOI: 10.1139/o02-021] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 0.7] [Reference Citation Analysis]
666 Bhalla KN. Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies. J Clin Oncol. 2005;23:3971-3993. [PMID: 15897549 DOI: 10.1200/jco.2005.16.600] [Cited by in Crossref: 241] [Cited by in F6Publishing: 90] [Article Influence: 14.2] [Reference Citation Analysis]
667 Zain J, Kaminetzky D, O’connor OA. Emerging role of epigenetic therapies in cutaneous T-cell lymphomas. Expert Review of Hematology 2014;3:187-203. [DOI: 10.1586/ehm.10.9] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 3.0] [Reference Citation Analysis]
668 Gould JJ, Kenney PA, Rieger-Christ KM, Silva Neto B, Wszolek MF, LaVoie A, Holway AH, Spurrier B, Austin J, Cammarata BK, Canes D, Libertino JA, Summerhayes IC. Identification of tumor and invasion suppressor gene modulators in bladder cancer by different classes of histone deacetylase inhibitors using reverse phase protein arrays. J Urol 2010;183:2395-402. [PMID: 20403623 DOI: 10.1016/j.juro.2010.02.004] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
669 Scott SA, Kimura T, Dong WF, Ichinohasama R, Bergen S, Kerviche A, Sheridan D, DeCoteau JF. Methylation status of cyclin-dependent kinase inhibitor genes within the transforming growth factor beta pathway in human T-cell lymphoblastic lymphoma/leukemia. Leuk Res 2004;28:1293-301. [PMID: 15475071 DOI: 10.1016/j.leukres.2004.03.019] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
670 Cerna D, Camphausen K, Tofilon PJ. Histone deacetylation as a target for radiosensitization. Curr Top Dev Biol 2006;73:173-204. [PMID: 16782459 DOI: 10.1016/S0070-2153(05)73006-4] [Cited by in Crossref: 42] [Cited by in F6Publishing: 22] [Article Influence: 2.6] [Reference Citation Analysis]
671 Horiuchi M, Morinobu A, Chin T, Sakai Y, Kurosaka M, Kumagai S. Expression and function of histone deacetylases in rheumatoid arthritis synovial fibroblasts. J Rheumatol 2009;36:1580-9. [PMID: 19531758 DOI: 10.3899/jrheum.081115] [Cited by in Crossref: 84] [Cited by in F6Publishing: 73] [Article Influence: 6.5] [Reference Citation Analysis]
672 Ard PG, Chatterjee C, Kunjibettu S, Adside LR, Gralinski LE, McMahon SB. Transcriptional regulation of the mdm2 oncogene by p53 requires TRRAP acetyltransferase complexes. Mol Cell Biol 2002;22:5650-61. [PMID: 12138177 DOI: 10.1128/MCB.22.16.5650-5661.2002] [Cited by in Crossref: 85] [Cited by in F6Publishing: 47] [Article Influence: 4.3</